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Abstract
Newcastle Disease Virus (NDV) is an avian Paramyxovirus that preferentially replicates in 
cancer cells and that has already been used successfully in the treatment of cancer. It has been 
suggested that defects in the interferon response present in many neoplastic cells make them 
prone to NDV infection. However, the exact mechanisms that underlie the tumour selective 
replication of NDV are not known. In this thesis the relation between the NDV susceptibility 
of cells and the basal and inducible expression of different type I interferon-related proteins 
was analysed. It was assessed what the differences in the interferon response were between 
tumour and normal cells and if these differences could explain the tumour selectivity of NDV.
It could be shown that tumour cells have defects in the basal and inducible expression of 
several antiviral, interferon-related genes. These genes include cytosolic viral RNA receptors 
such as RIG-I, transcription factors such as IRF3 and IRF7, type I interferons and antiviral 
effector  molecules  such  as  PKR.  In  addition  tumour  cells  displayed  defects  in  the 
responsiveness to interferon pretreatment with regard to the induction of an antiviral state by 
the upregulation of antiviral genes. A statistically significant, negative correlation was found 
between the expression of many of the tested interferon-related genes and the susceptibility to 
NDV  infection.  Furthermore  the  functional  significance  of  some  of  the  genes  for  the 
establishment of an antiviral response could be evaluated by the analysis of gene knock out 
macrophages.  These  functional  analyses  revealed  the  crucial  importance  of  the  type  I 
interferon receptor and to a lesser degree also of IRF3/7 for NDV resistance and interferon-
related gene expression. Some tumour cells were found to be unusually resistant to NDV 
infection, which could be connected to an exceptionally strong expression of antiviral genes.
All in all the results strongly indicate multiple defects in the interferon response of tumour 
cells as the cause for the tumour selective replication of NDV. There seems to be a general 
downregulation of the antiviral gene expression rather than defects in the expression of only a 
few interferon-related genes. These findings shed new light on the processes that take place in 
normal and tumour cells after NDV infection. In the future they might be used to improve the 
efficacy  of  cancer  treatment  with  NDV by the  prediction  of  the  virus  susceptibility  of  a 
tumour with the help of gene expression analysis before virus treatment.
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Zusammenfassung
Das  Newcastle Disease Virus (NDV) ist ein Vogelvirus das sich bevorzugt in Krebszellen 
repliziert und das schon erfolgreich in der Behandlung von Krebs angewendet worden ist. Es 
wird vermutet,  dass  Defekte  in  der  Interferonantwort  viele  Krebszellen  anfällig  für  NDV 
machen.  Die  genauen  Mechanismen,  die  der  tumorselektiven  Vermehrung  von  NDV 
zugrunde liegen, sind jedoch noch unbekannt.  In dieser Arbeit  wurde der Zusammenhang 
zwischen der Anfälligkeit von Zellen für NDV und der basalen und induzierbaren Expression 
verschiedener  Typ  I  interferonabhängiger  Proteine  untersucht.  Die  Unterschiede  in  der 
Interferonantwort  von  normalen  und  bösartigen  Zellen  wurden  analysiert  und  es  wurde 
getestet, ob diese Unterschiede die Tumorselektivität von NDV erklären können.
Es  konnte  gezeigt  werden,  dass  Tumorzellen  Defekte  in  der  basalen  und  induzierbaren 
Expression von einigen antiviralen, interferonabhängigen Genen aufweisen. Zu diesen Genen 
gehören zytosolische Rezeptoren für virale RNA wie RIG-I, Transkriptionsfaktoren wie IRF3 
und  IRF7,  Typ  I  Interferone  und  antivirale  Effektormoleküle  wie  PKR.  Darüber  hinaus 
zeigten Tumorzellen Defekte in der Reaktion auf Interferon bezüglich der Induktion eines 
antiviralen Zustandes durch die Hochregulation antiviraler Gene. Zwischen der Expression 
vieler der getesteten antiviralen Gene und der Anfälligkeit für NDV wurde eine statistisch 
signifikante, negative Korrelation beobachtet. Außerdem wurde die funktionelle Bedeutung 
einiger  Gene  für  die  Etablierung  einer  Interferonantwort  mit  Hilfe  von  Knock-out 
Makrophagen  bestimmt.  Diese  Analyse  zeigte  die  herausragende  Bedeutung  des  Typ  I 
Interferonrezeptors und von IRF3/7 für die  Resistenz gegen NDV und für die  Expression 
interferonabhängiger Gene. Einige Tumorzellen waren ungewöhnlich resistent gegen NDV, 
was mit der hohen Expression von antiviralen Genen erklärt werden konnte.
Zusammenfassend deuten die Ergebnisse auf multiple Defekte in der Interferonantwort von 
Tumorzellen als Ursache für die tumorselektive Vermehrung von NDV hin. Dabei scheint es 
eher eine generelle Abschwächung der antiviralen Genexpression als Defekte in nur wenigen 
interferonabhängigen  Genen  zu  geben.  Diese  Erkenntnisse  erhöhen  das  Verständnis  der 
Prozesse, die in normalen und bösartigen Zellen nach einer NDV-Infektion stattfinden. In der 
Zukunft könnte dieses Wissen die Krebsbehandlung mit NDV verbessern, indem vor einer 
Behandlung die Anfälligkeit des Tumors für NDV anhand der Genexpression bestimmt wird.
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 1 Introduction
 1.1 General introduction to cancer
Cancer is a leading cause of death worldwide. According to the World Health Organization 
(WHO; fact sheet no. 297, February 2006) cancer accounted for 7.6 million (or 13 %) of all 
deaths in the year 2005. In Germany 224,000 deaths (or 26.6 %) were attributable to cancer, 
making it the second leading cause of death after cardiovascular diseases (47.4 %). The main 
types of cancer leading to overall cancer mortality are in terms of deaths per year: lung (1.3 
million), stomach (1.0 million), liver (0.7 million), colon (0.7 million) and breast cancer (0.5 
million). 40 % of all cancer cases could be prevented by a healthy diet, physical activity and 
not using tobacco. Tobacco use is the single largest preventable cause of cancer in the world 
and causes a large variety of cancer types. In addition one-fifth of cancers worldwide are due 
to chronic infections, mainly from HBV (liver), HPV (cervix), Helicobacter pylori (stomach) 
schistosomes (bladder) and HIV (Kaposi sarcoma and lymphomas).
Cancer occurs because of changes of the genes responsible for cell growth and repair. These 
changes are the result of the interaction between genetic host factors and external agents such 
as physical  carcinogens (e.g.  UV or ionizing radiation),  chemical  agents  (e.g.  asbestos or 
tobacco smoke) and biological carcinogens (e.g. viruses, bacteria or contamination of food by 
mycotoxins like aflatoxins).
 1.1.1 The development of cancer
Cancer arises from a single cell. The transformation from a normal cell into a tumour cell is a 
multi-stage process, typically a progression from a pre-cancerous lesion to malignant tumours. 
The development of cancer may be initiated by external agents and inherited genetic factors. 
Ageing is another fundamental factor for the development of cancer. The incidence of cancer 
rises  dramatically  with  age,  most  likely  due  to  risk  accumulation  over  the  life  course 
combined with the tendency for cellular repair mechanisms to be less effective as a person 
grows older.
Cancer cells have acquired defects in regulatory circuits that govern normal cell proliferation 
and homeostasis. According to Hanahan et al. (2000) there are six essential alterations in cell 
1
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physiology that collectively dictate malignant growth (figure 1-1): self-sufficiency in growth 
signals,  insensitivity  to  growth-inhibitory  signals,  evasion  of  programmed  cell  death 
(apoptosis),  limitless  replicative  potential,  sustained angiogenesis,  and tissue  invasion and 
metastasis.
The order in which these capabilities are acquired is likely to vary across the spectrum of 
cancer types, but they will ultimately be shared by most kinds of tumours.
 1.1.2 Cancer therapy
 1.1.2.1 Classical therapy approaches
Treatment of cancer is aimed at curing, prolonging life and improving the quality of life of 
patients with cancer. Some of the most common cancer types such as breast cancer, cervical 
cancer and colorectal cancer have a high cure rate when detected and treated early. Classical 
treatment methods are surgery, radiation therapy and chemotherapy.
Surgery can cure cancer if the tumour can be completely removed. This is the case if the 
tumour has not spread throughout the body and if its removal does not damage vital organs 
such as the brain or the liver. However, if the tumour cannot be completely removed, other 
2
Figure 1-1: Acquired capabilities of cancer.
Tumour development takes place via a process analogous to evolution in which a succession of genetic changes 
leads to the progressive conversion of normal into cancer cells. The six capabilities acquired by cancer cells 
shown here are commonly shared by most tumours and give them growth and survival advantages. Adapted from 
Hanahan and Schreiber (2000).
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treatment methods have to be applied as well. One of these methods is radiation therapy, the 
use of ionising radiation to kill cancer cells. Radiation therapy works by damaging the DNA 
of cells and since cancer cells generally proliferate more and have acquired defects in the 
DNA  damage  repair,  they  are  more  susceptible  to  radiation-induced  DNA  damage  than 
normal, non-malignant cells. Another important way to treat cancer is chemotherapy, the use 
of drugs that interfere with cell division in different ways. Most forms of chemotherapy target 
all rapidly dividing cells and are not specific for cancer cells. There are several subgroups of 
chemotherapeutic  substances,  for  example,  alkylating  agents  such  as  cisplatin  that  work 
directly on the DNA and prevent the cell division process by cross-linking and breaking the 
DNA strands and causing abnormal base pairing. There are several other subgroups such as 
antimetabolites (e.g. 5-fluorouracil (5FU)), anthracyclines, monoclonal antibodies and so on. 
Since most chemotherapeutic drugs target all proliferating cells, normal replicating cells of 
the body such as bone marrow cells, intestinal cells or cells of hair follicles are also killed. 
This can lead to side-effects such as immunosuppression, diarrhoea or hair loss.
In addition to these classical treatment methods there are many other therapeutic approaches 
for  cancer  treatment.  In  general  the  best  successes  in  cancer  therapy can  be  achieved  if 
different treatments are combined, for example, by using chemotherapy after surgical removal 
of the primary tumour to target residual tumour cells in the body.
 1.1.2.2 The use of viruses in cancer treatment
Viruses  can  be  used  to  treat  cancer  in  different  ways,  because  many  tumour  cells  have 
acquired defects  in  their  antiviral  interferon response  that  might  give them a growth and 
survival advantage but that makes them also more susceptible to virus infections (Stojdl et al., 
2000).  The two principal  approaches  in  virus  therapy are  the  stimulation  of  the  immune 
system with virus-modified tumour cell vaccines and the use of live virus to target and kill 
tumour cells  in the body. Tumour cell  vaccines can be generated by infecting autologous 
tumour cells  ex vivo with virus and by gamma-irradiating them with a radiation dose that 
prevents further replication but that does not kill the cells immediately. The virus-modified 
tumour cell vaccine is then injected back into the patient. The idea behind the treatment is that 
in this vaccine multiple tumour-associated antigens from the patient-derived tumour cells are 
linked in the same cell with multiple danger signals from the virus infection such as dsRNA, 
3
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viral surface proteins or interferons. This linkage is thought to specifically activate innate or 
adaptive immune responses against the tumour cells. The vaccine can be further improved by 
the genetic engineering of viruses that express immune stimulatory molecules such as GM-
CSF. Examples of a successful  application of virus-modified tumour cell  vaccines can be 
found for the Newcastle disease virus (Ockert et al., 1996; Schirrmacher et al., 2002). As the 
tumour cell vaccines require an intact immune system, this approach is more likely to be used 
in early disease stages when the body is not yet markedly weakened by tumour- or therapy-
related effects.
The second principal approach in the treatment of cancer with viruses is the use of oncolytic 
viruses  in vivo. Oncolytic viruses selectively infect cancer cells, but not normal cells of the 
body. Some viruses are naturally attenuated (such as some strains of Newcastle disease virus 
(NDV), reovirus or vesiculostomatitis virus), while other viruses are genetically modified to 
mediate oncolytic effects (such as herpes simplex virus type 1 or adenovirus). The viruses are 
given intratumourally  or  systemically  into the  blood stream and then they infect  and kill 
tumour cells. One advantage of oncolytic viruses compared to other anticancer drugs is the 
possibility to add genes by recombinant  DNA technology that  code for toxic or immune-
stimulatory products or that improve the tumour targeting of the virus. In addition oncolytic 
viruses are self-replicating in cancer cells and thereby self-amplify their anti-tumour effect 
and they can also target metastases if given systemically. Problems that can occur especially 
with regard to systemic application are the immune clearance of the virus, insufficient tumour 
targeting and limited intratumoural dissemination.
An example of an oncolytic virus that has been used in clinical trials is the adenovirus H101, 
which is the only oncolytic virus to be tested in a phase III study to date (Xia et al., 2004) and 
which has been approved for cancer treatment in China in 2006 (Garber, 2006). NDV has also 
been used successfully as an oncolytic virus in a phase I study with the NDV strain PV701 
(Pecora  et al.,  2002) and in a phase I/II study with the NDV strain HUJ (Freeman  et al., 
2005). Before the use of NDV in cancer therapy will be discussed in detail, it is necessary to 
take a closer look at its molecular biology.
4
                                                                                                                                   Introduction  
 1.2 Newcastle Disease Virus (NDV)
The following information was mainly taken from Nagai  et al. (1989) and Modrow  et al. 
(2002) if not mentioned otherwise. Newcastle disease virus (NDV) belongs to the family of 
the Paramyxoviridae  which are widespread and can cause severe diseases in  animals  and 
humans. The measles and the mumps virus are examples of members of the Paramyxoviridae 
that are pathogenic for humans. NDV causes Newcastle disease which is a highly contagious 
bird  disease  affecting  many  domestic  and wild  avian  species.  NDV is  not  infectious  for 
humans and can cause only mild conjunctivitis and influenza-like symptoms,  for example, 
when workers in the poultry industry are exposed to high virus doses during an outbreak of 
Newcastle disease.
 1.2.1 The biology of NDV
NDV is  an  enveloped  virus  of  150  to  300 nm size  containing  a  non-segmented,  single-
stranded negative RNA genome of 15 kb size. The NDV genome codes for the following six 
genes given in order from the 3´-end (figure 1-2): nucleocapsid protein (NP), phosphoprotein 
(P),  matrix  protein  (M),  fusion  protein  (F),  hemagglutinin-neuraminidase  (HN)  and  large 
protein (L).
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Figure 1-2: The structure of the NDV virion.
The enveloped NDV virus particle contains a non-segmented, single-stranded negative RNA genome encoding 
six  genes:  NP  (nucleocapsid  protein),  P  (phosphoprotein),  M  (matrix  protein),  F  (fusion  protein),  HN 
(hemagglutinin-neuraminidase)  and  L  (large  protein).  Adapted  from:  www.microbiologybytes.com/virology/ 
Paramyxoviruses.html.
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The surface protein  HN is  anchored in the viral  envelope and it  is  indispensable  for  the 
attachment of the virus to sialic acid-containing cell  surface receptors (Iorio  et al., 1992). 
These  receptors  can  be  found on  most  mammalian  cells  and  hence  NDV binds  to  most 
mammalian cell types. HN can also cause hemagglutination, i.e. the agglutination of red blood 
cells, a characteristic that is used to quantify NDV dilutions. The F protein, which is also 
anchored in the viral envelope, mediates the fusion of the viral envelope with the host cell 
membrane  and  thereby  enables  the  entry  of  the  viral  capsid.  It  is  synthesised  as  an  F0 
precursor protein that is cleaved into the two parts F1 and F2 which remain connected via a 
disulfide bridge.  The cleavage exposes  a  strongly hydrophobic  area  in  the F1 part  that  is 
thought to be important for the membrane fusion. The sequence of the the F protein cleavage 
site contributes  to NDV pathogenicity  (Romer-Oberdorfer  et  al.,  2003).  The M protein is 
located between the viral capsid and the envelope and is important for the generation and 
packaging of viral RNA as well as for the assembly of new virus particles.
The nucleocapsid consists of three viral proteins that form a complex with the RNA genome. 
About 2,200 – 2,600 subunits of the NP protein form the nucleocapsid. A complex of the NP, 
the L and the P protein are involved in the transcription of the RNA genome. The L protein is 
an RNA-dependent RNA polymerase that is active only in a complex with the NP and the P 
protein.
The replication of NDV (figure 1-3) takes place solely in the cytosol with no participation of 
the nucleus. After HN-mediated binding the F protein induces the fusion of the viral envelope 
with the host cell membrane and the nucleocapsid enters the cytosol. Then the RNA genome 
is  uncoated  and  transcribed  into  mRNAs  by  the  L-NP-P  protein  complex  and  the  viral 
proteins are transcribed. Later on when enough NP protein has been produced a continuous 
positive RNA strand (antigenome) is synthesised that serves as matrix for the generation of 
new viral genomes. Finally all the viral components accumulate at the plasma membrane and 
are assembled into progeny virus. The virus is released from cells by budding. 
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In the process  of  RNA-dependent  RNA synthesis  viral  double-stranded RNA (dsRNA) is 
generated  in  the  cytosol.  Viral  dsRNA  is  thought  to  be  a  general  pathogen-associated 
molecular pattern (PAMP) that appears during the replication of many viruses and that can 
induce  antiviral  responses  mediated  by  pattern  recognition  receptors  (PRRs)  in  cells.  In 
mammalian cells dsRNA is thought to be an important signal limiting NDV infection (Kato et  
al., 2005; Yoneyama et al., 2004), as will be discussed later.
 1.2.2 The classification of NDV strains
NDV strains can be classified as highly virulent (velogenic), intermediate (mesogenic) or non-
virulent  (lentogenic),  based on the results  of the mean death time in chicken (Beard and 
Hanson, 1984). The virulence of Newcastle disease virus is determined by the cleavage site of 
the  fusion  protein  and  by  both  the  stem region  and globular  head of  the  hemagglutinin-
neuraminidase protein (de Leeuw et al., 2005). In addition NDV can be classified into mono- 
or multicyclically replicating strains according to the ability to generate infective progeny 
virus  in  mammalian  cells.  Besides  NDV strains  can  be  categorised  as  lytic  or  non-lytic. 
Viruses of both strain types can kill cancer cells, but lytic strains have the potential to do this 
more quickly because they damage the plasma membrane of infected cells. Non-lytic strains 
appear to kill by interfering with cell metabolism.
In this thesis mostly the lentogenic, non-lytic, monocyclically replicating NDV strain Ulster 
and the velogenic, lytic, multicyclically replicating NDV strain Italien were used. In addition 
the  two  recombinant,  EGFP-expressing  NDV  variants  NDFL-EGFP  and  NDFLtag-EGFP 
were used in some experiments in order to quickly follow NDV infection by flow cytometry. 
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Figure 1-3: The Newcastle disease virus replication cycle.
NDV replication takes places solely in the cytosol of the host cell. Viral RNA is synthesised by a viral RNA-
dependent RNA polymerase constituted by an L-NP-P protein complex. During RNA synthesis viral dsRNA is 
produced that can induce antiviral responses and that is thought to limit NDV infection in mammalian cells. 
Source: www.microbiologybytes.com/virology/Paramyxoviruses.html.
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Both EGFP-expressing NDV variants were based on the lentogenic NDV strain La Sota, but 
the NDFL-tagEGFP was mesogenic due to a modified cleavage site of the F protein (Al-Garib 
et al., 2003; Peeters et al., 1999).
 1.2.3 The use of NDV in cancer therapy
Since Newcastle disease virus is not pathogenic in humans and because it replicates only in 
the cytosol of host cells, which makes a virus-induced malignant transformation of infected 
cells unlikely, NDV is well suited for cancer therapy trials. NDV can replicate up to 10,000 
times better in cancer cells than in most normal cells (Bar-Eli  et al., 1996; Reichard  et al., 
1992; Schirrmacher et al., 1999a; Tzadok-David et al., 1995). The ability of NDV to replicate 
efficiently in human cancer cells has been demonstrated in both laboratory studies and animal 
studies. The lytic NDV strain 73-T has been shown to kill a variety of human cancer cells, 
while it did not harm most normal human cells (Lorence et al., 1988; Reichard et al., 1992; 
Zorn et al., 1994). Other NDV strains that have been demonstrated to replicate well in tumour 
cell lines are the lytic NDV Italien in human melanoma cell lines (Ahlert and Schirrmacher, 
1990), the lytic strain MTH-68/H in a wide range of transformed cells (Fabian et al., 2007) 
and the non-lytic NDV Ulster in a variety of human tumour cell lines (Schirrmacher  et al., 
1999a). The ability of NDV strains to kill human cancer cells  in vivo has been examined in 
xenograft studies. Intratumoural injection of the NDV strain 73-T caused the regression of 
xenografts  in  athymic  mice  from  different  human  tumours  such  as  neuroblastoma  or 
fibrosarcoma (Lorence et al., 1994a/b; Phuangsab et al., 2001).
Other laboratory and animal studies have shown that NDV and NDV-infected cancer cells can 
stimulate  a  variety  of  immune  system  responses  that  are  essential  for  the  successful 
immunotherapy of cancer. It could be shown that the infection of human immune system cells 
with NDV in vitro causes the cells to produce the cytokines interferon-α and tumour necrosis 
factor-α (Lorence et al., 1988; Zorn et al., 1994). Additional studies have shown that NDV-
infected  human  cancer  cells  are  better  at  activating  human  lymphocytes  than  uninfected 
cancer cells (Haas et al., 1998b). Bispecific antibodies that bind to the viral HN and to CD3 or 
CD28 on T cells  could  further  increase  the  T cell  stimulatory  capacity  of  NDV-infected 
human cancer cells (Haas et al., 1998a, 1999, 2005, 2006). There are indications from in vitro 
(Schirrmacher et al., 1997, 1999b) and in vivo experiments (Heicappell et al., 1986) that virus 
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proteins  inserted  into  the  plasma  membrane  of  NDV-infected  cancer  cells  may  help  the 
immune system to recognise tumour-specific antigens better, thereby leading to an enhanced 
killing of cancer cells.
The clinical  anticancer  potential  of  NDV has  been evaluated  for  oncolysates,  whole  cell 
vaccines  or  infection  of  patients  with  lytic  NDV.  Oncolysates  and  whole  cell  vaccines 
improve  the  recognition  of  tumour-associated  antigens  by  the  immune  system  by  their 
association with viral antigens. It has been found that whole cell vaccines can stimulate the 
immune system more efficiently than oncolysates (Kobayashi  et al., 1969), probably due to 
the importance of tumour cell membrane integrity for CTL activation (Schirrmacher and von 
Hoegen, 1993). NDV oncolysates have been mostly applied in the treatment of melanoma in 
phase I and phase II trials, in which an improved overall survival could be observed (Cassel 
and Murray, 1992; Murray et al., 1977). Improved disease-free survival could be found in a 
phase II trial with NDV oncolysates in the treatment of advanced renal cancer (Anton et al., 
1996).
Whole cell vaccines in the form of autologous tumour cell vaccines (ATV-NDV) increased 
the 2-year  survival rate in glioblastoma multiforme (Steiner  et al.,  2004) and disease-free 
(Schlag et al., 1992) or overall survival (Ockert  et al., 1996) in phase II trials for colorectal 
and for renal cell cancer (Pomer  et al., 1995). In addition an improved median survival in 
ovarian cancer could be observed after treatment with ATV-NDV (Möbus et al., 1993).
The infection of patients with NDV has the advantage that the cytotoxic effect is amplified by 
the generation of virus offspring and that NDV can spread to every cancer cell in the body. 
The  drawbacks  of  this  approach  are  virus  clearance  of  the  immune  system  by  virus-
neutralising antibodies. In case studies with the lytic NDV strain MTH-68/H in the treatment 
of glioblastoma multiforme a dramatical increase in survival was reported for the 4 treated 
patients when NDV was given on a daily basis (Csatary et al., 2004). Three phase I clinical 
trials with the oncolytic NDV strain PV701 demonstrated partial tumour regression in some 
patients (Hotte et al., 2007; Laurie et al., 2006; Pecora et al., 2002). In addition it was shown 
that a desensitisation with a low initial NDV dose and a low infusion rate can increase the 
maximum tolerable  dose  and can  reduce  flu-like  side  effects.  A phase  I/II  trial  with  the 
oncolytic  NDV strain  HUJ found good tolerability  of  NDV and there  was  one  complete 
response (Freeman et al., 2006).
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 1.3 The antiviral interferon response
 1.3.1 Interferons
Upon  virus  infection  the  expression  of  a  class  of  cytokines  called  interferons  (IFNs)  is 
induced. The name interferon is derived from their ability to interfere with viral replication in 
previously uninfected tissue culture cells (Isaacs and Lindenmann, 1957) and there are at least 
three distinct types of interferons: types I, II and III (Pestka  at al., 2004). Type I IFNs are 
composed of various genes including IFN-α, -β (Taniguchi  et al., 1980) and others such as 
IFN-ω, -ε and -κ (Pestka et al., 2004) and are the major antiviral IFNs. Type II IFN is referred 
to as IFN-γ that is represented by a single gene and that is structurally unrelated to type I 
IFNs. IFN-γ is  not directly induced by most viruses but is produced later  by cells  of the 
immune system such as T cells or NK cells and plays a role in the adaptive immune response 
against intracellular pathogens (Farrar and Schreiber, 1993). The recently discovered type III 
IFNs  IFN-λ1,  -λ2  and  -λ3  (also  known  as  interleukin-29  (IL-29),  IL-28A  and  IL28B, 
respectively) are produced in virally infected cells and these IFN genes may also be induced 
by mechanisms similar to those of IFN-α and -β (Honda et al., 2006a). Since the type I IFNs 
IFN-α and -β are thought to be the key cytokines defining antiviral responses, the induction 
and effects of these two IFNs will be discussed in the following.
In humans and mice there are 13 and 14 IFN-α genes, respectively,  while there is only a 
single IFN-β gene (Weissmann and Weber, 1986). All IFN-α/β genes lack introns. Although 
virtually all cells can produce IFN-α/β in response to viral pathogens, plasmacytoid dendritic 
cells (pDCs) are the strongest IFN-α/β producers in the body (Colonna  et al.,  2004). The 
transcription of IFN-α/β is induced by viral-associated molecular patterns such as viral nucleic 
acids that are detected by pattern recognition receptors (PRRs) of the innate immune system. 
IFN-α/β  signal  both  through a  common cell  surface  receptor,  the  IFNAR,  leading to  the 
transcription of hundreds of genes. Some of the induced proteins increase the resistance of 
cells  to  infection  by  directly  inhibiting  viral  replication.  In  addition  IFNs  upregulate  the 
expression of MHC class I and activate NK cells. NK cells preferentially kill cells with a low 
MHC class I level. Some viruses selectively prevent the export of MHC class I molecules to 
the cell  surface. Therefore, IFNs protect uninfected cells from NK cells by increasing the 
expression of  MHC class I  molecules,  while  infected cells  are  killed either  by the better 
antigen presentation to T cells or by the activated NK cells. 
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 1.3.2 The regulation of type I IFN gene transcription
The induction  of  IFN-α/β  is  regulated  primarily  at  the  transcriptional  level,  wherein  IFN 
regulatory factors (IRFs) play central roles (Taniguchi et al., 2001). The transcription of IFN-
α/β in a cell is induced upon detection of invariant molecular structures shared by pathogens 
of various origin, so called pathogen-associated molecular patterns (Medzhitov and Janeway, 
2002). Toll-like receptors (TLRs) 3, 7, 8 and 9 are the major pattern recognition receptors 
(PRRs) that recognise distinct types of virally-derived nucleic acids and activate signalling 
cascades that induce the production of IFN-α/β (Akira and Takeda, 2004). Recently, cytosolic 
receptors for viral RNA such as the retinoic acid inducible gene I (RIG-I) or the melanoma 
differentiation associated gene 5 (MDA5) have been identified and could be shown to induce 
IFN-α/β in a TLR-independent manner (Yoneyama  et al., 2004, 2005). The TLRs and the 
cytosolic  receptors  constitute  two  different  receptor  systems  that  are  located  in  different 
cellular compartments (figure 1-4).
TLRs detect viral nucleic acids mainly in endosomes and are expressed mainly by specialised 
cell types such as macrophages or dendritic cells. TLRs sample material entering cells from 
the outside and thus do not detect the presence of infection from within. The material often 
consists  of  viral  particles  that  become  degraded  upon  endosomal  acidification,  thereby 
exposing viral nucleic acids for recognition. After ligand binding through the leucine rich 
repeats (LRR) the TLRs dimerise and undergo the conformational change required for the 
recruitment of downstream signalling molecules such as MyD88 or TRIF via the TIR domain 
(Akira  and  Takeda,  2004).  The  further  signalling  leads  ultimately  to  the  activation  of 
transcription factors such as NF-κB or IRF3/7. At that point the TLR signalling converges 
with the signalling of the cytosolic viral receptors.
The second receptor system that is TLR-independent is represented by cytosolic viral RNA 
receptors such as RIG-I or MDA5. These receptors, which belong to the DExD/H box RNA 
helicases (Yoneyama et al., 2005; Zhang et al., 2000), are expressed ubiquitously and detect 
viral RNA in the cytosol of an infected cell (Stetson and Medzhitov, 2006). They bind viral 
RNA with their helicase domain leading to the activation of a downstream signalling cascade 
via the interaction of the CARD domain of the helicases with the CARD domains of a MAVS 
adaptor protein (also known as IPS-1, VISA or CARDIF) that is located in the membrane of 
mitochondria  (Kawai  et  al.,  2005;  Seth  et  al.,  2005).  Ultimately  this  signalling  cascade 
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activates transcription factors such as NF-κB or IRF3/7 mainly through phosphorylation by 
activated kinases.
The activated transcription factors induce the transcription of IFN genes in the nucleus which 
are  secreted  and  act  in  a  auto-  and  paracrine  manner  by  signalling  through  the  IFNAR. 
However, the  IFN-α/β genes are not expressed at the same level or with the same kinetics 
after virus infection. The expression of IFN-β and IFN-α4 is induced early through the action 
of the constitutively expressed IRF3 (Juang  et al., 1998), while the expression of the other 
IFN-α genes depends on IRF7. The transcription factor IRF7 is expressed at a low level in 
most cells in the absence of virus infection and is induced through a positive feedback loop by 
the early interferons IFN-α4/β (Levy et al., 2002; Yeow et al., 2000). Only after induction of 
IRF7 by the early IFNs are the other IFN-α genes transcribed, resulting in a full interferon 
response. 
The binding of IFN-α and IFN-β to the IFNAR activates janus kinase family members which 
in  turn  phosphorylate  and  activate  the  signal  transducer  and  activator  of  transcription  1 
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Figure 1-4: Regulation of type I IFN gene transcription.
There are two different receptor systems that signal upon the detection of virus-associated molecular patterns: 
Toll-like receptors (TLRs) and cytosolic receptors such as RIG-I. Both systems converge in the activation of 
transcription factors such as IRF3/7 that in turn induce the transcription of IFNs. There is a positive feedback 
loop that upregulates the expression of IRF7 by the early interferons IFN-β and IFN-α4, which is indispensable 
for the expression of other IFN-α genes and for a full interferon response. Adapted from Seth et al., 2006.
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(STAT1) and STAT2 proteins.  These transcription factors  associate  with  IRF9 to  form a 
heterotrimeric  complex,  the  IFN-stimulated  gene  factor  3  (ISGF3).  ISGF3  initiates  the 
transcription of several interferon stimulated genes (ISGs) by binding to the IFN-stimulated 
response elements (ISRE) in their promoter regions. Examples for ISGs with ISREs are the 
transcription  factor  IRF7  or  genes  with  direct  antiviral  effector  functions  such  as  PKR, 
OAS1a or Mx1. These proteins together with other  important  molecules  of the interferon 
response will be discussed in the next chapter.
 1.3.3 Key molecules of the interferon response
 1.3.3.1 The DExD/H-box RNA helicases RIG-I, MDA5 and LGP2
The cytosolic proteins RIG-I and MDA5 sense intracellular viral RNA and trigger a signal for 
innate antiviral responses including the production of type I interferons. RIG-I and MDA5 are 
members of the DExD/H-box helicase family and have a C-terminal RNA helicase domain as 
well as two N-terminal CARD domains (Yoneyama  et al., 2004, 2005). In addition the C-
terminal domain of RIG-I contains a repressor domain that is responsible for auto-repression 
by interacting with both CARD and helicase domains (Saito et al., 2007). RIG-I selectively 
binds with  the  dsRNA analogue poly (I:C)  as  well  as  with untranslated regions of  HCV 
genomic RNA, but not with double-stranded DNA (Sumpter  et al., 2005; Yoneyama  et al., 
2004).
These results suggest that RIG-I is a specific sensor for dsRNA, but in the case of influenza A 
virus IFN gene activation occurs without detectable dsRNA accumulation (Pichlmair  et al., 
2006). A recent hypothesis views 5´-triphosphate RNA as the ligand for RIG-I and as the 
means  for  the  discrimination  of  self  and  non-self  in  a  cell  (Hornung  et  al.,  2006). 
5 ´-triphosphate RNA is abrogated in cellular RNAs by posttranscriptional RNA processing in 
eukaryotes, but it is present in many RNA viruses.
The activation of RIG-I is ATP-dependent since a single mutation in the ATP binding motif 
of the helicase domain renders RIG-I into a dominant inhibitor (Yoneyama et al., 2004). The 
binding of viral dsRNA or 5´-triphosphate ssRNA together with ATP binding changes the 
conformation  of  RIG-I  and  releases  CARD  for  relaying  signalling  to  the  downstream 
molecule MAVS (Yoneyama and Fujita, 2007). MAVS is localised in the mitochondria and 
this localisation is crucial for its function (Li et al., 2005; Lin et al., 2006; Loo et al., 2006), 
13
Introduction                                                                                                                                    
although the precise mechanism is not known. RIG-I and MDA5 both appear to transmit 
signals via the MAVS protein (Kawai et al., 2005; Kumar et al., 2006). The signal is branched 
at MAVS, resulting in the activation of NF-κB by the protein kinases IKK-α/β/γ and of IRF3 
and IRF7 via TRAF3 (Saha et al., 2006) and the protein kinases TBK-1 and IKK-i(ε) (Hemmi 
et al., 2004; Perry et al., 2004). Recently it has been suggested that the functions of RIG-I, 
MDA5 and MAVS are negatively regulated by proteasomal degradation after conjugation to 
ubiquitin mediated by the ubiquitin ligase RNF125 (Arimoto et al., 2007).
A homologous protein to RIG-I and MDA5 is LGP2 (Miyoshi et al., 2001), which in contrast 
to the former two lacks the CARD domain and is incapable of transmitting a positive signal. 
LGP2 has been suggested as a negative regulator, but its role in vivo has yet to be established 
(Komuro and Horvath, 2006; Rothenfusser  et al., 2005; Yoneyama  et al., 2005). So far the 
data  indicate  a  disparate  regulatory  role  for  LGP2  in  the  triggering  of  innate  immune 
signalling pathways following RNA virus infection (Venkataraman et al., 2007).
The importance of RIG-I seems to be cell type specific. RIG-I is essential in NDV-induced 
IFN production, but it is dispensable for virus-induced IFN production by pDCs (Kato et al., 
2005). pDCs use a distinct signalling cascade to produce high levels of IFN-α and sense viral 
infection by TLR7/8 and TLR9 (Honda and Taniguchi,  2006b; Takeda and Akira,  2005). 
RIG-I and MDA5 have differential roles in the recognition of RNA viruses. RIG-I is essential 
for the production of interferons in response to viruses such as NDV, Sendai virus, VSV and 
influenza virus, while MDA5 is critical for picornavirus detection (Kato et al., 2006).
Several  viruses express proteins that  counteract  the functions of RIG-I  and MDA5. HCV 
expresses the NS3/4A protein that cleaves MAVS from the mitochondrial membrane, thereby 
preventing RIG-I or MDA5 downstream signalling (Li et al., 2005; Lin et al., 2006; Loo et  
al.,  2006).  The  NS1  protein  from  the  influenza  A  virus  inhibits  RIG-I  signalling  by 
sequestering dsRNA and by binding to RIG-I (Mibayashi et al., 2007; Pichlmair et al., 2006). 
The V protein of paramyxoviruses binds to MDA5 and inhibits its  downstream signalling 
(Andrejeva et al., 2004).
 1.3.3.2 The transcription factors IRF3 and IRF7
The interferon-regulatory factor (IRF) family of transcription factors was initially found to be 
involved in the induction of genes that encode type I interferons. IRFs have now been shown 
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to have functionally diverse roles in the regulation of the immune system. The mammalian 
IRF family comprises the nine members IRF1-9 that all contain a conserved DNA-binding 
domain (Lohoff and Mak, 2005; Taniguchi  et al.,  2001).  This region recognises an ISRE 
consensus DNA sequence that is found in the promoters of the genes that encode the type I 
IFNs  themselves  as  well  as  in  the  promoters  of  many  other  genes  that  are  involved  in 
immunity and oncogenesis (Honda et al., 2006). IRFs are essential in the signalling of PRRs 
that recognise PAMPs and that link innate and adaptive immune responses. There are two 
classes of PRRs: transmembrane PRRs such as the TLRs and cytosolic PRRs like RIG-I and 
MDA5. In the following the role of IRFs in cytosolic PRR signalling will be discussed.
The four IRFs IRF1/3/5/7 have been implicated as positive regulators of the transcription of 
type I IFN genes (Mamane et al., 1999; Taniguchi et al., 2001). However, IRF1 and IRF5 do 
not seem to be essential for type I gene expression since the induction of IFN-α/β by NDV in 
IRF1-/- and IRF5-/- MEFs is not changed (Matsuyama et al., 1993; Takaoka et al., 2005).
IRF3 and IRF7 are the two crucial transcription factors in the signalling of cytosolic PRRs. 
IRF3 is constitutively expressed, while IRF7 is present only at low levels in most cells. Upon 
the  recognition  of  viral  nucleic  acids  by  cytosolic  PRRs  they  are  both  activated  by 
phosphorylation  and form homo-  or  heterodimers.  After  translocation  to the  nucleus they 
induce the dimer-specific transcription of type I interferons and chemokines (Lin et al., 2000). 
The binding of type I interferons to the IFNAR results in the activation of the heterotrimeric 
transcriptional ISGF3 that is responsible for the induction of IRF7 (Marie et al., 1998; Sato et  
al., 1998). IRF3 is a potent activator of the IFN-β gene but not the IFN-α genes, except for the 
IFN-α4 gene, whereas IRF7 efficiently activates both IFN-α and IFN-β genes (Marie  et al., 
1998; Sato  et al., 1998, 2000). In addition it was demonstrated that the induction of type I 
interferons was severely impaired in IRF7-/- MEF (Honda et al., 2005). Therefore a two-step 
induction of type I interferons has been suggested in which IRF3 and low initial amounts of 
IRF7 are important for the early secretion of IFN-β and some IFN-α subtypes. These early 
interferons induce the expression of IRF7 in a positive-feedback loop through the IFNAR. In 
the late phase the newly synthesised IRF7 enables the expression of high amounts of most 
IFN-β and IFN-α genes (figure 1-5). As mentioned before IRF3 and IRF7 are phosphorylated 
by the protein kinases TBK1 and IKK-i that are activated after viral nucleic acid detection by 
RIG-I and MDA5 and subsequent downstream signalling via MAVS and TRAF3.
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 1.3.3.3 The IFNAR
The IFNAR is the only known receptor for type I interferon signalling. It is a cell-surface 
receptor with an extracellular ligand binding domain and an intracellular kinase domain that is 
activated after ligand-induced dimerisation (Darnell et al., 1994). The IFNAR has two chains, 
IFNAR1 and  IFNAR2c,  which  are  both  necessary  for  most  of  its  functions  (van  Boxel-
Dezaire et al., 2006). Interferon binding induces the phosphorylation of the JAK1 or TYK2 
Janus kinases and of STATs. Activated STATs dissociate from the receptor, translocate to the 
nucleus and induce the expression of  ISGs (Stark  et  al.,  1998).  In  many cells  the major 
transcription  factor  activated  upon  interferon  binding  is  ISGF3,  which  is  constituted  by 
STAT1/2 and IRF9 and which stimulates the transcription of genes that have the ISRE in their 
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Figure 1-5: Interferon-regulatory factors in positive-feedback regulation of type I interferon 
genes.
a) In the early phase of a virus infection, IRF3 and IRF7 are phosphorylated, form homo- or heterodimers and 
translocate to  the nucleus.  There  they induce the expression  of  chemokines such as CXCL10 and of small 
amounts of IFN-β and of certain IFN-α subtypes such as IFN-α4. b) In the later phase secreted IFNs bind and 
activate the type  I IFN receptor (IFNAR) in an auto- or paracrine manner, which leads to the activation of 
ISGF3,  a  heterotrimer  formed  by STAT1+2 and  IRF9.  ISGF3 translocates  to  the  nucleus  and  induces  the 
transcription of IRF7. Newly synthesised IRF7 is than activated following the recognition of viral nucleic acids 
by cytosolic  PRRs,  leading to  the  expression  of  large  amounts  of  IFN-β and many of  the  IFN-α proteins. 
Expression of the cytosolic PRRs RIG-I and MDA5 is also induced by type I IFNs (not shown). Adapted from 
Honda et al., 2006.
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promoter (figure 1-5).
Because different subtypes of type I IFN activate the same cell-surface receptor complex to 
mediate variable responses, it seems likely that different ligand-receptor interactions cause 
diverging  downstream responses,  probably  by  differences  in  critical  amino  acid  residues 
among the different type I IFN subtypes (Deonarain  et al., 2002). There is, for example, a 
distinct  binding site  on  IFNAR1 for  IFN-β and  some hybrid  IFN-α subtypes  (Platis  and 
Foster, 2003) and IFN-β also forms complexes with the extracellular domains of IFNAR2c 
and IFNAR1 with higher affinity than IFN-α2 (Lamken et al., 2004).
The IFNAR is crucial  in the defence against viral infection. Mice lacking the IFNAR are 
highly susceptible to a wide range of viral infections (van den Broek et al., 1995; Hwang et  
al., 1995; Luker  et al., 2003). Measles virus suppresses type I interferon responses by the 
inhibition of IFNAR signalling through the association of the MeV-accessory proteins C and 
V with the IFNAR1, which blocks the phosphorylation of JAK1 (Yokota  et al., 2003). In 
addition IFNAR-/- MEF and peritoneal macrophages show severe defects  in NDV-induced 
IFN-α/β gene expression (Harada et al., 1996).
 1.3.3.4 The antiviral effector molecules PKR, OAS1a and Mx1
The signalling through the IFNAR activates the inducible expression of hundreds of genes 
that together establish an antiviral state, i.e. an increased ability to resist viral infection (van 
Boxel-Dezaire et al., 2006; Stark et al., 1998). The exact function of many of these genes has 
not  yet  been  established,  but  for  some  molecules  the  antiviral  mechanisms  have  been 
demonstrated in detail. Three of these will be discussed in the following.
A well-studied IFN-induced antiviral effector that is induced by IFNs is the protein kinase 
PKR (Clemens and Elia, 1997; Meurs et al., 1990). Activation of PKR by dsRNA leads to the 
phosphorylation  of  the  translation  initiation  factor  eIF-2α,  causing  the  blockade  of  the 
translation of most cellular and viral mRNAs. PKR has profound effects on cell growth and 
apoptosis (Garcia et al., 2006; Tan and Katze, 1999). Many viruses have developed strategies 
to downregulate the activity  of PKR so that  virus replication is  not compromised by this 
molecule (Gale and Katze, 1998; Langland et al., 2006). 
2´-5´ oligoadenylate synthetase (OAS) family proteins are induced by IFNs (Kumar  et al., 
2000;  Rebouillat  and Hovanessian,  1999)  and also have broad antiviral  effects.  They are 
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activated  by  dsRNA  and  produce  2´-5´  oligoadenylates  that  in  turn  activate  the  latent 
ribonuclease  RNase  L  by  inducing  its  dimerisation.  RNase  L  activation  results  in  the 
degradation  of  host  and  viral  mRNAs  (Samuel,  2001).  In  addition  RNase  L  has  been 
implicated in specific apoptotic actions (Zhou et al., 1997) which could also contribute to its 
antiviral effects.
A third group of IFN induced proteins with antiviral activities are the myxovirus resistance 
(Mx) proteins. These proteins are GTPases that were first discovered as anti-influenza virus 
effector molecules (Staeheli, 1990). Mx proteins inhibit myxovirus multiplication by blocking 
either viral nucleocapsid transport or viral RNA synthesis (Haller  et al., 1998). Mx proteins 
increase the resistance of cells against viruses of the Orthomyxoviridae (e.g. influenza A + C 
virus),  Rhabdoviridae  (e.g.  VSV)  or  Paramyxoviridae  (e.g.  measles  virus)  among  others 
(Samuel, 2001), although the mechanism of the antiviral effect has not yet been established. 
 1.3.4 The antiviral response upon NDV infection
Many viruses have developed strategies that limit the antiviral responses in the host cell by 
the interaction of viral  proteins with key molecules for the establishment  of an interferon 
response (Haller  et al.,  2006).  Paramyxoviruses can inhibit  the interferon response by the 
interaction of their V proteins with the cytosolic viral RNA receptor MDA5 (Andrejeva et al., 
2004; Yoneyama et al., 2005). In addition the V protein can interact with and inhibit STAT-
mediated signalling from the IFNAR (Horvath, 2004). The IFN antagonist activity of the the 
NDV V protein, which is derived from the P protein via RNA editing (Steward et al., 1993), 
is species specific and only inhibits the interferon response in avian and not in mammalian 
cells (Park et al., 2003).
NDV is  a  potent  inducer  of  type  I  interferons  in  mammalian  cells.  In  mouse cells  NDV 
stimulates IFN secretion in vitro in murine spleen cells and fibroblasts (Ito et al., 1982; Yeow 
et al., 1997) and in vivo NDV rapidly induces the transcription of IFN-β and IFN-α4 mRNA 
(Guha-Thakurta and Majde, 1997). In human tumour cells the induction of interferons as well 
as of HLA, cell adhesion molecules and chemokines could be observed after NDV infection 
(Washburn and Schirrmacher, 2002). In addition NDV induces interferon-stimulated antiviral 
proteins  such  as  MxA and PKR in  human PBMC and tumour  cells  (Fiola  et  al.,  2006). 
Antiviral  responses seem to be stimulated by dsRNA and by the NDV HN protein via a 
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hemagglutinin lectin-cell interaction (Fournier et al., 2003; Zeng et al., 2002a/b).
 1.3.5 The interferon response in tumour cells
As discussed before (chapter 1.2.3) NDV replicates selectively in cancer cells. However, the 
mechanism by which NDV kills human tumour cells and the role of IFN in the spread of the 
virus in mammalian cells is not entirely known. Many tumour cells have acquired defects in 
the interferon response that might give them a growth and survival advantage (Pansky et al., 
2000; Paucker et al., 1962; Pitha, 2000; Stojdl et al., 2000; Sun et al., 1998; Wagner et al., 
2004).  Since type I interferons are key components in the antiviral response of cells against 
NDV it has been suggested that defects in the interferon response make tumour cells much 
more susceptible to NDV infection than normal cells. For some viruses such as VSV it is 
known that defects in the interferon response of tumour cells determines tumour selective 
replication  and  oncolytic  effects  (Barber,  2005;  Wollmann  et  al.,  2007).  The  tumour 
selectivity  of  NDV  has  also  been  related  to  a  restricted  interferon  response  in  human 
fibrosarcoma  cells  (Krishnamurthy  et  al.,  2006)  or  in  human  MCF-7,  BT-20  and  Jurkat 
tumour cells (Fiola et al., 2006).
 1.4 Aims of the project
The exact mechanisms that underlie the tumour selective replication of NDV are not clear. 
There are indications that differences in the interferon response in normal and tumour cells 
play an important role for the differences in NDV susceptibility. The working hypothesis to 
explain the variations in NDV susceptibility is shown in figure 1-6. Normal mammalian cells 
have an intact interferon response that is activated upon NDV infection and that induces the 
expression of antiviral genes. These genes establish an antiviral state in the cell that limits 
NDV replication. In contrast the interferon response in tumour cells is limited, causing only a 
low level of antiviral gene expression that is not sufficient to establish an effective antiviral 
state.
19
Introduction                                                                                                                                    
In this thesis the NDV susceptibility and the expression of interferon-related antiviral genes 
should be investigated in different normal and tumour cells types. It should be found out if 
there  were  correlations  between  the  degree  of  NDV susceptibility  and  parameters  of  the 
interferon response such as the basal and inducible expression of cytosolic viral nucleic acid 
receptors,  type I IFNs, essential  type I interferon transcription factors or antiviral effector 
molecules. A possible correlation should be analysed first in a cell-type homogeneous system 
consisting of murine macrophages and macrophage-like tumour cells. In order to determine 
general  differences  in  antiviral  gene  expression  between normal  and tumour  cells  and to 
calculate the degree of correlation between viral and antiviral gene expression, several normal 
and  tumour  cells  should  be  analysed  before  and  after  NDV  infection.  The  functional 
significance of certain key components of the interferon response for NDV susceptibility and 
antiviral gene expression should be tested in murine knock out macrophages. In addition the 
expression of the human RIG-I molecule was related to the expression of NDV genes during 
infection of normal and malignant human cells.
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Figure 1-6: Working  hypothesis  to  explain  differences  in  NDV  susceptibility  between 
normal and tumour cells.
NDV replicates better in tumour than in normal cells. In the above model this is implicated by a recombinant 
EGFP-expressing NDV that leads to an EGFP signal in tumour but not in normal cells. The hypothesis is that 
normal cells induce a strong interferon response when danger signals such as viral dsRNA are detected. In the 
course of the antiviral response IFNs are secreted that induce an antiviral state in the cell due to the expression of 
interferon-stimulated  antiviral  genes.  In  tumour  cells  the  interferon  response  is  defective,  preventing  the 
establishment of an antiviral state and enabling NDV to replicate and express EGFP.
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 2 Materials
 2.1 Equipment
Binocular microscope Zeiss, Jena
Biological safety cabinet Baker, Sanford (USA)
Cell culture incubator Labotec, Göttingen
Cell homogeniser Ultra-Turrax® T25 basic IKA®-Werke, Staufen
Centrifuge Biofuge fresco Heraeus, Hanau
Centrifuge Megafuge 2.0R Heraeus, Hanau
ELISA reader Perkin-Elmer, Überlingen
Film developing machine Agfa, Cologne
Flow cytometer FACSCalibur Becton Dickinson, Heidelberg
Flow cytometer FACSScan Becton Dickinson, Heidelberg
Freezer -20 °C Liebherr, Biberach an der Riss
Freezer -80 °C Thermo Fisher Scientific, Karlsruhe
Gel dryer Hoefer Scientific Instruments, San Francisco  
(USA)
GeneAmp® 5700 Sequence Detection Perkin-Elmer, Überlingen
System
Glass pipettes Hirschmann, Eberstadt
Glassware Schott, Mainz
Heatable magnetic stirrer Heidolph Instruments, Schwabach
Heat block Grant Instruments, Cambridgeshire (England)
Milli-Q water purification system Millipore, Eschborn
Mikrowave oven Bosch, Heidelberg
Neubauer cell counting chamber B. Braun, Melsungen
pH meter Wissenschaftliche  Technische  Werkstätten,  
Weilheim
Pipettes (2 – 1000 µL) Eppendorf, Hamburg
Pipetting aid Pipetboy acu INTEGRA Biosciences, Fernwald
Photometer GeneQuant pro Amersham Biosciences, Freiburg
Power supply for electrophoresis Pharmacia, Freiburg
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Quartz cuvette Hellma; Fa. Migge, Heidelberg
Scales Mettler-Toledo, Giessen
SDS-PAGE electrophoresis equipment Biorad, Munich
Shaker Mixer 5432 Eppendorf, Hamburg
Shaker Reax 2000 Heidolph Instruments, Schwabach
Table centrifuge WiFug, Sweden
Thermocycler PTC-100 MJ Research, Inc., Watertown, Mass. (USA)
UV transilluminator (254 nm) Bachofer, Reutlingen
Water baths Grant Instruments, Cambridgeshire (England)
Western blot equipment Biorad, Munich
 2.2 Software
Basic Local Alignment Search Tool National Center for Biotechnology
(BLAST), Web Interface Information, Bethesda, MD (USA)
Cellquest Pro 4 Becton Dickinson, Heidelberg
GeneAmp® 5700 SDS 1.3 PerkinElmer Wallac, Freiburg
GraphPad Prism 3 GraphPad Software Inc., San Diego (USA)
ImageJ 1.37 Wayne Rasband, National Institutes of Health
(USA)
Microsoft Excel 2000 Microsoft Corporation, Unterschleißheim
OpenOffice 2.0 Sun Microsystems, Berlin
Primer3, Web Interface Whitehead Institute for Biomedical  Research,
Cambridge, MA (USA)
WinMDI 2.8 Joe Trotter, The Scripps Research Institute, La 
Jolla, California (USA)
 2.3 Consumables
Aluminium foil Forti Folien, Neuruppin
Cell scrapers Renner, Dannstadt
Cell culture flasks (25, 75 and 125 cm2) Renner, Dannstadt
Cell culture dishes Renner, Dannstadt
Cell culture plates (6, 12, 24 and 48 well) Renner, Dannstadt
Cell strainer (40 µm) Becton Dickinson, Heidelberg
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Centrifuge tubes (15 and 50 mL) Greiner, Frickenhausen
Cover slips R. Langenbrinck, Teningen
Cryo vials Costar, Cambridge
Disposable scalpels PfM AG, Cologne
FACS tubes Greiner, Frickenhausen
Injection needles (Ø 0.3 – 0.7 mm) Becton Dickinson, Heidelberg
Laboratory gloves Kimberly-Clark, Zaventem (Belgium)
LeucoSep centrifuge tubes Greiner, Frickenhausen
Micro test tubes (1.5 – 2.0 mL) Eppendorf, Hamburg
Nitrocellulose membrane Schleicher & Schüll, Dassel
Parafilm American National Can, Greenwich (USA)
Pasteur pipettes Carl Roth, Karlsruhe
Petri dishes Renner, Dannstadt
Pipette tips (1 – 1000 µL) Greiner, Frickenhausen
Pipette filter tips (1 – 1000 µL) Starlab, Ahrensburg
Real-time PCR plates, 96 well Biozym, Hessisch-Oldendorf
Slides Renner, Dannstadt
Syringes (1 – 2 mL) Becton Dickinson, Heidelberg
(5 – 50 mL) Terumo, Leuven (Belgium)
Syringe-driven filter units, pore size 22 µm Millipore, Eschborn
Whatman 3MM paper Schleicher & Schüll, Dassel
X-ray film Amersham Biosciences, Freiburg
 2.4 Chemicals
Acrylamide Carl Roth, Karlsruhe
Agarose Gibco BRL, Eggenstein
ε-Aminocaproic acid Sigma-Aldrich, Schnelldorf
APS Serva, Heidelberg
Bromine phenol blue Serva, Heidelberg
DMSO Merck, Darmstadt
ECL Amersham Biosciences, Freiburg
EDTA Merck, Darmstadt
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Ethanol, p.a. Merck, Darmstadt
Ethidium bromide solution (10 mg/mL) Merck, Darmstadt
Ficoll Paque Plus Pharmacia, Freiburg
GelCode® Blue Stain Reagent Pierce, Bonn
Glacial acetic acid Merck, Darmstadt
Glycerol Merck, Darmstadt
Glycine Carl Roth, Karlsruhe
HEPES Merck, Darmstadt
High-Range Rainbow™ protein marker Amersham Biosciences, Freiburg
Isopropanol, p.a. Merck, Darmstadt
β-Mercaptoethanol Gibco BRL, Eggenstein
Methanol, p.a. Merck, Darmstadt
Molecular weight marker for Western blot Amersham Biosciences, Freiburg
(High-Range Rainbow™)
Milk powder Carl Roth, Karlsruhe
PBS powder Biochrom, Berlin
Potassium chloride Merck, Darmstadt
di-Potassium hydrogen phosphate Merck, Darmstadt
Propidium iodide Sigma-Aldrich, Schnelldorf
SDS, 10 % Merck, Darmstadt
Sodium azide Merck, Darmstadt
Sodium chloride Merck, Darmstadt
di-Sodium hydrogen phosphate Merck, Darmstadt
Sodium hydroxide pellets Carl Roth, Karlsruhe
TEMED Sigma-Aldrich, Schnelldorf
Tris-Base Sigma-Aldrich, Schnelldorf
Tris HCl Sigma-Aldrich, Schnelldorf
Trypan blue Serva, Heidelberg
Trypsin-EDTA solution, sterile Life Technologies, Karlsruhe
Tween20 Merck, Darmstadt
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 2.5 Commercial kits
Name Used for Provider
Plasmid Maxi Kit Preparation of plasmids from bacteria Qiagen, Hilden
QIAprep Spin Miniprep 
Kit Preparation of plasmids from bacteria Qiagen, Hilden
QIAquick Gel 
Extraction Kit Preparation of DNA from agarose gels Qiagen, Hilden
RNeasy Mini Kit Preparation of RNA from cells or tissues Qiagen, Hilden
qRT-PCR Core Kit Real-time PCR amplification and detection of DNA
Eurogentec, Seraing 
(Belgium)
qRT-PCR Core Kit for 
SYBR® green
Real-time PCR amplification and 
detection of DNA
Eurogentec, Seraing 
(Belgium)
 2.6 Enzymes / Reagents
CellLytic™-M Sigma-Aldrich, Schnelldorf
dNTP Mix Invitrogen, Karlsruhe
jetPEI™ transfection reagent Biomol, Hamburg
Lipofectamine™ 2000 transfection reagent Invitrogen, Karlsruhe
Oligo(dT)12-18 Primer Invitrogen, Karlsruhe
Protease Inhibitor Cocktail for use with Sigma-Aldrich, Schnelldorf
mammalian cell and tissue extracts
RNAlater Ambion, Austin, Rexas (US)
RNaseOUT Recombinant Ribonuclease Invitrogen, Karlsruhe
Inhibitor
SuperScript™ II Reverse Transcriptase Invitrogen, Karlsruhe
 2.7 Oligonucleotides
 2.7.1 Primer pairs used for quantitative real-time PCR
Name Species Gene Primer [nM] MgCl2 [mM]
Arbp_1/2 Mouse Acidic ribosomal phosphoprotein PO 600 3.5
β-2-microg_1/2 Mouse β-2-Microglobulin 300 3.5
bactin_1/2 Mouse β-Actin 300 4.0
hb-actin_1/2 Human β-Actin 300 3.5
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Name Species Gene Primer [nM] MgCl2 [mM]
hRIG-I_11/12 Human Retinoic acid-inducible gene I 600 3.0
IFNb_1/2 Mouse Interferon β 300 3.5
IRF3_7/8 Mouse Interferon regulatory factor 3 300 4.5
IRF7_1/2 Mouse Interferon regulatory factor 7 300 3.5
LGP2_5/6 Mouse D11lgp2 300 3.5
matrix_1/2 NDV NDV matrix protein 300 4.0
mda-5_1/2 Mouse Melanoma differentiation-associated gene-5 300 3.5
Mx_1/2 Mouse Myxovirus (influenza virus) resistance 1 600 4.5
OAS1a_5/6 Mouse 2'-5' Oligoadenylate synthetase 1A 300 3.5
PKR_3/4 Mouse Protein kinase PKR 300 3.5
RIG-I_3/4 Mouse Retinoic acid-inducible gene I 300 3.5
The  primers  were  either  designed  with  the  Primer3  software  (optimised  for  a  melting 
temperature of 60 °C) based on the respective mRNA sequence (as in the NCBI nucleotide 
database)  or  they  were  taken  from  publications.  The  primers  were  ordered  from MWG 
Biotech, Ebersberg bei München. The sequences and a detailed description of the primers and 
their origin can be found in the appendix (see table 7.2.1).
 2.7.2 Labelled oligonucleotides used for quantitative real-time PCR
Gene Species Detection chemistry Oligo [nM]
β-Actin Mouse FAM-TAMRA 100
Matrix protein NDV FAM-TAMRA 100
The sequences and a detailed description of the primers can be found in the appendix (table 
7.2.2).
 2.8 Plasmids
Human RIG-I wildtype and kindly provided by Dr. Takashi Fujita, Tokyo 
human RIG-I IKA-mutated Metropolitan Organization for Medical 
Research, Tokyo (Japan)
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EGFP expression plasmid 'psuperEGFP' kindly provided by Prof. Peter Altevogt, 
DKFZ Heidelberg
Plasmid 241 (coding for an anti-CD3-IL2 own production
construct)
 2.9 Antibodies
Primary antibodies
Mouse anti-NDV HN, IgG2a, clone HN.B Ioro (USA), own production
Rat anti-mouse F4/80 Cedarlane Laboratories, Burlington (Canada)
Secondary antibodies
Goat F(ab')2 anti-mouse IgM, IgG, IgA Southern Biotech, Birmingham (USA)
(H+L), PE-conjugated
Goat anti-rabbit IgG, PO-conjugated Dianova, Hamburg
Polyclonal antibodies
Rabbit anti-human RIG-I AXXORA, Lörrach
Antibodies for media supplementation
Anti-mouse IFN-α, hybridoma clone 4EA1 kindly provided by Prof. Rainer Zawatzky, 
DKFZ Heidelberg
Anti-mouse IFN-β, hybridoma clone 7FD3 kindly provided by Prof. Rainer Zawatzky, 
DKFZ Heidelberg
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 2.10 Cell culture media and supplements
 2.10.1 Media
αMEM Cambrex, Verviers (Belgium)
DMEM Gibco Invitrogen, Karlsruhe
RPMI 1640 Gibco Invitrogen, Karlsruhe
 2.10.2 Media supplements
FCS Gibco Invitrogen, Karlsruhe
HEPES Gibco Invitrogen, Karlsruhe
Murine interferon-α4 Provided  by  Prof.  Dr.  Rainer  Zawatzky 
(Division  of  Viral  Transformation 
Mechanisms, German Cancer Research Center 
Heidelberg)
M-CSF-containing supernatant Prepared from M-CSF-producing L929 cells
β-Mercaptoethanol Sigma-Aldrich, Schnelldorf
Penicillin / streptomycin Gibco Invitrogen, Karlsruhe
 2.11 Cells
 2.11.1 Primary cells
Human PBMC Prepared from centrifuged human blood (buffy coat); blood was 
acquired from the blood bank in Heidelberg
Murine macrophages Generated from murine bone marrow cells
Murine bone marrow cells Prepared from murine bones
Murine spleen cells Prepared from murine spleen
 2.11.2 Murine cell lines
B16 Skin melanoma; ATCC, Rockville (USA)
CT26 (p/wt) Colon carcinoma; ATCC, CT26wt from Rockville (USA); CT26p were kindly 
provided Dr. O. van Tellingen, The Netherlands Cancer Research Institute,  
Amsterdam (The Netherlands)
DA3 Breast adenocarcinoma (strain DBA/2); ATCC, Rockville (USA)
Eb Non-metastasising T cell lymphoma (Schirrmacher et al., 1979)
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Esb 289 Highly metastasising T cell lymphoma (Larizza et al., 1984)
L929 Fibroblast; ATCC, Rockville (USA)
J774A.1 Macrophage-derived  reticulum  cell  sarcoma  (strain  BALB/c);  ATCC,  
Rockville (USA)
MEF Embryonic fibroblast (strain C57BL/6); ATCC, Rockville (USA)
NIH/3T3 Embryonic fibroblast; ATCC, Rockville (USA)
RAW 264.7 Macrophage-derived Abelson murine leukemia virus-induced tumour (strain  
BALB/c); ATCC, Rockville (USA)
 2.11.3 Human cell lines
Hela Cervical adenocarcinoma; ATCC, Rockville (USA)
Jurkat Lymphoblastoid T cell lymphoma; ATCC, Rockville (USA)
MCF-7 Breast adenocarcinoma; ATCC, Rockville (USA)
U937 Histiocytic lymphoma; ATCC, Rockville (USA)
 2.12 Newcastle Disease Virus strains
NDV strains can be differentiated on the basis of their pathogenicity for chickens into strains 
of high (velogenic), intermediate (mesogenic) or low (lentogenic) virulence. The following 
strains of NDV were used in this thesis:
NDFL-EGFP Lentogenic  recombinant  strain  expressing  the  jellyfish  EGFP  protein, 
based on the NDV strain LaSota, provided by Dr. Ben Peeters (Institute 
for Animal Science and Health, Lelystad (The Netherlands)), see also Al-
Garib et al., 2003
NDFLtag-EGFP Mesogenic  recombinant  strain  expressing  the  jellyfish  EGFP  protein, 
based on the NDV strain LaSota, provided by Dr. Ben Peeters (Institute 
for Animal Science and Health, Lelystad (The Netherlands)), see also Al-
Garib et al., 2003
NDV Italien Velogenic strain, provided by H.D. Klenk (University of Giessen)
NDV Ulster Lentogenic  strain,  provided  by  Dr.  P.  Russell  (Department  of 
Microbiology and Parasitology, Royal Veterinary College, University of 
London (England))
 2.13 Mouse strains
BALB/c wildtype Fa. Charles River, Sulzfeld
B6/129 mixed background IFNAR-/- Provided by Prof. Dr. Rainer Zawatzky (Division of 
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Viral Transformation Mechanisms, German Cancer 
Research Center Heidelberg)
C57BL/6 knock out mice Provided by Dr. Anne Krug (Institute for Medical 
(IRF3-/-, IRF7-/-, TLR3-/-, TLR7-/-) Microbiology, Immunology and Hygiene, Technical 
University Munich)
C57BL/6 wildtype Fa. Charles River, Sulzfeld
DBA/2 wildtype Fa. Charles River, Sulzfeld
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 3 Methods
 3.1 Molecular biological methods
 3.1.1 Buffers and solutions
TAE, 50x 242 g/L Tris base
37.2 g/L Na2EDTA*2H2O
57.1 mL/L glacial acetic acid
in ddH2O, pH 8.5, storage at room temperature
 3.1.2 Preparation of agarose gels
For a 1 % (w/v) gel 1 g agarose was dissolved in 100 mL 1x TAE buffer and was brought to 
boil  in  a  microwave oven to  melt  the  agarose.  After  cooling  down to  about  50 °C 1 µL 
ethidium bromide stock solution (10 mg/mL) was added and it  was mixed thoroughly but 
gently to avoid introducing bubbles. The agarose solution was poured into a clean, dry gel 
tray and allowed to set for about 30 minutes.
 3.1.3 Preparation of DNA from agarose gels
For the extraction of DNA from agarose gels the QIAquick Gel Extraction Kit from Qiagen 
was used according to the manufacturers instructions (Qiagen, www.qiagen.com, QIAquick® 
Spin Handbook as at July 2002).
 3.1.4 Preparation of total RNA from animal cells or tissues
Cell pellets were either frozen at -80 °C after removal of the medium or used immediately for 
RNA preparation.  Animal  tissue  samples were used immediately for  RNA preparation  or 
stored in RNAlater. For archival storage the tissue samples in RNAlater were kept first at 
4 °C for 1 – 2 days to enable the RNAlater to penetrate the tissue and then they were stored at 
-20 °C.
For the extraction of total RNA from animal cells or tissues the RNeasy Mini Kit from Qiagen 
was used according to the manufacturers instructions (Qiagen,  www.qiagen.com, RNeasy® 
Mini Handbook as at April 2006). For cells the 'Purification of Total RNA from Animal Cells 
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Using Spin Technology' protocol (pp. 25-30) was used and for animal tissues the 'Purification 
of Total RNA from Animal Tissues' protocol (pp. 39-44). The samples were homogenised 
using a rotor-stator homogeniser (21,500 rpm, step 3b in the protocol). The optional step 9 of 
the protocol was left out. In step 10 the RNA was eluted with 40 µL RNAse-free water and 
before  using  the  extracted  RNA  in  further  experiments  the  RNA  concentration  was 
determined photometrically (see chapter 3.1.7).
 3.1.5 Reverse transcription of total RNA
Total RNA was reversely transcribed using the SuperScript™ II Reverse Transcriptase from 
Invitrogen  according  to  the  manufacturers  instructions  (Invitrogen,  www.invitrogen.com, 
SuperScript™ II Reverse Transcriptase protocol as at 11 November 2003). In general about 
500 ng total RNA per sample were reversely transcribed using oligo(dT)12-18 primers and the 
generated cDNA was used in subsequent PCR reactions.
 3.1.6 Quantitative real-time PCR
Quantitative  real-time  PCR  is  a  technique  to  quantify  a  specific  part  of  a  given  DNA 
molecule.  In  contrast  to  traditional  PCR  it  is  not  only  possible  to  determine  whether  a 
sequence  is  present  in  a  sample,  but  it  is  also  possible  to  determine  the  amount  of  this 
sequence. The PCR is termed 'real-time' since the DNA amount is measured after each cycle 
during the PCR and not only after the last cycle as in traditional PCR. When combined with 
reverse transcription quantitative real-time PCR can be used to determine gene expression by 
determining the mRNA amount of a gene in a given sample.
 3.1.6.1 Optimisation of the primer pairs
Only primers that bound just once in the genome when tested in a database search (BLAST, 
NCBI) were chosen for PCR. The primers were optimised to show a melting curve with one 
peak only (as in figure 3-1a) and to have approximately the same amplification efficiency as 
the gene used for normalisation (as in figure 3-1b, described in: User Bulletin #2, ABI PRISM 
7700  Sequence  Detection  System.  Applied  Biosystems,  December  11,  1997  (updated 
10/2001),  p.  11-15;  www.appliedbiosystems.com).  The  master  mix  was  prepared  as 
recommended by the manufacturer (Eurogentec, Seraing (Belgium)) and the concentrations 
for the primers and for MgCl2 were adjusted as described in the above table (2.7.1).
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 3.1.6.2 Relative quantification of mRNA content
For the quantification of the analysed genes the comparative cT method was used as described 
in  the  User  Bulletin  #2  for  the  ABI  Prism  7700  Sequence  Detection  System 
(www.appliedbiosystems.com, as at December 11, 1997 (updated 10/2001), p. 11-15). The 
amount of the target genes analysed throughout this thesis was mostly expressed as follows: 
relative gene expression = 2-ΔcT*1000, with ΔcT = cT (target gene) – cT (reference gene). The 
ratio of the relative gene expressions from different experiments can be used to compare the 
gene expression in these experiments. For example, if the gene expression is 40 REU (relative 
expression units) in experiment 1 and 80 REU in experiment 2, the gene expression is twice 
as high in the latter experiment.
In some cases the target gene expression was given relative to its  expression in a certain 
reference sample. For instance, in the kinetics of gene expression the time point 0 (t0) was 
often used as reference and the relative gene expression was calculated as 2-ΔΔcT, with ΔΔcT = 
ΔcT (t0) – ΔcT (sample).
The cT for the target and the reference gene in a sample was determined in triplicates and the 
cT was  set  as  the  mean  of  these  measurements  ± the  standard  deviation.  The  standard 
deviation of the ΔcT was calculated as follows: SDΔcT = SDcT12 + SDcT22 .
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Figure 3-1: Typical real-time PCR melting curve and amplification efficiency plot.
(A) Melting curve for the acidic ribosomal phosphoprotein PO (Arbp) amplicon generated during a real-time 
PCR. T = temperature (B) Correlation between the cT and the cDNA dilution for the NDV matrix (■) and the 
murine β-actin gene (▲), and relative efficiency plot for the two genes (♦).
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 3.1.7 Determination of nucleic acid concentration
The DNA/RNA concentration in a sample was determined photometrically via the absorbance 
at 260 nm (A260) using the following formula: concentration of RNA sample [µg/mL] = ε * 
A260 * dilution factor with εDNA = 50 and εRNA = 40. The ratio A260/A280 was taken as a measure 
of the purity of an RNA sample.
 3.2 Cell biological methods
 3.2.1 Buffers and solutions
PBS 8 g/L NaCl
0.2 g/L KCl
0.2 g/L KH2PO4
2.85 g/L Na2HPO4*12 H2O
in ddH2O, pH 7.2, storage at 4 °C
Freezing medium 20 % (v/v) DMSO
80 % (v/v) FCS
prepared freshly before use
Trypsin / EDTA 0.5 g/L trypsin
0.2 g/L EDTA
in sterile PBS, storage at 4 °C
Trypan blue solution 0.16 % (w/v) trypan blue
0.9 % (w/v) NaCl
0.1 % (w/v) NaN3
in ddH2O, filtered (0.45 µm), storage at 4 °C
RBC lysis solution 8.3 g/L NH4Cl
1 g/L KHCO3
0.037 g/L EDTA
in ddH2O, pH 7.2 – 7.4, autoclave, storage at 4 °C
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 3.2.2 Cell culture methods
 3.2.2.1 Culture of cells
All cells were grown at 37 °C in a cell incubator in a 5 % carbon dioxide / 100 % humidity 
atmosphere.  If  not  mentioned  otherwise  all  cell  culture  media  were  supplemented  with 
100 U/mL penicillin and 100 µg/mL streptomycin.  The FCS added to the media was heat 
inactivated  at  56 °C  for  1 h  before  use.  All  media  supplements  were  filtered  (pore  size: 
22 µm) before addition to the media.
Most adherent cells were detached from the surface of the cell culture flasks with the help of a 
trypsin / EDTA solution. Before the detachment the growth medium was removed and the 
cells were washed by the careful addition and subsequent removal of 10 – 20 mL PBS. Then 
40 µL trypsin / EDTA solution  per square centimetre surface was added and the cells were 
kept for 5 – 10 minutes at 37 °C in a cell incubator. When the cells were detached they were 
washed in 10 – 20 mL growth medium to inactivate the trypsin / EDTA and used for further 
experiments.
Murine macrophages
The murine macrophages used in the experiments were always generated from bone marrow 
cells.  They  were  generated  in  DMEM supplemented  with  10 % FCS and  20 % M-CSF-
containing L929 cell supernatant. The macrophages grew adherently and showed the typical 
spindle-like  morphology.  For  a  detailed  description  of  the  generation  and  culture  of 
macrophages see chapter 3.2.3. 
Murine spleen and bone marrow cells
The murine spleen and bone marrow cells were cultured in RPMI 1640 supplemented with 
10 % FCS. Both cell populations consisted of round cells of varying size that did not adhere 
to the surface of the cell culture dishes. Since the two cell populations did not proliferate and 
were mostly cultured for two days at the most, no splitting was necessary.
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J774A.1, RAW 264.7 cells
The macrophage-like J774A.1 and RAW 264.7 cells grew adherently and were cultured in 
DMEM supplemented with 10 % FCS. Originally the J774A.1 were derived from a reticulum 
cell sarcoma and the RAW 264.7 cells were induced by Abelson murine leukemia virus. They 
showed a heterogeneous morphology ranging from round to spindle-like forms. In order to 
culture the cells they were harvested when the cell layer in the cell culture flask was 80 – 
90 % confluent. To harvest the cells from the flask the growth medium was removed and the 
cell layer was washed once with PBS. Then PBS was added again (e.g. 10 mL PBS for a flask 
with 75 cm2 surface area) and the cells were carefully detached from the surface with a cell 
scraper. After washing once with 10 – 20 mL growth medium (250 g, 5 min.) 1/5th to 1/20th of 
the cells were transferred into a new cell culture flask.
MEF, NIH/3T3 and L929 cells
These three mouse fibroblast cell lines grew adherently and were harvested using trypsin / 
EDTA  solution  when  there  was  a  confluent  monolayer.  They  were  cultured  in  DMEM 
supplemented with 10 % FCS and usually split 1:10 twice every week.
CT26wt/p, DA3, Eb and Esb cells
The CT26wt/p and DA3 mouse tumour cell lines grew adherently and were harvested using 
trypsin / EDTA solution. The two murine colon carcinoma cell  lines CT26wt and CT26p 
differed in their origin (see 2.11.2). They were cultured in DMEM with 10 % FCS and split 
1:10 twice every week. The mouse breast carcinoma cell line DA3 was grown in RPMI 1640 
with 10 % FCS supplemented with  β-mercaptoethanol in a final concentration of 0.05 mM 
and split twice every week 1:15. The murine non-metastasising T cell lymphoma cell line Eb 
and  the  highly  metastasising  Esb  289  cell  line  grew  in  suspension  in  RPMI  1640 
supplemented with 10 % FCS. For the Esb cells the growth medium was also supplemented 
with 0.05 mM β-mercaptoethanol. Both cell lines were split 1:10 twice a week.
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Jurkat, U937, MCF-7 and Hela cells
The human T cell lymphoma cell line Jurkat and the human histiocytic lymphoma cell line 
U937 grew in suspension and were cultured in RPMI 1640 with 10 % FCS. They were split 
1:10 twice a week. The human breast carcinoma cell line MCF-7 and the human cervical 
adenocarcinoma cell  line Hela grew adherently and were harvested using trypsin / EDTA 
solution. They were cultured in RPMI 1640 with 10 % FCS and were split twice a week 1:8. 
 3.2.2.2 Freezing and thawing of cells
In order to freeze mammalian cells, 1*106 to 1*107 cells were suspended in 500 µL of the 
respective growth medium. To the cell suspension 500 µL freezing medium (see  3.2.1) was 
added and the samples were transferred immediately to -80 °C. After one week at -80 °C the 
cells were transferred to liquid nitrogen containers and stored at -196 °C.
In order to thaw cells,  37 °C warm growth medium was added to the frozen cells  with a 
Pasteur pipette. One washing step was performed in 10 mL growth medium (250 g, 5 min.) to 
remove the DMSO. After that the cells were seeded in fresh medium in a cell culture flask.
 3.2.2.3 Determination of cell number and viability
Cells were counted with the help of a hemocytometer (Neubauer cell counting chamber, depth 
0.1 µL) and an optical microscope. To distinguish live and dead cells, trypan blue was added 
to the cell suspension in different dilutions ranging from 1:2 up to 1:10. Trypan blue stains 
only dead cells. The suspension was diluted enough so that the cells did not overlap each 
other on the counting grid. Cells that overlapped the top or left ruling of a large square were 
counted, whereas cells overlapping the bottom or right ruling were not counted. At least 100 
living cells were counted for each sample in order to produce a statistically significant count. 
The cell titre was calculated using the following formula:
Cells [mL-1] =
Total cell count
Number of counted large squares
 ∗ Dilution factor  ∗ 104 .
The viability of a cell population could be determined by calculating the percentage of living 
cells.
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 3.2.3 Generation of macrophages from murine bone marrow cells
The macrophages used for this thesis were always generated from murine bone marrow cells. 
4*106 freshly  harvested  bone  marrow cells  were  seeded  into  10 cm diameter  cell  culture 
dishes and were grown for 8 – 12 days in RPMI 1640 with 10 % FCS and 20 % M-CSF 
containing supernatant from L929 cells. After removal of the medium the macrophages were 
harvested in PBS with a cell scraper and washed once in growth medium (250 g, 5 min.). 
Before the use in further experiments the phenotype was tested with an anti-F4/80 antibody.
To generate the L929 supernatant, a dense L929 cell monolayer was split 1:10 and then grown 
for one week in DMEM with 10 % FCS. Then the supernatant was harvested, centrifuged 
(250 g, 5 min.) and used in further experiments. 
 3.2.4 Generation of supernatant containing anti-IFN-α and anti-IFN-β 
antibodies
To generate supernatant containing anti-IFN-α and anti-IFN-β antibodies for blocking assays, 
7FD3 and 4EA1 hybridoma cells were grown in RPMI 1640 with 10 % FCS until there was a 
dense monolayer. Then the cells were harvested using trypsin / EDTA solution and the cells 
were seeded again in a vessel  of the same size in RPMI 1640 without  FCS to avoid the 
presence of foreign proteins in the supernatant. After four days the supernatants was harvested 
and the cells were removed by centrifugation (250 g, 5 min.). Finally the neutralisation titre of 
the supernatants against mouse interferon was determined.
 3.2.5 Preparation of human PBMC
The human PBMC used in the experiments were prepared from buffy coats, a fraction of a 
centrifuged blood sample that contains most of the leukocytes.  LeucoSep centrifuge tubes 
were filled with 15 mL Ficoll solution and centrifuged shortly (250 g, 1 min.). The buffy coat 
was diluted 1:4 in serum-free RPMI 1640 and loaded onto the prepared LeucoSep tubes with 
35 mL volume per tube. The tubes were centrifuged (800 g, 20 min., no brake), leading to an 
interphase enriched in PBMC between the Ficoll solution and the plasma. This interphase was 
collected with a Pasteur pipette and washed with serum-free RPMI 1640 (800 g, 10 min.). 
Two more washing steps with serum-free RPMI 1640 followed (250 g, 5 min. and 100 g, 
5 min.). The cell pellet was resuspended in PBS and filtered with a cell strainer (40 µm).
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 3.2.6 Transfection of mammalian cells with jetPEI
To transfect mammalian cells with plasmid DNA, the cationic polymer transfection reagent 
jetPEITM was  used  according  to  the  manufacturers  instructions  (PolyPlus,  www.polyplus-
transfection.com, In vitro Transfection Protocol, Ref: CPT 101, Version H). The transfections 
were usually carried out on a 12 to 24 well scale.
 3.2.7 Determination of interferon in supernatants
The determination of biologically active interferon was done in the laboratory of Prof. Dr. 
Rainer Zawatzky, Division of Viral Transformation Mechanisms, German Cancer Research 
Center Heidelberg. The assay was based on the induction of an antiviral state in murine L929 
cells protecting against subsequent VSV infection.
The supernatants to be tested were diluted in steps of two and these dilutions were given to 
L929  cells  over  night.  In  parallel  a  dilution  series  of  a  solution  with  known  IFN-α/β 
concentration was used to later generate a standard curve. The next day VSV was added to all 
pretreated L929 cells and cell lysis was measured 2 days later. The dilution of a supernatant 
that protected 50 % of the cells against lysis contained by definition 1 IU/mL interferon. The 
standard  curve  generated  with  the  known  amounts  of  IFN-α/β  was  used  to  correct  for 
variations in interferon responsiveness of the L929 cells in different assays.
 3.3 Virological methods
 3.3.1 Production of NDV stocks
The different NDV strains used in this thesis were propagated in embryonated chicken eggs. 
Fertilised eggs  were first  incubated for  10 days  at  37 °C and 62 % humidity.  During this 
period they were turned over every 4 hours. At day 10 the eggs were candled to sort out dead 
embryos and to mark the air cell on the eggshell. Through the air cell 100 µL of an NDV 
inoculation stock was injected into the egg and the puncture in the shell  was sealed with 
paraffin. After further incubation for 3 days the eggs were incubated for 4 hours at 4 °C to kill 
the  embryos.  The  eggshell  above  the  air  cell  was  removed  and  the  allantoic  fluid  was 
harvested  with  a  Pasteur  pipette.  Debris  was  removed  from  the  allantoic  fluid  by 
centrifugation (1800 g, 30 min., 4 °C) and the NDV was sedimented by ultra-centrifugation 
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(50000 g, 1 h, 4 °C). The NDV pellet was resuspended in 0.5 mL PBS and purified by ultra-
centrifugation (97000 g, 1 h, 4 °C) on a saccharose cushion. The band containing the NDV 
particles was harvested and the NDV was sedimented again by ultra-centrifugation (50000 g, 
1 h, 4 °C). The NDV pellet was resuspended in a PBS / 0.1 % EDTA solution and the NDV 
amount was quantified by a hemagglutination assay (see chapter 3.3.2). Thereafter, the NDV 
solution was diluted and divided up into appropriate aliquots if desired and the virus solutions 
were kept at -70 °C or in liquid nitrogen for archival storage.
 3.3.2 NDV quantification with the hemagglutination assay
After NDV production the virus amount was determined in a hemagglutination assay that uses 
the ability of NDV to adsorb to and agglutinate sheep erythrocytes. Sheep erythrocytes were 
washed twice in PBS and adjusted to a concentration of 1 % (w/v) in PBS. In 96 well round 
bottom plates  1:2  PBS  dilution  series  of  the  virus  samples  to  be  tested  were  seeded  in 
duplicates.  Then the 1 % sheep erythrocyte  solution was added to the  wells  and after  an 
incubation  period  of  60  –  90  minutes  at  room temperature  the  virus  titre  was  read  out. 
1 hemagglutination  unit  (HU)  was  defined  as  the  smallest  virus  concentration  leading  to 
visible sheep erythrocyte agglutination.
 3.3.3 Infection of cells with NDV
Cells were washed with serum-free growth medium (250 g, 5 min.) and counted. The cells 
were then mixed with  the  respective  amount  of  NDV in 100 µL serum-free  medium per 
106 cells. The mixture was kept at 37 °C for 1 h and every 15 minutes during that time the 
samples were homogenised with a cell shaker. The cells were washed twice in their respective 
growth  medium  and  for  NDV  binding  assays  the  infected  cells  were  now  used  in  flow 
cytometric analysis. For the study of viral replication the infected cells were seeded into cell 
culture flasks or plates to be harvested at a later time point for analysis.
 3.3.4 UV inactivation of NDV
NDV was UV inactivated for some experiments by exposure for 5 min. to UV-light (254 nm, 
2 mW/cm2, 7 cm distance). After UV inactivation the virus particles were thought to be intact 
but the NDV was no longer able to replicate due to irreparable damage to its RNA genome.
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 3.4 Protein chemical methods
 3.4.1 Buffers and solutions
SDS poly-acrylamide gel electrophoresis
Acrylamide solution 37.5 % acrylamide
1 % bis-acrylamide
Sample buffer, 2x 0.5 M Tris HCl (pH 6.8)
10 % (w/v) glycerol
2 % SDS
5 % β-mercaptoethanol
0.1 % (v/v) bromophenol blue
storage at 4 °C
Separating gel (12.5 %) 4.525 mL ddH2O
4.15 mL acrylamide/bis-acrylamide
1.325 mL Tris HCl (3 M, pH 8.8)
0.1 mL SDS (10 %)
40 µL APS
5 µL TEMED
Stacking gel 3 mL ddH2O
0.675 mL acrylamide/bis-acrylamide
1.25 mL Tris HCl (0.5 M, pH 6.8)
50 µL SDS (10 %)
50 µL APS
5 µL TEMED
Electrophoresis buffer 25 mM Tris-HCl (pH 8.3)
0.19 M glycine
0.1 % (w/v) SDS
storage at room temperature
Western blot
Buffer 1 0.04 M ε-aminocaproic acid
0.025 M Tris HCl
pH 9.4, storage at room temperature
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Buffer 2 0.3 M Tris HCl
pH 10.4, storage at room temperature
Buffer 3 0.025 M Tris HCl
pH 10.4, storage at room temperature
TBS solution 10 mM Tris HCl
150 mM NaCl
pH 8.0, storage at room temperature
T-TBS solution (0.1 %) 0.1 % (v/v) Tween 20
in TBS
Blocking buffer (5 %) 5 % (w/v) powdered milk
in T-TBS (0.05 %)
 3.4.2 Generation of cell lysates
Cells  were  harvested,  washed  once  in  PBS  (250 g,  3 min.)  and  counted.  The  PBS  was 
removed again by centrifugation (250 g, 3 min.) and 125 µL CellLytic™-M (mixed with 2 % 
(v/v) Protease Inhibitor Cocktail) was added per 1*107 cells. The cells were homogenised in 
the buffer by pipetting up and down and then they were incubated for 15 minutes on a shaker 
at room temperature. After centrifugation in a table centrifuge (16.000 g, 15 min.) the protein-
containing supernatant was transferred to a chilled test tube and stored at -80 °C.
 3.4.3 Bradford protein assay
The  Bradford  protein  assay  is  a  method  commonly  used  to  determine  the  total  protein 
concentration  of  a  sample.  The  assay  is  based  on  the  observation  that  the  absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 
595 nm when binding to protein occurs. Both hydrophobic and ionic interactions stabilise the 
anionic form of the dye, causing a visible colour change. Within the linear range of the assay 
it can be assumed that the more protein is present, the more Coomassie dye binds to proteins.
Standardised  samples  with  known  FCS  concentration  (0.1  –  1.4 mg/mL)  were  used  to 
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generate a standard curve. 100 µL of the standardised and the test samples were transferred 
onto a 96 well flat bottom plate in duplicates. Then 100 µL Coomassie Brilliant Blue was 
added to each well and after 5 minutes the absorbance at 595 nm was read out in an ELISA 
reader.
 3.4.4 SDS poly-acrylamide gel electrophoresis
SDS poly-acrylamide gel electrophoresis (SDS-PAGE) is used to determine the molecular 
weight and the purity of proteins. SDS is used to denature the proteins to the same linear 
shape and to coat them with many negative charges. In poly-acrylamide the proteins migrate 
towards the positive pole when an electric field is applied and the migration speed depends 
only  on  the  size  of  the  protein.  The  separation  starts  in  an  ion  gradient  to  enhance  the 
sharpness of the protein bands within the stacking gel, which represents a rather wide-meshed 
polymer. The actual separation takes place in the fine-meshed separating gel.
The separating gel was prepared as described earlier (3.4.1) and poured into the gel cassette 
until the gel level reached a position of about one centimetre from the bottom of the comb that 
would form the loading wells. After solidification the stacking gel was poured on top and also 
allowed  to  solidify.  The  cassette  with  the  complete  gel  was  fixed  in  the  electrophoresis 
chamber which was then filled with electrophoresis buffer. The samples were mixed 1:1 with 
sample buffer and heated for 5 minutes at 95 °C. 20 µL of these samples were loaded into the 
wells  and  a  molecular  weight  marker  was  loaded  in  parallel  in  a  separate  well.  The 
electrophoresis was run with a constant current of 75 mA until the bromophenol blue of the 
sample buffer had run out of the gel. At that point the electrophoresis was stopped and the 
separating gel was taken out of the cassette.
 3.4.5 Staining of poly-acrylamide gels with Coomassie
The gels were washed three times for 20 minutes in distilled water on a shaker (50 rpm) and 
then they were incubated for 45 minutes in 20 mL of the GelCode® Blue Stain Reagent. Then 
the gels were washed three times for 30 minutes in distilled water.
 3.4.6 Drying of gels
To preserve the gels they were placed on a piece of Whatman paper and covered with cling 
film. The gels were then dried at 80 °C for 30 minutes in a vacuum gel drier.
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 3.4.7 Western blot
 3.4.7.1 Transfer of proteins onto anitrocellulose membranes
After  gel  electrophoresis  (3.4.4)  the  separating  gel  was  transferred  onto  a  nitrocellulose 
membrane using a semi-dry apparatus. 6 sheets of Whatman paper were soaked in buffer 2 
and three sheets were soaked in buffer 3. The pre-wetted paper sheets were then placed on the 
graphite plate constituting the anode without the inclusion of air bubbles. The next layer was 
the nitrocellulose membrane that had been washed in buffer 3 and pre-wetted in methanol. On 
the membrane the separating gel  was placed after  pre-wetting in buffer  3.  The last  layer 
consisted of 9 sheets of Whatman paper that had been soaked in buffer 1. On top the cathode 
plate  was  placed and the blot  was  run for  90 minutes  at  0.8  mA/cm2.  After  the  blotwas 
finished the bands of the molecular weight marker were marked on the membrane.
 3.4.7.2 Staining of nitrocellulose membranes
After the protein transfer the nitrocellulose membranes were blocked for one hour in 5 % 
blocking buffer on a shaker (50 rpm). Then the primary antibody binding to the protein of 
interest was diluted in 10 mL of 5 % blocking buffer and added to the membranes.  After 
incubating for 2 hours at room temperature or over night at 4 °C the membranes were washed 
once for  15 minutes  in  0.1 % T-TBS solution and twice for  5  minutes  in  0.05 % T-TBS 
solution.  A  peroxidase-conjugated  secondary  antibody  was  diluted  in  10 mL  of  2.5 % 
blocking buffer (0.08 µg antibody / mL) and added to the membranes for one hour at room 
temperature. The membranes were washed again once in 0.1 % T-TBS solution and twice in 
0.05 % T-TBS solution.
Detection was carried out with the ECL system. The detection solutions were mixed 1:1 and 
given to the membranes for one minute. Excess solution was removed with paper towels and 
the membranes were placed in cling film. The chemiluminescence on the membranes was 
detected with x-ray film and the time for development varied depending on the intensity of the 
chemiluminescence.
 3.4.7.3 Densitometric analysis of the Western blot films
The Western blot films were analysed with the ImageJ software (Wayne Rasband, National 
Institutes of Health). The films were scanned and then the digital image was inverted and 
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stored  in  TIF  format.  The  mean  signal  intensity  of  the  background  was  measured  and 
automatically subtracted from all subsequent measurements. Then an area was drawn around 
the largest band and the mean of the bands was determined be moving this area over the band 
to be analysed before measurement of the mean.
 3.5 Immunobiological methods
 3.5.1 Buffers and solutions
FACS buffer 5 % (v/v) FCS
0.1 % (w/v) NaN3
in sterile PBS, storage at 4 °C
PI solution 1 ng/µL propidium iodide
in PBS, lightproof storage at 4 °C
 3.5.2 Flow cytometry
 3.5.2.1 Determination of cell surface antigens with flow cytometry
Flow cytometry or FACS can be used to distinguish cells according to their size, structure, 
cell surface properties and internal composition. Often cells are labelled with antibodies that 
bind to certain cellular structures. These antibodies are either conjugated themselves with a 
fluorescing dye or are detected with a secondary antibody that is connected to a fluorescing 
dye. In addition cells can be labelled with fluorescing dyes that stain, for example, only dead 
cells. In a flow cytometer the cells are moving in a laminar flow and pass a laser beam. On the 
one hand the light excites the dyes that subsequently emit a fluorescence of a characteristic 
wave length that is detected by sensors. On the other hand the light is refracted by the cell 
depending on its size and granularity and the refraction can be used to determine the latter two 
properties of a cell.
In order to measure the fluorescence of cells  expressing EGFP or cells stained with dye-
labelled antibodies 1*105 to 1*106 cells per sample were resuspended in FACS buffer and 
loaded into FACS tubes. The cells were washed once in FACS buffer (250 g, 3 min., 4 °C) 
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and EGFP expressing cells were taken up in 200 µL FACS buffer and used immediately in 
flow cytometric analysis. To stain surface antigens the cells were resuspended in 40 µL FACS 
buffer containing an appropriate amount of the antibody (usually around 10 µg/mL) binding 
to the antigen in question. After incubation for 20 minutes on ice in the dark the cells were 
washed twice in FACS buffer (250 g, 3 min., 4 °C) and if the antibody was directly labelled 
with a fluorescing dye the cells were taken up in FACS buffer and analysed by FACS. If the 
primary antibody was not labelled, the cells were now resuspended in 40 µL FACS buffer 
containing a dye-labelled secondary antibody. After incubation for 20 minutes on ice in the 
dark the cells were washed twice in FACS buffer (250 g, 3 min.,  4 °C) and used in flow 
cytometry.
When the cells were analysed in a flow cytometer the settings were adjusted with unstained 
control  cells.  The forward and the side scatter  were adjusted  to distinguish the main cell 
populations  and  the  autofluorescence  of  the  cells  was  set  in  the  first  decade  of  the 
fluorescence channels. If the cells had been stained with more than one antibody and/or dye 
with overlapping fluorescence spectra, the signals in a channel derived from dyes other than 
the one to be measured in this channel were neutralised by compensation. For this purpose, 
samples that generated only a single fluorescence signal were used, for example cells that 
were only stained with one type of a dye-labelled antibody.
After  the settings and the compensation were completed,  10,000 to 100,000 cells of each 
sample were measured. The analysis  was carried out later on with the WinMDI 2.8 flow 
cytometry data analysis software.
 3.5.2.2 Determination of dead cells with propidium iodide
Propidium iodide can be used to distinguish dead and living cells in flow cytometry. Dead 
cells have disruptions in their cell and nuclear membrane and propidium iodide (PI) can enter 
the cells and intercalate in the DNA. Dead cells show therefore a fluorescence signal in the 
FACS channel three induced by the PI, whereas living cells have intact membranes and show 
no PI induced fluorescence signal in this channel.
Just  before  flow cytometry  PI  was  added to  the  cell  samples  in  FACS buffer  to  a  final 
concentration of 1 µg/mL.
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 3.6 In vivo experiments
 3.6.1 Preparation of murine spleen cells
Mice were sacrificed by CO2 inhalation and the fur was sterilised with 70 % ethanol. All the 
following steps were carried out under sterile conditions in a tissue culture hood. The mice 
were placed on a preparation pad and fastened with metal pins. They were then cut open on 
the ventral side through the skin and the peritoneum, and the spleen was taken out and placed 
in a 60 mm dish filled halfway with PBS. With a cell scraper the cells were carefully pushed 
out of the spleen by repeated strokes from the centre of the spleen towards its ends. This 
procedure was continued until all of the cells were in suspension in the PBS and only the 
outer skin of the spleen remained. The cell suspension was filtered with a 40 µm cell strainer 
to remove tissue residues. The cells were washed once in PBS (250 g, 5 min.) and to the cell 
pellet 1 mL RBC lysis buffer was added. After 1 minute the cells were washed in PBS (250 g, 
5 min.) and in growth medium (250 g, 5 min.) and then they were counted and used in the 
subsequent experiments.
 3.6.2 Preparation of murine bone marrow cells
To prepare  bone  marrow cells,  mice  were  sacrificed  by  CO2 inhalation  and the  fur  was 
sterilised with 70 % ethanol. All the following steps were carried out under sterile conditions 
in a tissue culture hood. The mice were cut open and the femurs were taken out and placed in 
a 60 mm dish filled halfway with PBS. For sterilisation the femurs were first transferred in a 
60 mm dish filled with 70 % ethanol and after one minute they were again transferred into a 
new dish filled with PBS. In yet another dish filled with PBS the femurs were carefully cut at 
the ends and the bone marrow cells were flushed out with a syringe with a 0.4 mm Ø injection 
needle. The femurs were flushed three times from every end with 2 mL PBS.
After  flushing the  femurs  the  cell  suspension  in  the  dish was  filtered  with a  40 µm cell 
strainer to remove tissue residues. The cells were washed once in PBS (250 g, 5 min.) and to 
the cell pellet 1 mL RBC lysis buffer was added. After 1 minute the cells were washed in PBS 
(250 g, 5 min.) and in growth medium (250 g, 5 min.) and then they were counted.
 3.6.3 Organ preparation for RNA extraction
For organ preparation the mouse was sacrificed by CO2 inhalation and the fur was sterilised 
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with 70 % ethanol. The mouse was placed on a preparation pad and fastened with metal pins. 
It was then cut open on the ventral side through the skin and the peritoneum which were fixed 
with  metal  pins.  The  organs  such  as  liver,  kidney  or  spleen  were  removed  carefully  by 
severing their main blood vessels and their main tissue connections. To remove the lung the 
rib cage was cut open along the sternum and fixed on the side. The organs were placed on 
6 cm diameter petri dishes and 3 squares with an edge length of about 3 mm were cut from 
different regions of the organ with a disposable scalpel. This was done to get an average of 
the whole organ, for example, by taking one square of each the outer, middle and inner part of 
the organ. The organ samples were immersed in 500 µL RNAlater and kept at 4 °C for 1 – 2 
days before they were transferred to -20 °C for archival storage.
 3.7 Statistical methods
To test the statistical significance of the results, the p-value was calculated using the Student's 
t-test.  The  unpaired  t-test  was  employed  and  experimental  results  were  regarded  as 
statistically significant if the two-tail p-value was below 0.05. The groups that were compared 
were labelled in the figures and the exact p-values were given in the figures or in the legends. 
All error bars indicated the standard deviation if not mentioned otherwise.
Correlation  analyses  were  done  calculating  the  Pearson  product-moment  correlation 
coefficient  using the Microsoft  Excel  spreadsheet  software.  Correlations were regarded as 
strong if the absolute value of the correlation coefficient was higher than 0.5.
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 4 Results
 4.1 NDV infection of spleen and DA3 tumour cells
NDV can replicate substantially better in cancer cells than in most normal cells (Reichard et  
al.,  1992;  Schirrmacher  et  al.,  1999a).  The most  important  protection mechanism against 
NDV infection is the interferon response, which is mediated by the type I interferons IFN-α 
and IFN-β. Many tumour cells have acquired defects in the interferon response that might 
give  them a  growth  and  survival  advantage  (Fiola  et  al.,  2006,  Stojdl  et  al.,  2000).  To 
investigate a connection between NDV susceptibility and the antiviral interferon response in 
normal and tumour cells, primary mouse spleen cells and the murine mammary carcinoma 
cell  line DA3 were compared with regard to NDV infection and the expression of genes 
involved  in  the  antiviral  response.  Before  the  results  of  these  analyses  are  shown,  the 
sensitivity of the real-time PCR detection system will be examined, since most of the gene 
expression results were obtain with this technique.
 4.1.1 The sensitivity of the real-time PCR detection system
The gene expression in many different cell types and tissues was analysed in this thesis with 
the help of quantitative real-time PCR after reverse transcription of mRNA into cDNA. The 
PCR is a sensitive molecular biological method since the target DNA is amplified manifold 
and in theory one copy of target DNA is sufficient to yield a signal. In order to find out what 
the practical limit of detection for the real-time PCR system used for this thesis was, a dilution 
series of samples with known copy number was analysed for the expression of the NDV 
matrix and the murine β-actin gene. In addition, the copy number per cell for the murine β-
actin  gene  was  calculated  to  determine  the  lowest  number  of  cells  necessary  for  gene 
expression analysis.
The real-time PCR detection limit for the NDV matrix gene was determined with a plasmid 
containing the M gene sequence of the NDV strain La Sota (kindly provided by Ben Peeters, 
Institute for Animal Science and Health (ID-Lelystad), The Netherlands).  A 10-fold dilution 
series of this plasmid was tested in real-time PCR and the detection limit was found to be at 
4.98*10-11 µg plasmid. The plasmid was 6551 bp long and contained 1 copy of the M gene. 
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With  an  average  base  pair  weight  of  660 g/mol  the  detection  limit  for  the  M gene  was 
calculated  as  follows:  4.98*10-17 g  /  (6651 bp  *  660 g/mol)  *  NA =  6.83.  That  is,  about 
7 copies of the M gene per sample could still be detected with the real-time PCR system used 
in this thesis.
The  detection  limit  for  the  murine  β-actin  gene  that  was  used  to  normalise  the  M gene 
expression was determined with a PCR product amplified from murine cDNA containing a 
part of the β-actin gene. The PCR product had a length of 677 bp and was amplified using 
primers designed with the Primer3 software (forward primer: 5 ´-AGC CAT GTA CGT AGC 
CAT CC-3 ´; reverse primer: 5 ´-ACA TCT GCT GGA AGG TGG AC-3´). This PCR product 
was cut out from an agarose gel and after photometrically determining the DNA concentration 
a 10-fold dilution series of the amplicon was tested in real-time PCR. The detection limit was 
found to  be  at  2.4*10-17 g PCR product,  corresponding to a  copy number  of  2.4*10-17 g / 
(677 bp * 660 g/mol) * NA = 32.34. Hence, about  32 copies of the murine β-actin gene per 
sample could still be detected.
To estimate the number of mRNA copies in a tumour cell total RNA was extracted from one 
million DA3 mouse mammary carcinoma tumour cells. After reverse transcription of 240 ng 
total RNA, 3 out of 40 µL of a 1-500 dilution of the cDNA was used for the detection of β-
actin in real-time PCR. The ensuing cT (24.13) was used in the following formula derived 
from a standard curve generated with a dilution series of the above mentioned β-actin PCR 
product: copy number = 10  -0.3072 * cT +  11.876. Therefore, the β-actin mRNA copy number per 
DA3 cell  was  29,058*500*(40/3)/1*106 =  194 copies  per  DA3 cell.  Translated  into  cell 
numbers the detection limit for β-actin was 32/194 = 0.165 DA3 cells.
In conclusion it can be said that the real-time RT-PCR technology applied in this thesis was 
very sensitive and could detect down to a few copies of the NDV M gene and the murine β-
actin gene. It was also possible to analyse the gene expression of a single cell since the β-actin 
detection limit was at 1/6 cell. The exact number of cells that can still be detected per sample 
might vary depending on the cell type since cells with a larger volume such as certain tumour 
cells  can  be  expected  to  contain  more  β-actin  mRNA copies  than  normal  cells  and will 
therefore have a lower cell detection limit. 
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 4.1.2 NDV susceptibility
In general NDV can successfully infect only tumour cells, whereas primary, non-malignant 
cells are almost completely resistant to infection. In order to compare the susceptibility to 
NDV infection between primary murine spleen cells and murine mammary adenocarcinoma 
DA3 cells these two cell types were infected with the monocyclically replicating NDV strain 
Ulster. An infection kinetics was established over a period of two days by extracting RNA at 
different  time points  and determining the amount  of  the viral  M gene in the cDNA as a 
measure for viral replication with the help of real-time RT-PCR. In addition, spleen cells were 
infected with different amounts of NDV Ulster to analyse the correlation between the virus 
infection level and the ensuing M gene expression level and to determine the maximum M 
gene expression level in these cells.
Figure  4 -1a shows that there was a large difference in M gene expression after NDV Ulster 
infection between spleen and DA3 cells. Spleen cells reached a plateau of expression at 8 
hours after infection which was only slightly higher than the initial level at 4 hours. After 8 
hours  the  expression  decreased  slightly.  DA3 cells  showed  a  strong  increase  in  M gene 
expression between 4 and 8 hours after infection and reached the maximum at 24 hours. The 
maximum M gene expression in DA3 cells was approximately 5000 times higher than that in 
spleen cells. In figure 4-2b it can be seen that the plot follows a saturation curve culminating 
at  about  500 REU (relative  expression  units),  which  was  about  20  times  lower  than  the 
maximum M gene expression obtained in DA3 cells.
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The spleen cells were highly resistant to NDV infection compared to DA3 cells even when 
infected with high doses of NDV. Antiviral mechanisms in spleen cells seem to have become 
active early after infection and to have stopped viral replication. Since there were pronounced 
differences  in  NDV  replication  between  spleen  and  DA3  cells,  there  must  have  been 
differences in the antiviral response of these two cell types.
 4.1.3 Interferon-related gene expression
In order to find out more about the differences in the antiviral response that could cause the 
strong differences in NDV susceptibility between murine spleen and DA3 tumour cells, the 
expression of genes related to an antiviral interferon response in these two cell types was 
analysed.  The RNA samples taken in the NDV Ulster  infection kinetics  as shown before 
(4.1.2) were used to analyse the expression of seven genes known to be important for the 
establishment and effectiveness of an antiviral response (see for example Sen, 2001; Seth et  
al., 2006). The change in gene expression relative to the basal level was determined with real-
time RT-PCR, first within the murine spleen cells.
Figure  4 -2 shows an increase in the expression of all  of the seven genes analysed after 
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Figure  4 -1: NDV replication in murine spleen and DA3 tumour cells. 
(A) Murine DA3 mammary adenocarcinoma cells  and freshly isolated spleen  cells  from DBA/2 mice  were 
infected with 10 HU NDV Ulster per 106 cells. At 0, 4, 8, 24 and 48 hours total RNA was prepared and after 
reverse transcription NDV M gene cDNA was quantified in a real-time PCR with the comparative CT method 
using  β-actin for normalisation.  At 0 hours no M gene could be detected (data not shown). The results are 
represented as the mean of three measurements. (B) Murine spleen cells were infected with different amounts of 
NDV Ulster and total RNA was prepared 24 hours after infection. After reverse transcription the NDV M gene 
cDNA was quantified in a real-time PCR with the comparative CT method using β-actin for normalisation. The 
results are represented as the mean of three measurements. Bars indicate standard deviation.
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infection with NDV Ulster. The expression increased until it peaked at 8 hours and decreased 
afterwards. The expression level at 48 hours was still higher than the basal level before NDV 
infection.  The  highest  increase  in  expression  could  be  observed  for  the  antiviral  effector 
molecule Mx1. The RIG-I gene expression showed only a slight increase. For the other genes 
the maximum expression level was about 30 – 50 times higher than the basal expression.
The spleen cells showed a clear increase in the expression of all analysed genes after NDV 
infection. The gene expression kinetics correlated with the NDV M gene expression observed 
before in that it peaked at 8 hours and declined thereafter.
Next the RNA samples taken in the NDV Ulster infection kinetics for the DA3 cells as shown 
before (4.1.2) were used to analyse the expression kinetics of the interferon-related genes.
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Figure  4 -2: Inducible expression of genes related to the interferon response in murine spleen 
cells infected with NDV Ulster.
Murine spleen cells were infected with 10 HU NDV Ulster per 106 cells and total RNA was prepared 0, 4, 8, 24 
and 48 hours after infection (see Figure  4 -1). After reverse transcription the respective gene was quantified by 
real-time  PCR with  the  comparative  CT method using  β-2-microglobulin  for  normalisation.  The  results  are 
represented as the mean of three measurements. The expression level of each gene is shown relative to the basic 
level  at  0 hours  and the results  are represented as  the mean of three measurements.  Bars indicate  standard 
deviation.
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In  figure  4-3 it  can  be  seen  that  the  expression  of  the  analysed  genes  increased  during 
infection with NDV Ulster except for the IRF7. The increase peaked at 24 hours except for 
the RIG-I gene, which displayed a maximum at 8 hours. The increase compared to the basal 
expression  was  highest  for  the  antiviral  effector  molecule  OAS1a  being  about  45-fold, 
followed by Mx1 with a 30-fold increase. For the other genes the expression increased 2 – 10-
fold.
The DA3 cells showed a heightened gene expression that peaked at a later time point then in 
the spleen cells. In general, the increase relative to the basal expression level was lower than 
in spleen cells.
In  order  to  compare  the  absolute  gene  expression  in  DA3 and spleen cells  during  NDV 
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Figure  4 -3: Inducible expression of genes related to the interferon response in murine DA3 
tumour cells infected with NDV Ulster.
Murine DA3 mammary tumour cells were infected with 10 HU NDV Ulster per 106 cells and total RNA was 
prepared 0, 4, 8, 24 and 48 hours after infection (see Figure  4 -1). After reverse transcription the respective gene 
was quantified  by real-time PCR with the comparative CT method using  β-2-microglobulin for normalisation. 
The expression level of each gene is shown relative to the basic level at 0 hours and the results are represented as 
the mean of three measurements. Bars indicate standard deviation.
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infection, the expression levels were plotted relative to the basal level of the DA3 cells.
Figure  4 -4 shows that the expression level for the IRF7 transcription factor, for interferon-β 
and for Mx1 were clearly higher in spleen cells during NDV infection. For OAS1a the same 
maximum expression was reached at 8 hours for the spleen cells and at 24 hours for the DA3 
cells. The basal expression level of all analysed genes was comparable except for MDA5 and 
PKR, which were lower in spleen cells (10-fold and 100-fold respectively).
The main difference in the antiviral interferon response between spleen and DA3 cells seemed 
to be a much faster and stronger induction of the expression of some antiviral genes in spleen 
cells. These differences could explain the high susceptibility of DA3 tumour cells and the 
resistance of spleen cells to NDV infection. The basal gene expression levels were similar and 
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Figure  4 -4: Comparison of the interferon-related gene expression in spleen cells and DA3 
tumour cells after infection with NDV Ulster.
Murine spleen cells and DA3 mammary tumour cells were infected with 10 HU NDV Ulster per 106 cells and 
total RNA was prepared 0, 4, 8, 24 and 48 hours after infection (see Figure  4 -1). After reverse transcription the 
respective gene was quantified with by real-time PCR the comparative CT method using β-2-microglobulin for 
normalisation. The expression level of each gene is shown relative to the basic level at 0 hours in DA3 cells and 
the results are represented as the mean of three measurements. Bars indicate standard deviation.
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hence could not be connected with the differences in NDV susceptibility.
However, since spleen cells represent a heterogeneous mixture of different normal cell types 
such as T and B cells, dendritic cells, macrophages and the like, it would be more informative 
to compare primary and tumour cells of the same cell  type to compensate for expression 
differences related to cell  type.  This  approach was followed in the next  but  one chapter. 
Before the question if NDV could also induce gene expression in vivo was addressed.
 4.1.4 Interferon-related gene expression in vivo after systemic NDV 
application
NDV can be used systemically in tumour therapy for the generation of anti-tumour vaccines 
or as a direct oncolytic agent in virotherapy. To find out whether and to what extent NDV also 
induces the expression of interferon-related genes in vivo, NDV was injected into the blood 
stream of mice, and spleen and bone marrow cells were extracted after 12 hours. After RNA 
extraction real-time RT-PCR was used to determine the expression level of the NDV M gene 
and of seven genes related to an antiviral interferon response.
NDV M gene expression could only be detected in the cDNA from spleen cells at a low level 
(0.27 REU). No M gene could be detected in the bone marrow samples (data not shown).
Figure  4  -5 shows an increase  in the gene expression in spleen cells  12 hours after  the 
systemic application of NDV Ulster for all genes. In bone marrow cells an increase in gene 
expression could only be observed for the IRF7 transcription factor and for the two antiviral 
effector molecules PKR and Mx1. In general the gene expression level in the PBS control 
mice was several times higher in bone marrow than in spleen cells. 
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The fact  that  spleen cells  displayed  a  higher  induction of  gene  expression  than the  bone 
marrow cells could be explained by a better accessibility of the spleen for NDV. Firstly, M 
gene expression can only be detected in the spleen samples and secondly, the spleen has an 
exceptionally good connection to blood vessels since its main purposes are the collection of 
antigens from the blood and the disposal of senescent red blood cells. The generally higher 
basal  expression  of  interferon-related  genes  in  bone  marrow  cells  especially  in  the  PBS 
control mice points to a higher responsiveness of these cells to virus infection. This could be 
due to a higher number of plasmacytoid dendritic cells, which are known to produce large 
amounts of type I interferons in response to virus infection (Siegal  et al., 1999) and which 
have been shown to be several times more frequent in the mouse bone marrow compared to 
spleen (Asselin-Paturel et al., 2003).
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Figure  4 -5: Changes in interferon-related gene expression in vivo after systemic application 
of NDV Ulster.
750 HU NDV Ulster or PBS were injected with a volume of 300 µL into the tail vein of DBA/2 mice. Spleen 
and bone marrow cells were isolated 12 hours later and after total RNA extraction and reverse transcription a 
real-time PCR was carried out to determine the expression levels of the listed genes. The expression level of the 
genes  was  determined  with the  comparative  CT method  using  β-2-microglobulin  for  normalisation.  The 
expression level of the each gene is shown relative to the level in spleen cells from mice treated with PBS. The 
results are represented as the mean of three measurements. Bars indicate standard deviation.
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 4.2 NDV infection of macrophages and the macrophage-
derived tumour cell lines J774A.1 and RAW 264.7
In order to examine the properties that make tumour cells susceptible to NDV infection it is 
best to compare tumour and normal cells that belong to the same cell type. By this approach 
one can rule out that the differences that are observed between tumour and normal cells are 
due to a difference in cell type and not due to variation in malignancy. For this purpose, 
murine bone marrow-generated macrophages and the two murine macrophage-like tumour 
cell lines J774A.1 and RAW 264.7 were used. These three cell types were compared with 
regard  to  NDV susceptibility,  growth  characteristics,  basal  and  NDV-induced  interferon-
related gene expression and interferon secretion upon infection. Moreover the influence of the 
pretreatment  with  anti-interferon-α +  -β antibodies  and  with  interferon-α4  on  the 
aforementioned cell properties was analysed. In the end it should be determined what cellular 
characteristics correlate with NDV susceptibility and whether these characteristics could be 
found predominantly in tumour cells.
 4.2.1 Expression of the F4/80 macrophage marker
It  was  important  to  determine  if  the  macrophage-like  phenotype  is  comparable  in  the 
generated macrophages and in the two cell lines. An equal macrophage-like phenotype was an 
important prerequisite for the following experiments to exclude that observed variations were 
due  to  cell  type  differences  and not  due  to  differences  in  malignancy.  To  determine  the 
macrophage-like  phenotype,  the  expression  of  the  pan-macrophage  marker  F4/80,  a  cell 
surface glycoprotein that is expressed on a wide range of mature tissue macrophages (Leenen 
et al., 1994), was tested.
Figure  4 -6 shows that the F4/80 antigen was expressed similarly on the three cell types.
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After it was ensured that the macrophage-like phenotype was comparable for the three cell 
types, their further characterisation was continued.
 4.2.2 NDV infection after interferon or anti-interferon antibody 
pretreatment
The susceptibility for NDV infection of the bone marrow-derived macrophages and the two 
macrophage-like tumour cell lines J774A.1 and RAW 264.7 was assessed to correlate it with 
other  cell  characteristics  measured  later  on.  In  addition the influence of  externally  added 
interferon or of interferon secreted by the cells themselves before NDV infection was tested. 
It is known, for example, that a low secretion of interferon can also be found in the absence of 
virus infection and that this secretion is important for the ability of cells to defend against 
virus infection (Prof. Rainer Zawatzky, oral communication).
 4.2.2.1 NDV infection without pretreatment
It  was  necessary  to  determine  the  infectability  of  the  three  cell  types  with  NDV  since 
according to the working hypothesis an increased NDV susceptibility of a cell type points to 
defects in the antiviral response mechanisms which will be analysed later in this chapter. To 
this  end the cells  were infected with the lentogenic  NDV Ulster  and the velogenic  NDV 
Italien and then cell  samples  were taken at  different  time points  after  infection for RNA 
extraction. The RNA was used for M gene expression analysis by real-time RT-PCR and also 
for antiviral  gene expression analysis  (4.2.5 and  4.2.6).  In addition the supernatants  were 
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Figure  4 -6: The  expression  of  the  F4/80  macrophage  marker  on  bone  marrow-derived 
macrophages, J774A.1 and RAW 264.7 cells.
Bone marrow-derived macrophages, J774A.1 and RAW 264.7 cells were stained with a FITC-conjugated anti- 
F4/80 antibody and the surface expression of this marker was determined in flow cytometry.
Macrophages J774A.1 RAW 264.7
F4/80 expression 
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collected and analysed for the interferon content (4.2.4).
Figure  4 -7 shows distinct differences in M gene expression for the three cell types analysed. 
After 2 hours M gene expression was similar for all cells with the J774A.1 cells having a 
slightly lower level for both viruses. For the macrophages the M gene level remained at this 
low starting level of about 10 REU (NDV Ulster) or even decreased at later time points (NDV 
Italien). For the other two cell types the M gene level increased with a similar kinetics to 
reach a plateau at 12 hours after infection. The M gene expression of the RAW 264.7 cells 
was generally about 10-fold higher than that of the J774A.1 cells. At the plateau the ratio of 
J774A.1 versus RAW 264.7 M gene was about 1:18 (240 versus 4200 REU) for NDV Ulster 
and about 1:6 (1225 versus 7160 REU) for NDV Italien. When the peak in M gene expression 
for the macrophages (11 REU for NDV Ulster and 23 REU for NDV Italien) is compared to 
the highest expression of the two cell lines, it can be said that the J774A.1 cells were 20 – 50 
times better infectable than the macrophages and the RAW 264.7 300 – 400 times better. 
Overall the M gene expression was 2 – 5 times higher when the three cell types were infected 
with NDV Italien compared to the NDV Ulster infections.
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Figure  4 -7: M  gene  expression  in  macrophages,  J774A.1  and  RAW  264.7  cells  after 
infection with NDV Ulster or NDV Italien, respectively.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU NDV Ulster (A) or NDV Italien (B) per 106 cells. At 0, 2, 4, 8, 12 and 24 hours the cells were 
harvested and total RNA was extracted. After reverse transcription the expression level of the NDV M gene was 
determined by real-time PCR with the comparative CT method using β-actin for normalisation. At 0 hours no M 
gene could be detected (data not shown). The results are represented as the mean of three measurements. Bars 
indicate standard deviation.
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The NDV infection kinetics revealed pronounced differences in the M gene expression levels 
for the three cell types. The macrophages proved to be NDV resistant with a low and even 
decreasing M gene level during infection. The RAW 264.7 cells were highly susceptible to 
NDV infection with an M gene level several hundred times that of the macrophages. The 
J774A.1 cells showed an intermediate M gene expression.
To confirm these results for NDV susceptibility of the three cell types, another parameter for 
NDV replication  was  used.  The cells  were infected  with  recombinant  NDV variants  that 
expressed EGFP during the viral replication cycle and the EGFP signal was taken as indicator 
of viral replication. The cells were infected with NDFL-EGFP and NDFLtag-EGFP and one 
day later the EGFP signal of the cells was measured in flow cytometry.
Figure  4 -8 demonstrates that the RAW 264.7 cells had the highest EGFP signal, followed by 
the J774A.1 and then by the macrophages, which again showed to have the lowest signal. 
There was no clear difference in the EGFP signal between the lentogenic NDFL-EGFP and 
mesogenic NDFLtag-EGFP.
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The  analysis  of  the  EGFP  signal  derived  from  the  infection  with  recombinant  EGFP 
confirmed the  results  of  the M gene expression  after  infection.  The RAW 264.7 had the 
strongest signal, the macrophages displayed almost no signal and the strength of the EGFP 
signal of the J774A.1 cells was in between that of the two other cell lines.
 4.2.2.2 Binding of NDV to J774A.1 and RAW 264.7 tumour cells
Since the differences observed in the M gene or EGFP signal after NDV infection could be 
due to differences in the ability of NDV to bind to the cells, the cell binding of NDV was 
analysed. J774A.1 and RAW 264.7 cells were infected with NDV Ulster and one hour later 
the NDV HN surface molecule was stained on the cells and measured by flow cytometry. At 
this time point the majority of the HN molecules on the cell surface could only come from 
bound virus particles, since the virus replication and expression of newly synthesised HN 
takes more than one hour.
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Figure  4 -8: EGFP  expression  after  infection  of  macrophages,  J774A.1  and  RAW  264.7 
tumour cells with NDFL-EGFP or NDFLtag-EGFP, respectively.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells NDFL-EGFP (A) or NDFLtag-EGFP (B, J774A.1 and RAW 264.7 only). After 24 h 
EGFP expression was determined in flow cytometry.
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Figure  4 -9 shows that NDV Ulster bound similarly to the J774A.1 than to the RAW 264.7 
cells.
The RAW 264.7 cells displayed a higher M and EGFP signal after virus infection than the 
J774A.1 cells, but the virus binding was equal. Hence the virus binding could not explain the 
higher NDV susceptibility of the RAW 264.7 cells. It was likely that there were differences in 
the antiviral interferon response of the three macrophage-like cells. Important factors in this 
response  are  interferon  secretion  and  responsiveness  to  external  interferon,  which  were 
analysed in the next chapter.
 4.2.2.3 Influence of interferon-α4 or interferon-α and -β antibody 
pretreatment on NDV infection
To control viral infection it is important for cells to secrete type I interferons and to react to 
type I interferon in an auto- or paracrine fashion, both at a low level before and also after 
infection. In order to analyse these parameters in the three macrophage cell types, one part of 
the cells was pretreated with anti-interferon-α and -β antibodies before infection to prevent the 
effect of a low basal interferon secretion that could be important for a constitutively increased 
defensiveness against virus infection. Without the effect of this basal interferon secretion the 
cells should be rendered more susceptible to NDV infection. Another part of the cells was 
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Figure  4 -9: Binding of NDV to J774A.1 and RAW 264.7 cells.
106 J774A.1 or RAW 264.7 tumour cells, respectively, were incubated for one hour with 10 HU NDV Ulster. 
The cells were then stained with a mouse antibody against the NDV surface protein HN and with a PE-labelled 
GaM secondary antibody.
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pretreated with interferon-α4, a crucial player  in the first  phase of the interferon response 
(Marié et al., 1998), in order to start an antiviral response before contact of the virus with the 
cells. So the main points that should be compared between the cells were the secretion of 
interferon and the responsiveness to external interferon. To that end the cells were pretreated 
as described before an then the percentage of EGFP-expressing cells was measured in flow 
cytometry one day after infection with NDFL-EGFP. Additionally the M gene expression was 
determined by real-time RT-PCR one day after infection with NDV Ulster.
Figure  4 -10 demonstrates that the EGFP and the M gene expression after NDV infection 
could almost be completely blocked in the macrophages pretreated with interferon-α4. Also in 
the J774A.1 cells a strong blocking could be observed after the pretreatment with interferon-
α4. In the RAW 264.7 cells the EGFP and M gene expression after infection could also be 
blocked, but only by 63 %. With IFN-α4 pretreatment the RAW 264.7 cells displayed still an 
EGFP and M gene expression level that was about twice as high as that of J774A.1 cells 
without pretreatment.
The pretreatment with anti-interferon-α and -β antibodies slightly increased the EGFP and M 
gene expression except for the EGFP in macrophages and for the M gene in J774A.1 cells. 
For  macrophages  the  M  gene  expression  was  increased  2-fold,  for  J774A.1  the  EGFP 
expression 2.5-fold and for RAW 264.7 cells the increase was 1.1-fold for the EGFP and 1.4-
fold for the M gene. 
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Interferon-α4 pretreatment could block NDV infection almost completely in macrophages and 
the J774A.1, whereas the blocking was incomplete in RAW 264.7 cells. This pointed to a 
lower  IFN-α4  responsiveness  in  the  latter  cells.  The  anti-interferon-α and  -β antibody 
pretreatment did slightly increase the EGFP and M gene expression. The increase was higher 
in macrophages and J774A.1 cells than in RAW 264.7 cells. In order to analyse the kinetics of 
NDV infection after IFN-α4 pretreatment, the M gene expression was determined at several 
time points after infection with NDV Ulster with the help of real-time RT-PCR.
Figure  4 -11 shows that in J774A.1 cells after IFN-α4 pretreatment no increase in the M gene 
expression could be observed at any time point. In RAW 264.7 cells between 4 and 8 hours 
the M gene expression increased much more in the control cells than in the pretreated cells. 
Between 8 and 20 hours the rate of increase is similar for the pretreated and for the control 
RAW  264.7  cells.  Again  the  IFN-α4  pretreated  RAW  264.7  cells  displayed  an  M gene 
expression level that was about twice as high as that of J774A.1 cells without pretreatment.
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Figure  4 -10: The influence of anti-IFN-α and -β antibody or IFN-α4 pretreatment on the 
infection of macrophages, J774A.1 and RAW 264.7 tumour cells with NDV.
Bone marrow-derived macrophages, J774A.1 and RAW 264.7 tumour cells were grown for 7 days either in 
normal growth medium (■ control group) or in medium supplemented with 1500 U/mL anti-IFN-α and 1900 
U/mL anti-IFN-β antibody (■ anti-IFN-α + -β group and ■ IFN-α4 group). For 16 hours before NDV infection 
one  group  of  cells  (■ IFN-α4  group)  was  grown  in  medium  supplemented  with  120  IU/mL  IFN-α4.  The 
percentage of EGFP expression blocking in comparison to the control is indicated. (A) 24 hours after infection 
with 10 HU NDFL-EGFP per 106 cells EGFP expression of the cells was determined in flow cytometry. (B) 24 
hours  after  infection  with  10 HU NDV Ulster  per  106 cells  the expression  level  of  the  NDV M gene was 
determined by real-time RT-PCR with the comparative CT method using β-actin for normalisation. The results 
are  represented  as  the  mean  of  three  measurements.  The  percentage  of  M  gene  expression  blocking  in 
comparison to the control is indicated. Bars indicate standard deviation.
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When pretreated with IFN-α4 M gene expression after  NDV infection was  suppressed in 
J774A.1 cells at every time point analysed. In RAW 264.7 cells the rate of increase in M gene 
expression at early time points was clearly lower in the IFN-α4 pretreated cell  population 
compared to the control. At later time points the rate of increase became similar. In summary 
the results indicated a much lower IFN-α4 responsiveness in RAW 264.7 cells compared to 
macrophages and J774A.1 cells.
 4.2.3 Growth characteristics of J774A.1 and RAW 264.7 cells
In order to further characterise the two macrophage-like tumour cell lines J774A.1 and RAW 
264.7, their growth was followed in the presence or absence of IFN-α4. Macrophages were 
not included in the experiments, because as most differentiated cells they were not expected to 
show any growth.
The working hypothesis was that the more malignant the phenotype of a cell, the faster its 
growth and the lower the antiproliferative effect of IFN. The generation time G, the time it 
takes  the  cells  to  double,  was  calculated  using  the  following  formula:
G = t / 
log N−log N 0
log 2
where N = final cell number, N0 = initial cell number and t = elapsed 
time.
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Figure  4 -11: The influence of IFN-α4 pretreatment on the NDV Ulster infection kinetics in 
J774A.1 and RAW 264.7 cells.
J774A.1 and RAW 264.7 tumour cells were grown in normal growth medium (■ control group) or in medium 
supplemented with IFN-α4 in a final concentration of 120 IU/mL (■ IFN-α4 group) 1 day before infection with 
NDV Ulster. For the infection 10 HU per 106 cells NDV Ulster was used and total RNA was extracted at 0, 4, 8 
and  20  hours  after  infection.  After  a  reverse  transcription  the  expression  level  of  the  NDV M  gene  was 
determined by real-time PCR with the comparative CT method using β-actin for normalisation. The results are 
represented as the mean of three measurements. Bars indicate standard deviation.
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Figure  4 -12 shows that without IFN-α4 pretreatment the J774A.1 cells grew slower than the 
RAW 264.7 cells. The generation time G between day 0 and day 5 was  1.87 days for the 
J774A.1 cells and 1.32 days for the RAW 264.7 cells, i.e. the RAW 264.7 grew about 40 % 
faster than the J774A.1 cells. With IFN-α4 pretreatment the generation time was increased for 
the J774A.1 cells to 4.4 days, less than half the normal generation time. For the RAW 264.7 
the generation time was with 1.25 days slightly lower than that of the control.
Without pretreatment the RAW 264.7 cells grew distinctly faster than the J774A.1 cells. IFN-
α4 pretreatment could more than halve the generation time of the J774A.1 cells, whereas the 
the RAW 264.7 cells did not respond to IFN-α4 with a significant change in the generation 
time.
Next the growth of the two macrophage-like cell lines in the presence of NDV was analysed 
to find out if and how long they could resist a single virus infection. J774A.1 and RAW 264.7 
cells were infected once with NDV Ulster or NDV Italien and the cell growth was followed 
for several days.
As can be seen in figure 4-13 the J774A.1 cells stopped to grow after infection with NDV 
Ulster or NDV Italien. The total cell number fell after 1 day and than it stabilised at about 
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Figure  4 -12: The influence of IFN-α4 on the growth of J774A.1 and RAW 264.7 cells.
3*105 J774A.1 and RAW 264.7 cells per well were seeded in 6 well plates in normal growth medium (control) or 
in medium supplemented with 120 IU/mL IFN-α4. Afterwards at each time point up to 6 days the number of 
living cells per well was determined with a hemocytometer and an optical microscope. G = generation time
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330,000 per well for NDV Ulster and at about 150,000 for NDV Italien. When infected with 
NDV Italien almost no living RAW 264.7 cells could be found any more from the first day 
after infection on. After infection with NDV Ulster the number of RAW 264.7 cells decreased 
at day 1, but then it started to increase again and the growth rate was as high as in the control 
between day 3 and day 4. The generation time for the control from day 0 to day 4 was 2.04 for 
the J774A.1 cells and 1.19 for the RAW 264.7 cells. 
The most striking difference between the growth of the two cell lines was that the RAW 264.7 
cells started to grow again after infection with the monocyclically replicating NDV Ulster, 
whereas the J774A.1 cell number remained at a constant level. Thus a fraction of both cell 
lines survived the infection, but the J774A.1 cells did not start to grow again, perhaps due to 
their ability to respond to danger signals such as interferon (as in figure 4-12). When infected 
with the multicyclically replicating NDV Italien, a part of the J774A.1 cells survives and the 
cell number remains constant. In contrast, almost all RAW 264.7 cells die, probably due to a 
higher susceptibility to NDV Italien. The few RAW 264.7 cells that did survive did not start 
to regrow, perhaps as a result of the viable viral offspring that was generated during infection 
and that could reinfect the cells.
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Figure  4 -13: Growth of J774A.1 and RAW 264.7 cells after NDV infection.
7.5*105 J774A.1 (A) and RAW 264.7 (B) cells were infected with 10 HU NDV Ulster or Italien and seeded in 6 
well plates. Subsequently at each time point up to 4 days the number of living cells in one well was counted with 
a hemocytometer and an optical microscope. In order to stain dead cells trypan blue was used.
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 4.2.4 Interferon secretion after NDV infection
An important part in an antiviral response of cells is the synthesis and release of interferons 
into the  supernatant  as  part  of  a  positive  feedback loop to induce an  effective  interferon 
response, for example, by stimulating the expression of crucial transcription factors such as 
IRF7 (Sato et al., 1998). In order to analyse the interferon secreted upon NDV infection in the 
three macrophage-like cell  types,  samples of the supernatants were taken at different time 
points  after  infection.  The  amount  of  biologically  active  interferon  in  these  samples  was 
determined in a VSV protection assay (3.2.7), in which L929 cells were pretreated with the 
supernatants and then infected with VSV. The protection against VSV-induced cell death due 
to the stimulation of an antiviral state conferred by the interferons in the supernatant was then 
used to determine the amount of interferons.
Figure  4 -14 shows that the macrophages already started to secrete interferons 4 hours after 
infection, whereas the two tumour cell lines J774A.1 and RAW 264.7 began only after 12 
hours to secrete detectable amounts of interferon. The amount of interferon in the supernatant 
of macrophages peaked 12 hours after infection at 700 IU (international units) and then it 
slightly decreased. Total interferon in the supernatants of the two tumour cell lines peaked at 
24 hours and was 1200 IU for the J774A.1 cells and 120 IU for the RAW 264.7 cells.
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Figure  4 -14: Interferon  secretion  of  macrophages,  J774A.1  and  RAW  264.7  cells  after 
infection with NDV Ulster.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells NDV Ulster and 2*106 cells per well were seeded in 12 well plates with 2 mL growth 
medium (see Figure  4 -7). After 2, 4, 8, 12 and 24 hours supernatant was collected and the interferon-α/β level 
was determined in a VSV based interferon bioassay (3.2.7).
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The most striking difference between the primary macrophages and the two tumour cell lines 
was  the  early  beginning  of  interferon  secretion  in  macrophages.  The  total  amount  of 
interferon secreted was higher in the J774A.1 tumour cells than in the primary cells. Since the 
J774A.1  cells  were  more  susceptible  to  NDV  than  macrophages,  the  rapid  secretion  of 
interferons seemed to be of greater importance for NDV resistance than the total amount of 
secreted interferons at later time points.
 4.2.5 Basal expression of interferon-related genes
In order to determine the responsiveness to viral infection in macrophages and J774A.1 and 
RAW 264.7 tumour cells before virus infection, the basal expression level of important genes 
of the interferon response was determined by real-time RT-PCR. The genes analysed were the 
two cytosolic double-stranded RNA receptors RIG-I and MDA5, the two transcription factors 
IRF3 and IRF7, interferon-β and the three antiviral effector molecules PKR, OAS1a and Mx1.
Figure  4 -15 demonstrates that the basal expression level of all the analysed genes was higher 
in macrophages and than in the two tumour cell  lines.  The lowest  expression showed the 
RAW 264.7 cells  and J774A.1  always had an intermediate  expression  level.  The biggest 
differences in the gene expression level could be found for IRF7 and MDA5, in which the 
expression in macrophages was 12 to 15 times higher than in RAW 264.7 cells. On average 
the gene expression in macrophages was about 8.0 times and in J774A.1 2.3 times higher than 
in RAW 264.7 cells.
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The basal gene expression level of the analysed interferon-related genes correlated inversely 
with  the  NDV susceptibility,  with  the  RAW 264.7  cells  showing  a  low,  the  J774A.1  an 
intermediate and the macrophages a high expression level.
 4.2.6 Inducible interferon-related gene expression
An important characteristic of the interferon response are positive feedback mechanisms that 
are  necessary  for  an  effective  antiviral  response.  By  these  feedback  mechanisms  the 
expression of key molecules such as IRF7, which in the absence of viral infection is expressed 
only at low level in most cells, is stimulated. Only in the presence of a sufficient amount of 
IRF7 and other key molecules can there be an effective interferon response. To find out if 
there were differences in the inducibility of interferon-related genes in the course of viral 
infection, the expression of these genes was followed after NDV infection. In some cases 
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Figure  4 -15: Basal expression level of interferon-related proteins in macrophages, J774A.1 
and RAW 264.7 cells.
Total RNA was extracted from bone marrow-derived BALB/c macrophages, J774A.1 and RAW 264.7 tumour 
cells and after reverse transcription a real-time PCR was carried out to determine the expression levels of the 
listed genes. The expression level of the genes was determined with the comparative CT method using the acidic 
ribosomal phosphoprotein PO for normalisation. The expression level of each gene is shown relative to the level 
in RAW 264.7 cells.  The results are represented as the mean of three measurements.  Bars indicate standard 
deviation.
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NDV was UV-inactivated  before infection and a  successful  inactivation  of  the  virus  was 
confirmed by the absence of M gene expression in the respective samples (data not shown).
 4.2.6.1 The cytosolic double-stranded RNA receptors RIG-I, MDA5 and LGP2
The retinoic acid-inducible gene I (RIG-I) and the melanoma differentiation associated gene 5 
(MDA5)  are  cytosolic  double-stranded  RNA  receptors  that  signal  the  presence  of  viral 
dsRNA in cells (Yoneyama et al., 2005). They have overlapping functions, but it seems that 
RIG-I is of more importance for the signalling after NDV infection then MDA5 (Kato et al., 
2006).  The  D11lgp2 gene (LGP2)  belongs  to  the  same class  of  molecules  but  acts  as  a 
negative regulator  interfering  with  RIG-I  and MDA5.  LGP2 lacks that  signalling  domain 
necessary for the signal transmission after binding of double-starnded RNA.
In  order  to  assess  the  inducibility  of  these  three  genes  in  macrophages  and  the  two 
macrophage-like tumour cell lines J774A.1 and RAW 264.7, the gene expression level was 
measured at different time points after infection with real-time RT-PCR. The infections were 
done with NDV Ulster  and/or  NDV Italien and in some cases also UV-inactivated  NDV 
Ulster was used. 
Figure  4 -16 shows the inducible expression of RIG-I. When infected with live NDV Ulster 
(part A), RIG-I expression was induced in all three cell types. The induction of expression 
started at 2 hours after infection in macrophages and J774A.1 cells, and at 8 hours in RAW 
264.7 cells. The maximal expression level compared to the basal level in RAW 264.7 cells 
was highest for macrophages with 67-fold, lower for J774A.1 cells with 42-fold and lowest 
for RAW 264.7 cells with 15-fold. After infection with UV-inactivated NDV Ulster (part B), 
the induction of RIG-I expression was highest for macrophages 8 hours after infection with 
69-fold. In J774A.1 cells the maximum induction of expression was 15-fold and in RAW 
264.7 cells  it  was  4-fold.  In  contrast  to  infection  with  live  NDV Ulster,  the  RIG-I  gene 
expression dropped sharply  after  8  hours.  After  infection  with  NDV Italien  (part  C),  the 
general picture was similar to that after infection with NDV Italien. In macrophages induction 
was highest with 41-fold, in J774A.1 cells it was lower with 23-fold and RAW 264.7 cells it 
was lowest with 10-fold.
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RIG-I  expression  was  inducible  after  NDV  infection  with  the  highest  expression  levels 
reached in macrophages, lower levels attained in J774A.1 cells and the lowest levels found in 
RAW 264.7 cells. NDV Ulster infection led to slightly higher RIG-I expression levels than 
infection with NDV Italien. UV-inactivated NDV Ulster induced a high RIG-I expression in 
macrophages that subsided early 8 hours after infection, pointing to a mechanism of induction 
that  was independent  of NDV replication.  Next,  the inducible expression of the cytosolic 
dsRNA receptor MDA5 after NDV infection was tested.
Figure  4  -17 shows that  after  infection with NDV Ulster  the expression of  MDA5 was 
induced in all three cell types.  The maximum of induction compared to the basal level in 
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Figure  4 -16: Changes in retinoic acid-inducible gene I (RIG-I) gene expression after NDV 
infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A), UV-inactivated NDV Ulster (B) or live NDV Italien (C). At 
different time points  after  the infection total RNA was extracted and after reverse transcription the level of 
retinoic acid-inducible gene I (RIG-I) expression was determined  by real-time PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The gene expression level is shown 
relative to the level in RAW 264.7 cells.  The results are represented as the mean of three measurements. Bars 
indicate standard deviation.
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RAW 264.7 cells was reached earliest in macrophages at 12 hours with 312-fold and at 24 
hours for J774A.1 and RAW 264.7 cells with 84-fold or 12-fold, respectively. When infected 
with UV-inactivated NDV Ulster (part B) there was a strongly increased MDA5 expression 
after 8 hours for macrophages with 91-fold. The expression dropped again sharply after this 
time point. In J774A.1 cells the expression increased up to 16-fold and in RAW 264.7 cells 
there was no induction of MDA5 expression by UV-inactivated NDV Ulster. Infection with 
NDV Italien (part C) induced MDA5 gene expression in macrophages to 203-fold at 12 hours 
and after 12 hours the gene expression had dropped to 1/4th of this value. For J774A.1 and 
RAW 264.7 cells the induced expression level of 102-fold or 27-fold respectively fell only 
slightly after the maximum had been reached.
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Figure  4 -17: Changes  in  melanoma  differentiation  associated  protein  5  (MDA5)  gene 
expression after NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A), UV-inactivated NDV Ulster (B) or live NDV Italien (C). At 
different time points  after  the infection total RNA was extracted and after reverse transcription the level of 
melanoma differentiation associated protein 5 (MDA5) expression was determined  by real-time PCR with the 
comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. The gene expression 
level  is  shown relative  to  the level  in  RAW 264.7 cells.  The  results  are  represented  as  the mean of  three 
measurements. Bars indicate standard deviation.
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MDA5 expression was inducible by all types of NDV except for UV-inactivated NDV Ulster 
in RAW 264.7 cells. The induction was always strongest in macrophages at 8 hours after 
which  it  markedly  declined.  The  stimulation  of  MDA5  expression  was  always  lower  in 
J774A.1 and lowest in RAW 264.7 cells. In contrast to the macrophages the induced gene 
expression fell only slightly in the two tumour cell lines in the course of the experiments. The 
general induction pattern of MDA5 gene expression was similar to that of RIG-I. One minor 
difference was that for macrophages the MDA5 expression fell markedly after attaining the 
maximum 8 hours after infection, whereas the RIG-I expression usually was more stable.
Since the LGP2 molecule is thought to act as a negative regulator of the RIG-I and MDA5 
signalling,  an analysis  of the LGP2 expression kinetics could indicate its  role after  NDV 
infection.  One  possible  hypothesis  could  be,  for  example,  that  LGP2  is  expressed  more 
strongly in tumour cells and that it makes them therefore more susceptible to NDV infection 
by inhibiting the signalling of cytosolic dsRNA receptors.
Figure  4 -18 demonstrates that LGP2 was highly inducible after NDV Ulster infection in the 
three cell types. The increase compared to the basal level in RAW 264.7 cells was strongest in 
macrophages with 925-fold, lower in J774A.1 cells with 395-fold and lowest for RAW 264.7 
cells with 194-fold. The expression maximum was reached earlier in macrophages (12 hours) 
than in the two tumour cell lines (24 hours).
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Figure  4 -18: Changes in likely ortholog of mouse D11lgp2 (LGP2) gene expression after 
NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster. At different time points after the infection total RNA was extracted 
and after reverse transcription the level of likely ortholog of mouse D11lgp2 (LGP2) expression was determined 
by  real-time  PCR with  the  comparative  CT method  using  the  acidic  ribosomal  phosphoprotein  PO  for 
normalisation. The gene expression level is shown relative to the level in RAW 264.7 cells.  The results are 
represented as the mean of three measurements. Bars indicate standard deviation.
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The inducible LGP2 expression pattern was similar to that  of RIG-I and MDA5 with the 
macrophages having the highest expression level, followed by the J774A.1 and then by the 
RAW 264.7 cells. The relative values of expression were high because the basal expression 
level  in  RAW  264.7  cells,  to  which  they  were  related,  was  very  low.  Since  the  LGP2 
expression pattern was analogous to that of the two cytosolic dsRNA receptors and since the 
LGP2 expression level corresponded inversely with the NDV susceptibility, the expression of 
the LGP2 protein could not explain the differences in sensitivity to NDV infection.
 4.2.6.2 The transcription factors IRF3 and IRF7
The transcription  factors  IRF3 and IRF7 are  activated  upon virus  infection  by signalling 
cascades beginning with pattern recognition receptors such as RIG-I, which recognise virus 
associated molecular patterns such as double-stranded RNA. After activation IRF3 and IRF7 
induce the transcription of interferons and are therefore crucial  in the establishment of an 
antiviral  response.  IRF3  is  constitutively  expressed  in  most  cell  types  (Au  et  al.,  1995) 
whereas IRF7 is induced in most cells by interferons (Sato  et al., 1998). The expression of 
these two transcription factors was followed after NDV infection by real-time RT-PCR in 
macrophages, J774A.1 and RAW 264.7 cells.
Figure  4 -19 shows that the IRF3 expression was increased after NDV Ulster infection. The 
macrophages had already a 6-fold higher basal expression level than the RAW 264.7 cells and 
they attained the highest level with 17-fold. The second highest expression level was found 
for the J774A.1 cells with 5-fold, followed by the RAW 264.7 cells with 2-fold.
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IRF3 also  proved to be  inducible  upon virus  infection,  but  the  increase  in expression  in 
relation to the basal level was low compared to the other genes analysed so far, as could be 
expected from the literature. The situation was expected to be different for IRF7, which was 
known to be inducible by interferons.
Figure  4 -20 demonstrates that IRF7 was induced upon infection with NDV Ulster (part A) 
with the highest expression in macrophages with 760-fold, followed by the J774A.1 and the 
RAW 264.7 cells with 263- and 37-fold respectively. A marked increase in IRF7 expression 
started earlier in macrophages (4 hours after infection) than in the two tumour cell lines (12 
hours  after  infection).  UV-inactivated  NDV  Ulster  (part  B)  stimulated  a  peak  of  IRF7 
expression  at  8  hours  with  604-fold  that  levelled  out  at  about  250-fold.  The  maximum 
expression level  reached for J774A.1 cells  was 39-fold,  whereas no IRF7 expression was 
induced in RAW 264.7 cells. Upon infection with NDV Italien (part C) the maximum IRF7 
expression level was slightly higher in macrophages (378-fold) than in J774A.1 cells (291-
fold). At 24 hours after infection the expression level for macrophages fell below that of the 
J774A.1 cells. In RAW 264.7 cells the IRF7 level attained a maximum at 38-fold.
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Figure  4 -19: Changes in interferon regulatory factor 3 (IRF3) gene expression after NDV 
infection.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster. At different time points after the infection total RNA was extracted 
and after reverse transcription the level of interferon regulatory factor 3 (IRF3) expression was determined by 
real-time PCR with the comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. 
The gene expression level is shown relative to the level in RAW 264.7 cells. The results are represented as the 
mean of three measurements. Bars indicate standard deviation.
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The expression of IRF7 turned out to be highly inducible in the tested cells, with macrophages 
showing the highest induction followed by the J774A.1 and finally by the RAW 264.7 cells. 
In macrophages NDV Ulster induced a higher IRF7 expression than NDV Italien, a fact that 
had also been observed for other genes such as RIG-I or MDA5. Interestingly, UV-inactivated 
NDV Ulster markedly increased the IRF7 expression which remained at a high level up to the 
end of the experiment. This pointed to a mechanism of induction that was independent of 
NDV replication  and  that  could  nevertheless  sustain  IRF7  expression  at  a  high  level  in 
macrophages. Compared to IRF3 the IRF7 gene was highly inducible by NDV infection.
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Figure  4 -20: Changes in interferon regulatory factor 7 (IRF7) gene expression after NDV 
infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A), UV-inactivated NDV Ulster (B) or live NDV Italien (C). At 
different time points after the infection total RNA was extracted and after reverse transcription the level of 
interferon regulatory factor 7 (IRF7) expression was determined  by real-time PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The gene expression level is shown 
relative to the level in RAW 264.7 cells.  The results are represented as the mean of three measurements. Bars 
indicate standard deviation.
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 4.2.6.3 Interferon-β
Interferon-β is synthesised early in a virally induced interferon response and is an important 
factor in a positive feedback loop by which other key components such as IRF7 are induced 
(Juang  et  al.,  1998).  To find out  whether  this  function in an early interferon response is 
reflected  in  its  expression  pattern,  the  interferon-β  expression  was  followed  after  NDV 
infection by real-time RT-PCR.
Figure  4 -21 shows that upon infection with live NDV Ulster (part A) only the macrophages 
had a strong induction of interferon-β expression up to 459-fold of that of the basal RAW 
264.7  expression.  This  marked  induction  quickly  fell  soon  afterwards.  For  macrophages 
infected with UV-inactivated NDV Ulster and for J774A.1 and RAW 264.7 cells there was 
only a low induction up to 20-fold. After infection with NDV Italien (part B) all three cell 
types  displayed  an  increased  interferon-β  expression  which  was  earliest  and  highest  in 
macrophages (161-fold) and later and lower for J774A.1 and RAW 264.7 cells (95- and 32-
fold  respectively).  The  interferon-β  fell  markedly  for  all  three  cell  types  12  hours  after 
infection.
The  induction  of  interferon-β  gene  expression  was  strongest  at  early  time  points  after 
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Figure  4 -21: Changes in interferon-β (IFN-β) gene expression after NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live or UV-inactivated NDV Ulster (A) or live NDV Italien (B). At different time 
points after the infection total RNA was extracted and after reverse transcription the level of interferon-β (IFN-β) 
expression  was  determined  by  real-time  PCR with  the  comparative  CT method  using  the  acidic  ribosomal 
phosphoprotein PO for normalisation. The gene expression level is shown relative to the level in RAW 264.7 
cells. The results are represented as the mean of three measurements. Bars indicate standard deviation.
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infection and dropped substantially thereafter in all three cell types. This was different to the 
other genes analysed so far and pointed to a special importance of this gene in the early stages 
of viral infection. Except for macrophages NDV Italien induced a stronger expression than 
NDV Ulster.
 4.2.6.4 The antiviral effector molecules PKR, OAS1a and Mx1
The three proteins protein kinase PKR (PKR), 2'-5' oligoadenylate synthetase 1A (OAS1a) 
and Myxovirus (influenza virus) resistance 1 (Mx1) are induced by interferons and are known 
to  have  antiviral  activities.  The  PKR  inhibits  protein  translation,  OAS1a  leads  to  the 
degradation  of  viral  RNA  and  Mx1  inhibits  viral  nucleocapsid  transport  or  viral  RNA 
synthesis. To analyse if the expression pattern of these molecules in macrophages, J774A.1 
and RAW 264.7 tumour cells corresponded to the NDV susceptibility, their expression was 
followed after NDV infection by real-time RT-PCR, starting with the PKR.
Figure  4 -22 demonstrates that the PKR expression was increased the most in J774A.1 cells 
when infected with live NDV Ulster  (part  A) or NDV Italien (part  C,  40-fold or 54-fold 
respectively). The induction was lower in macrophages (25-fold and 43-fold respectively) and 
lowest  in  RAW  264.7  cells  (13-fold  or  23-fold  respectively).  After  infection  with  UV-
inactivated  NDV  Ulster  (part  B)  the  induction  of  PKR  expression  was  highest  for 
macrophages  (22-fold),  lower  for  J774A.1  cells  (16-fold)  and  for  RAW  264.7  cells  no 
induction could be observed. In macrophages the expression declined again markedly after the 
peak had been reached, whereas it remained stable in the J774A.1 cells.
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In contrast to the genes analysed so far the J774A.1 and not the macrophages displayed the 
strongest induction of expression for the PKR gene. This was true for the infection with NDV 
Ulster as well as for that with NDV Italien. Only after the infection with UV-inactivated NDV 
Ulster was the PKR level highest in macrophages and declined it at later time points after 
infection. Next, the expression kinetics of the OAS1a was analysed.
Figure  4 -23 demonstrates that OAS1a expression was induced earlier in macrophages than in 
the two tumour cell lines (8 hours versus 24 hours) and that macrophages attained a slightly 
higher maximal expression level than the J774A.1 tumour cells. The OAS1a induction was 
clearly lower than that of the other two cell types. The expression kinetics after infection with 
NDV Ulster (part A) or NDV Italien (part C) was similar, the only distinct difference being 
that the maximum for J774A.1 cells was reached at a later time point. After infection with 
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Figure  4 -22: Changes in protein kinase PKR (PKR) gene expression after NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A), UV-inactivated NDV Ulster (B) or live NDV Italien (C). At 
different time points after the infection total RNA was extracted and after reverse transcription the level of 
protein kinase PKR (PKR) expression was determined by real-time PCR with the comparative CT method using 
the acidic ribosomal phosphoprotein PO for normalisation. The gene expression level is shown relative to the 
level in RAW 264.7 cells. The results are represented as the mean of three measurements. Bars indicate standard 
deviation.
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UV-inactivated NDV Ulster (part B) macrophages showed a peak of expression after 8 hours 
which was comparable to that reached after infection with live NDV, but which fell rapidly 
thereafter. In J774A.1 cells there was only a low but persistent increase in OAS1a expression 
after infection with UV-inactivated NDV Ulster, while in RAW 264.7 cells the expression 
was not increased.
For the OAS1a gene the induction of expression after NDV infection was slightly higher for 
macrophages than for J774A.1 cells, while RAW 264.7 cells displayed merely a low increase 
in  OAS1a  expression.  A  clear  increase  in  gene  expression  could  be  observed  earlier  in 
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Figure  4 -23: Changes in 2'-5' oligoadenylate synthetase 1A (OAS1a) gene expression after 
NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A), UV-inactivated NDV Ulster (B) or live NDV Italien (C). At 
different time points after the infection total RNA was extracted and after reverse transcription the level of 2'-5' 
oligoadenylate synthetase 1A (OAS1a) expression was determined by real-time PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The gene expression level is shown 
relative to the level in RAW 264.7 cells.  The results are represented as the mean of three measurements. Bars 
indicate standard deviation.
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macrophages than in the two tumour cells lines. Last, the expression kinetics of the Mx1 gene 
was determined after NDV infection.
Figure  4 -24 shows that the Mx1 expression after infection with NDV Ulster (part A) was 
noticeably increased early on, reaching a maximum of 581-fold. The induction was clearly 
lower and later for the J774A.1 cells reaching a maximum of 65-fold, while the RAW 264.7 
cells  displayed  no  clear  increase  in  Mx1 expression.  After  infection  with  UV-inactivated 
NDV Ulster (part B) a slight increase in gene expression could be observed for J774A.1 cells, 
whereas the Mx1 expression level of RAW 264.7 cells declined during the infection.
For the Mx1 expression kinetics there was a pronounced difference between the three cell 
types.  The macrophages  showed a strong and early  induction of  expression,  the  J774A.1 
displayed a lower and delayed induction and in RAW 264.7 cells gene expression remained 
the same or even decreased after infection.
In summary it can be said that the inducible expression of the genes analysed in this chapter 
correlates  with  NDV  resistance.  An  early  and  high  induction  could  usually  be  found  in 
macrophages, which were most resistant to NDV infection. The J774A.1 cells, which had an 
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Figure  4 -24: Changes in Myxovirus (influenza virus) resistance 1 (Mx1) gene expression 
after NDV infection.
Bone marrow-derived macrophages from DBA/2 mice, J774A.1 and RAW 264.7 tumour cells were infected 
with 10 HU per 106 cells live NDV Ulster (A) or UV-inactivated NDV Ulster (B). At different time points after 
the infection total RNA was extracted and after reverse transcription the level of Myxovirus (influenza virus) 
resistance 1 (Mx1) expression was determined by real-time PCR with the comparative CT method using the 
acidic ribosomal phosphoprotein PO for normalisation. The gene expression level is shown relative to the level 
in RAW 264.7 cells.  The results are represented as the mean of three measurements.  Bars indicate standard 
deviation.
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intermediate NDV resistance, generally displayed a later induction of gene expression with a 
lower maximum. The RAW 264.7 cells mostly showed an increase in expression at similar 
time points as the J774A.1 cells, but the maximum level that was reached in the course of the 
infection was clearly lower.
The velogenic NDV Italien induced in general a lower gene expression than the lentogenic 
NDV Ulster,  which  might  be  connected  to  the  increased cytotoxicity  of  the  former.  The 
hypothesis in this case would be that if a virus stimulates a weaker antiviral response, it can 
replicate better and is for that reason more cytotoxic.
Viral  replication  seemed  to  be  necessary  to  induce  a  strong  and  sustainable  interferon 
response, since UV-inactivated NDV, which cold not replicate any more, induced only a low 
increase  in  gene  expression.  One  interesting  phenomenon  was  that  macrophages  when 
infected with UV-inactivated NDV Ulster displayed a strong peak of expression at 8 hours 
after infection which could not be found in the tumour cell lines and which declined sharply 
after  this  time  point.  This  indicates  a  mechanism  of  inducing  interferon-related  gene 
expression in the absence of viral replication which was only active in the very early phase of 
an infection and only in macrophages. This mechanism could be related to the HN molecule 
of NDV, which is known to be able to induce interferons in the absence of viral replication 
(Fournier et al., 2003).
 4.2.7 The influence of IFN-α4 on the interferon-related gene expression
Since it had been demonstrated that the pretreatment with IFN-α4 could block NDV infection 
in  macrophages  and  two  macrophage-like  tumour  cells,  it  was  speculated  that  this 
pretreatment  induced  the  expression  of  genes  with  antiviral  properties  to  an  extent  that 
correlated with the degree of the blocking. According to this hypothesis it was expected, for 
example,  that  in  macrophages  the  induction  of  interferon-related  gene  expression  was 
strongest since they displayed the most complete blocking. In order to test this hypothesis the 
expression  of  RIG-I,  IRF3,  IRF7  and  IFN-β  was  analysed  with  and  without  IFN-α4 
pretreatment before and after NDV infection with real-time RT-PCR.
Figure  4 -25 shows that the IFN-α4 pretreatment induced RIG-I expression in all three cell 
types. The induction was about 5-fold in macrophages, 2-fold in J774A.1 cells and 3-fold in 
RAW 264.7 cells.  In  all  three  cell  types  NDV Ulster  infection induced a  stronger  RIG-I 
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expression than the pretreatment with IFN-α4. When pretreated with IFN-α4 macrophages 
displayed a higher RIG-I expression level after NDV infection, while in the two tumour cell 
lines the level was reduced compared to the control. In addition the pretreated macrophages 
had a basal RIG-I expression level that was higher than that in the tumour cells after NDV 
infection.
RIG-I could be induced by IFN-α4 in all three cell types and the extent of induction correlated 
with NDV resistance and the blocking of NDV infection as determined before. The induction 
was strongest  in macrophages,  lower in J774A.1 cells and lowest in RAW 264.7 cells.  A 
difference between the macrophages and the two tumour cell  lines with regard to IFN-α4 
responsiveness  was  that  after  NDV  infection  the  RIG-I  expression  level  was  higher  in 
pretreated  macrophages  than  in  pretreated  tumour  cells.  Following  the  analysis  of  the 
cytosolic  dsRNA receptor RIG-I,  the IRF3 transcription factor expression was determined 
with and without IFN-α4 pretreatment.
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Figure  4 -25: The influence of IFN-α4 pretreatment on the RIG-I expression in macrophages, 
J774A.1 and RAW 264.7 tumour cells after NDV infection.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were grown for 
7 days either in normal growth medium (control group) or in medium supplemented with 1500 U/mL anti-IFN-α 
and  1900 U/mL anti-IFN-β antibody  (IFN-α4  group).  To  the  latter  group  IFN-α4 was  added  with  a  final 
concentration of 120 IU/mL 16 hours before NDV infection. The cells were then infected with  10 HU NDV 
Ulster per 106 cells (see Figure  4 -10) and total RNA was extracted directly before infection (0 h) or 20 hours 
after infection. The level of RIG-I expression was determined by real-time RT-PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The results are represented as the mean 
of three measurements. Bars indicate standard deviation.
0
200
400
600
800
control IFN-α4 control IFN-α4 control IFN-α4
macrophages J774A.1 RAW 264.7
R
el
at
iv
e 
R
IG
-I 
ex
pr
es
si
on
0 h
20 h
Results                                                                                                                                            
Figure  4 -26 demonstrates that IRF3 was not inducible by IFN-α4. The IRF3 expression level 
was almost the same in the pretreated as in the control cells or it even decreased slightly as in 
the RAW 264.7 cells. NDV Ulster infection only stimulated IRF3 expression in macrophages 
and not in the two tumour cell lines. There was no clear difference in the IRF3 expression 
level between the IFN-α4 pretreated and the control group for all three cell types.
In contrast to RIG-I, IRF3 expression did not seem to be IFN-α4-dependent. In the interferon 
signalling cascade IRF3 stimulates the transcription of IFN-α4 after activation, but there did 
not appear to be a feedback loop that in turn influenced the IRF3 expression via IFN-α4. Next, 
the induction of IRF7 by IFN-α4 was investigated.
Figure  4 -27 shows that  IRF7 was inducible  by IFN-α4 in all  three cell  types,  with the 
induction being strongest in macrophages with about 30-fold, lower in J774A.1 cells with 
about 8-fold and lowest  in RAW 264.7 cells with about 4-fold.  Compared to the IFN-α4 
pretreatment  infection  with  NDV  Ulster  stimulated  the  IRF7  expression  much  more 
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Figure  4 -26: The influence of IFN-α4 pretreatment on the IRF3 expression in macrophages, 
J774A.1 and RAW 264.7 tumour cells after NDV infection.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were grown for 
7 days either in normal growth medium (control group) or in medium supplemented with 1500 U/mL anti-IFN-α 
and  1900 U/mL anti-IFN-β antibody  (IFN-α4  group).  To  the  latter  group  IFN-α4 was  added  with  a  final 
concentration of 120 IU/mL 16 hours before NDV infection. The cells were then infected with  10 HU NDV 
Ulster per 106 cells (see Figure  4 -10) and total RNA was extracted directly before infection (0 h) or 20 hours 
after infection. The level of IRF3 expression was determined by real-time RT-PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The results are represented as the mean 
of three measurements. Bars indicate standard deviation.
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pronouncedly in all three cell types. IFN-α4 pretreatment reduced the IRF7 expression after 
NDV infection compared to the control.
In contrast to IRF3, IRF7 turned out to be highly inducible by IFN-α4. As for RIG-I the extent 
of IRF7 induction correlated with NDV resistance and the blocking of NDV infection as 
determined before. The induction was strongest in macrophages, lower in J774A.1 cells and 
lowest in RAW 264.7 cells. Compared to the basal expression level the IFN-α4 pretreatment 
induced IRF7 expression markedly stronger than the expression of RIG-I. Last, the expression 
of IFN-β after IFN-α4 pretreatment was analysed.
Figure  4 -28 demonstrates that IFN-β expression was induced after IFN-α4 pretreatment only 
in macrophages, while it remained stable in the two tumour cell lines. Again, NDV Ulster 
infection induced gene expression in almost all cells and except for macrophages the IFN-β 
expression after NDV infection was lower than in the control cells. 
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Figure  4 -27: The influence of IFN-α4 pretreatment on the IRF7 expression in macrophages, 
J774A.1 and RAW 264.7 tumour cells after NDV infection.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were grown for 
7 days either in normal growth medium (control group) or in medium supplemented with 1500 U/mL anti-IFN-α 
and  1900 U/mL anti-IFN-β antibody  (IFN-α4  group).  To  the  latter  group  IFN-α4 was  added  with  a  final 
concentration of 120 IU/mL 16 hours before NDV infection. The cells were then infected with  10 HU NDV 
Ulster per 106 cells (see Figure  4 -10) and total RNA was extracted directly before infection (0 h) or 20 hours 
after infection. The level of IRF7 expression was determined by real-time RT-PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The results are represented as the mean 
of three measurements. Bars indicate standard deviation.
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The IFN-β expression appeared to depend little on the presence of IFN-α4, since only a slight 
increase  in  expression  could  be  observed  only  in  macrophages.  Solely  NDV  infection 
produced a marked increase in IFN-β expression.
In summary it could be said that IFN-α4 induced the expression of IRF7 and RIG-I and also 
to a lower degree that of IFN-β, whereas the expression of IRF3 proved to be independent of 
IFN-α4 in the three cell types. The responsiveness to IFN-α4 with regard to interferon-related 
gene  expression  correlated  with  NDV  resistance  and  blocking  of  NDV  infection  as 
determined before (4.2.2.3). In macrophages the increase in gene expression was noticeably 
higher than in J774A.1 and RAW 264.7 tumour cells. NDV infection induced gene expression 
more  strongly  than  the  IFN-α4  pretreatment,  perhaps  because  upon  NDV  infection  the 
secretion of IFN-α4 is stronger and additional danger signals such as other interferons are 
secreted. In macrophages often the IFN-α4 pretreatment did not reduce gene expression after 
NDV infection, although the infection was completely blocked by the pretreatment and no 
replication  could  be  expected  to  take  place.  This  could  have  been  due  to  the  ability  of 
macrophages to increase antiviral gene expression even in the absence of NDV replication, as 
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Figure  4 -28: The influence of IFN-α4 pretreatment on the IFN-β expression in macrophages, 
J774A.1 and RAW 264.7 tumour cells after NDV infection.
Bone marrow-derived macrophages from BALB/c mice, J774A.1 and RAW 264.7 tumour cells were grown for 
7 days either in normal growth medium (control group) or in medium supplemented with 1500 U/mL anti-IFN-α 
and  1900 U/mL anti-IFN-β antibody  (IFN-α4  group).  To  the  latter  group  IFN-α4 was  added  with  a  final 
concentration of 120 IU/mL 16 hours before NDV infection. The cells were then infected with  10 HU NDV 
Ulster per 106 cells (see Figure  4 -10) and total RNA was extracted directly before infection (0 h) or 20 hours 
after infection. The level of IFN-β expression was determined by real-time RT-PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The results are represented as the mean 
of three measurements. Bars indicate standard deviation.
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had been observed before in infections with UV-inactivated NDV (4.2.6).
 4.3 Analysis of knock outs in genes involved in the interferon 
response
The experiments carried out so far in macrophages and macrophage-like tumour cells pointed 
to the importance of key molecules of the interferon response being connected to an increased 
susceptibility to NDV infection. In order to analyse the functional significance of some of the 
proteins involved in an antiviral response, macrophages were generated from mice with gene 
knock outs of these antiviral molecules. Five single gene knock outs could be obtained and 
investigated with regard to NDV infection and to an antiviral response. They were knock outs 
for the transcription factors IRF3 and IRF7, the two Toll-like receptors TLR3 and TLR7, 
recognizing viral  double-stranded or single-stranded RNA respectively,  and for the type  I 
interferon receptor IFNAR. The parameters analysed were NDV infection with IFN or anti-
IFN pretreatment, virally induced interferon secretion and interferon-related gene expression.
 4.3.1 NDV replication in knock out macrophages
The first characteristic measured in the knock out macrophages was the infection with NDV. 
Since the proteins missing in the knock outs were important factors in the establishment of an 
interferon response,  it  was hypothesised that compared to the wildtype there might be an 
increase in NDV susceptibility at least in some of the knock outs. The macrophages were 
pretreated with anti-IFN-β or IFN-α4 and then infected with NDFL-EGFP. The EGFP signal 
was measured by flow cytometry one day later.
Figure  4  -29 shows that  IFN-α4 pretreatment  completely blocked an EGFP signal  upon 
NDFL-EGFP infection in all knock out macrophages except for the IFNAR knock out. The 
latter knock out displayed the highest EGFP signal of all cells for the control and for the two 
pretreatment groups. In addition the EGFP expression in IFNAR knock out macrophages that 
were pretreated with anti-IFN-β or IFN-α4 was lower than in the control. The EGFP signal of 
the two Toll-like receptors was very similar to that of the wildtype. In the IRF3 and IRF7 
knock outs the EGFP signal was slightly increased in comparison with the wildtype, with the 
signal in IRF3 knock outs being higher than in the IRF7 knock outs. In general the anti-IFN-β 
pretreatment  either did not change the EGFP expression (wildtype,  TLR3-/-,  TLR7-/-)  or it 
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slightly decreased it (IRF3-/-, IRF7-/-).
In comparison to the wildtype the strongest increase in the EGFP expression was found in 
IFNAR knock out macrophages, pointing to the outstanding importance of this molecule in an 
antiviral response. It was also evident that IFN-α4 signalling took place only via the IFNAR, 
since  compared  to  the  control  and  to  the  anti-IFN-β  pretreated  cells  there  was  no  clear 
blocking of infection in the IFNAR knock outs in contrast to all other macrophages tested. 
IFN-α4 could block NDV infection when compared to the control, indicating that for example 
the  induction  of  IRF7  by  IFN-α4,  which  had  been  shown  before,  did  not  appear  to  be 
necessary for an effective antiviral response in this experimental setting. The IRF3 knock outs 
exhibited a higher EGFP signal than the wildtype and to a lesser degree this was also true for 
the IRF7 knock outs. This indicated that the early phase in the interferon response, which 
depends on IRF3, was more important in impeding NDV infection than the late phase. TLR3 
and TLR7 did not seem to be important for an anti-NDV response in the cells as well as 
interferon-β secreted before NDV infection, since the anti-IFN-β pretreatment did not clearly 
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Figure  4 -29: EGFP  expression  in  macrophages  with  different  knock-outs  in  interferon-
related genes infected with NDFL-EGFP after  pretreatment  with anti-IFN-β 
antibody or IFN-α4.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7, TLR3, TLR7 and 
IFNAR were grown for 7 days either in normal growth medium (■ control group) or in medium supplemented 
with  1900 U/mL anti-IFN-β antibody (■ anti-IFN-β group and  ■ IFN-α4 group).  For  4  hours  before  NDV 
infection one group of cells (■ IFN-α4 group) was grown in medium supplemented with 120 IU/mL IFN-α4. 24 
hours after infection with 10 HU NDFL-EGFP per 106 cells EGFP expression of the cells was determined in 
flow cytometry. 
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influence the EGFP signal.  Another parameter  that  was determined next to analyse  NDV 
infection was the viral M gene, which was measured in the knock outs after NDV Ulster 
infection with real-time RT-PCR.
Figure  4 -30 demonstrates that also the M gene expression was highest in IFNAR knock outs 
and that IFN-α4 pretreatment had no influence on the M gene expression after NDV Ulster 
infection.  In contrast  IFN-α4 pretreatment  strongly reduced the M gene expression in the 
wildtype  and the IRF3 and IRF7 knock outs. On average the M gene expression in IRF3 
knock outs was about 10 times lower than that in IFNAR knock outs and about 40 times lower 
in IRF7 knock outs. Related to the wildtype M gene expression in IRF3 and IRF7 knock outs 
was markedly higher with about 100-fold or around 25-fold respectively.
The analysis of the M gene expression in the knock out macrophages after NDV infection 
underlined the crucial importance of the IFNAR for the generation of an antiviral state and for 
the induction of NDV resistance by IFN-α4. It also proved the role of IRF3 and to a lesser 
extent that of IRF7 in limiting M gene expression after NDV infection. In addition it seemed 
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Figure  4 -30: NDV Ulster M gene expression in macrophages with different knock-outs in 
interferon-related genes after pretreatment with anti-IFN-β antibody or IFN-α4.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7 and IFNAR were 
grown for 7 days either in normal growth medium (■ control group) or in medium supplemented with 1900 
U/mL anti-IFN-β antibody (■ anti-IFN-β group and  ■ IFN-α4 group). For 4 hours before NDV infection one 
group of cells (■ IFN-α4 group) was grown in medium supplemented with 120 IU/mL IFN-α4.  20 hours after 
infection with 10 HU NDV Ulster per 106 cells the expression level of the NDV M gene was determined by real-
time RT-PCR with the comparative CT method using β-actin for normalisation. The results are represented as the 
mean of three measurements. Part B of the figure shows the same data as part A without the IFNAR -/- samples to 
better  visualise  the  M gene  expression  differences  between  the  IRF3-/- and  the  IRF7-/- cells.  Bars  indicate 
standard deviation.
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again that interferon-β that might be secreted constitutively without viral infection did not 
influence  the  M  gene  expression  after  NDV  infection.  To  gain  further  insight  in  the 
importance of the genes that were knocked out especially with regard to their influence at 
certain time points  after  infection,  a kinetics  of the M gene expression after  NDV Ulster 
infection was generated.
Figure  4 -31 shows that none of the knock outs had a higher M gene expression than the 
wildtype 4 hours after NDV Ulster infection. There was also no clear difference in M gene 
expression between the wildtype and the TLR3 and TLR7 knock outs at any other time point. 
The M gene level compared to the wildtype was increased 8 and 20 hours after NDV infection 
in the IRF3 and IRF7 knock outs. 8 hours after infection the M gene expression was similar 
between the IRF3 and IRF7 knock out, but 20 hours after infection the M gene level in IRF3 
knock out macrophages had increased, whereas it had decreased in IRF7 knock outs.
The kinetics of the M gene expression after NDV infection demonstrated again that TLR3 and 
TLR7 did not have an influence on the M gene level. At earlier time points IRF3 and IRF7 
appeared to have the same influence on the M gene expression, but at later time points the M 
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Figure  4 -31: NDV Ulster M gene expression kinetics in macrophages with different knock-
outs in interferon-related genes.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7, TLR3 and TLR7 
were infected with 10 HU NDV Ulster per 106 cells and total RNA was extracted 4, 8 and 20 hours later. After 
reverse  transcription  the  expression level  of  the  NDV M gene  was  determined by real-time  PCR with  the 
comparative  CT method  using  β-actin  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements. Bars indicate standard deviation.
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gene level could be reduced in IRF7 knock outs, whereas it increased in IRF3 knock outs. 
This pointed to a  higher importance of the IRF3 gene in the containment  of the M gene 
expression  at  later  time  points  after  NDV  infection.  Next,  the  influence  of  anti-IFN-β 
antibodies and  IFN-α4  on  the  M  gene  expression  kinetics  after  NDV  infection  was 
determined.
Figure  4 -32 shows that when macrophages were pretreated with anti-IFN-β antibodies (part 
A) the M gene expression compared to the wildtype was increased in IRF3 and IRF7 knock 
outs at 8 and 20 hours after infection with NDV Ulster. At 8 hours the two knock outs showed 
around the  same level,  while  at  20 hours  the  level  had increased in the  IRF3 knock out 
macrophages and decreased in IRF7 knock out macrophages. When pretreated with IFN-α4 
(part B) M gene expression was very low compared to the anti-IFN-β pretreated cells. The M 
gene expression level was slightly increased at 4 and 8 hours for the IRF7 knock outs, but a 
20 hours all three cell types had about the same M gene level.
The  M  gene  expression  kinetics  of  cells  pretreated  with  anti-IFN-β  antibodies  was  very 
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Figure  4 -32: NDV Ulster M gene expression kinetics in macrophages with different knock-
outs in interferon-related genes after pretreatment with anti-IFN-β antibody or 
IFN-α4.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3 and IRF7 were grown for 
7  days in  medium supplemented  with  1900 U/mL anti-IFN-β antibody (A + B).  For  4  hours  before  NDV 
infection one group of cells was grown in medium supplemented with 120 IU/mL IFN-α4 (B). 4, 8 and 20 hours 
after infection with 10 HU NDV Ulster per 106 cells total RNA was extracted and the expression level of the 
NDV  M  gene  was  determined  by  real-time  RT-PCR  with  the  comparative  CT method  using  β-actin  for 
normalisation. The results are represented as the mean of three measurements. Bars indicate standard deviation.
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similar to that of control cells without pretreatment analysed before, thereby indicating that 
IFN-β secretion ahead of NDV infection did not play an important role in acting upon NDV 
replication.  The  results  demonstrated  again  that  IRF3  was  important  to  lower  M  gene 
expression  at  later  time points,  whereas  IRF7 seemed to  have  less  influence  on  M gene 
expression at later time points after infection. Finally, the role of the IFNAR in the M gene 
expression kinetics after NDV infection was tested.
Figure  4 -33 demonstrates that there was a strong increase in M gene expression between 4 
and 8 hours after NDV Ulster infection. Between 8 and 20 hours there was again an increase 
in the M gene expression level of about 50 % in all three groups. The macrophages pretreated 
with  anti-IFN-β  antibodies  had  a  somewhat  higher  M gene  level,  while  in  macrophages 
pretreated with IFN-α4 the expression level was slightly lower.
The results demonstrated that the IFNAR was essential in containing the M gene expression 
already at early time points after NDV infection. The differences between the pretreated and 
the control macrophages were unlikely to be genuine and probably due to chance variations 
since no influence of type I interferons could be conceived in the absence of the only known 
receptor for these interferons.
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Figure  4 -33: NDV Ulster M gene expression kinetics in IFNAR-/- macrophages after NDV 
Ulster infection.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the IFNAR gene were grown for 7 days 
either in normal growth medium (■ control group) or in medium supplemented with 1900 U/mL anti-IFN-β 
antibody (■ anti-IFN-β group and  ■ IFN-α4 group).  For  4  hours  before  NDV infection  one  group of  cells 
(■ IFN-α4) was grown in medium supplemented with 120 IU/mL IFN-α4. 4, 8 and 20 hours after infection with 
10 HU NDV Ulster per 106 cells the expression level of the NDV M gene was determined by real-time RT-PCR 
with the comparative CT method using β-actin for normalisation. The results are represented as the mean of three 
measurements. Bars indicate standard deviation.
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To summarise the results of the NDV infections in the analysed knock out macrophages it can 
be stated that the IFNAR clearly plays the most important role in the defence against NDV 
since its absence caused the strongest EGFP or M gene signals. It also became clear that type 
I interferon signalling in macrophages took place only via the IFNAR, for IFN-α4 produced a 
strong blocking of NDV infection in all except the IFNAR knock out macrophages.
In addition the IRF3 and IRF7 transcription factors also appeared to be involved in an anti-
NDV response, with the IRF3 having a somewhat stronger influence than the IRF7 protein 
with regard to the M gene expression at later time points. One explanation would be that in 
the IRF3 knock out macrophages there was no early phase of the interferon response that is 
usually mediated by IRF3. Without this early phase there was probably also no second phase, 
since  this  second  phase  has  to  be  induced  by  the  first  phase.  In  the  IRF7  knock  out 
macrophages on the other hand there was at least a functioning first phase in the interferon 
response that could in part block NDV replication.
The TLR3 and TLR7 seemed to have no measurable influence on the outcome of an NDV 
infection. After determining the influence of the knock out genes on NDV infection, their role 
in  shaping other  parameters  of  an  interferon response  such as  interferon  secretion  or  the 
expression of interferon-related genes was tested.
 4.3.2 Interferon secretion after NDV infection in knock out 
macrophages
The secretion of type I interferons upon viral infection is considered to be an important factor 
in the establishment of an antiviral state in cells. An effective interferon response depends 
strongly on positive feedback loops for the induction of key components such as IRF7. These 
feedback signals are  transmitted by type  I  interferons that  signal in  an auto- or paracrine 
manner exclusively via the IFNAR. In order to investigate the influence of genes related to an 
interferon response on the secretion of type I interferons after NDV infection, macrophages 
from knock out mice were generated, infected with NDV and then the interferon content in 
the supernatants was determined in a bioassay detecting only biologically active interferons 
(3.2.7). The macrophages were also pretreated with anti-IFN-β antibodies and with IFN-α4 
before infection to examine the influence of the knocked out genes on the effect of these 
pretreatments.
95
Results                                                                                                                                            
Figure  4 -34 shows that in the wildtype the secretion of interferons was equal in the control 
and in the anti-IFN-β antibody pretreated macrophages, while it was reduced to about 1/3rd in 
the IFN-α4 pretreated cells. In the absence of the IFNAR no interferon was secreted after 
NDV Ulster infection. The IRF7 knock out macrophages displayed a low interferon secretion 
and secreted 7 times less interferon then the controls for all three conditions tested. In the 
IRF3 knock out macrophages the interferon secretion was slightly lower than in the wildtype 
for the control and for the IFN-α4 pretreated cells. In the anti-IFN-β pretreated cells the IFN 
secretion was twice that in the control. Compared to the wildtype the macrophages with knock 
outs in the TLR3 and TLR7 genes showed a lower interferon secretion in the control and anti-
IFN-β groups and a higher interferon level in the IFN-α4 groups. 
The IFNAR appeared to be a crucial molecule for the secretion of interferons in response to 
viral infections, indicating also the importance of positive feedback loops in the induction of 
interferon  secretion  mediated  by  this  receptor.  IRF7  proved  to  be  of  importance  in  the 
induction  of  type  I  interferon  secretion  since  its  absence  strongly  reduced  the  interferon 
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Figure  4 -34: Interferon secretion in macrophages with different  knock-outs infected with 
NDV.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7, TLR3, TLR7 and 
IFNAR were grown for 7 days either in normal growth medium (■ control group) or in medium supplemented 
with  1900 U/mL anti-IFN-β antibody (■ anti-IFN-β group and  ■ IFN-α4 group).  For  4  hours  before  NDV 
infection one group of cells (■ IFN-α4 group) was grown in medium supplemented with 120 IU/mL IFN-α4. 
After infection with 10 HU per 106 cells NDV Ulster 2*106 cells per well were seeded in 12 well plates with 
2 mL growth medium (see Figure  4 -29). After 20 hours supernatant was collected and the interferon-α/β level 
was determined in a VSV based interferon bioassay. IU = International units
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levels.  IRF3 seemed  to  have  only  a  minor  function  in  interferon  secretion  except  in  the 
presence of anti-IFN-β antibodies. The strong increase in the interferon level in the presence 
of these antibodies could indicate a negative regulatory effect of IFN-β in IRF3 knock out 
macrophages.  The two Toll-like  receptor  knock outs  only had a  minor  effect  by slightly 
reducing interferon secretion. Regarding the pretreatments in general IFN-α4 led to a slight 
increase in interferon, perhaps by limiting viral replication and viral danger signals that could 
induce  interferons,  whereas  anti-IFN-β  did  not  show  a  clear  effect.  Next  an  interferon 
secretion kinetics was used to test for the importance of the gene knock outs at specific times 
after infection.
Figure  4 -35 shows that in the control medium (part A) at 4 hours after infection interferon 
could only be detected in the supernatants of wildtype macrophages. There was interferon 
secretion in IFNAR knock out macrophages that led to a detectable interferon concentration 
from 8 hours on, but the interferon level remained at a low level that was about 100-fold 
lower  than  that  of  wildtype  macrophages  20  hours  after  infection.  In  IRF3  knock  out 
macrophages interferon was not detectable until 20 hours after infection, at which point it 
attained almost the same level as the wildtype.  In IRF7 knock out macrophages interferon 
secretion could be observed from 8 hours on, but the final level was about 10 times lower than 
that in the wildtype. When pretreated with anti-IFN-β antibodies there was a similar picture 
for the interferon secretion in IRF3 and IRF7 knock out macrophages (part B). In the IRF3 
knock out cells interferon could only be observed 20 hours after infection, but at that point it 
had reached the same level as the wildtype. In the IRF7 knock out macrophages interferon 
could already be detected after 4 hours, but the final level was about 8 times lower than that of 
the wildtype.
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The results of the interferon secretion kinetics suggested different roles for the IRF3 and the 
IRF7 transcription factors. IRF3 seemed to be important for the secretion of interferons at 
early time points after infection, but its absence did not diminish the final interferon level. In 
contrast IRF7 did not appear to be important for the interferon secretion at early time points, 
but was necessary for reaching normal interferon levels at later time points. Since the IRF3 
knock out macrophages were more susceptible to NDV infection than the IRF7 knock outs, it 
could be hypothesised that in the tested setting the early secretion of low type I interferon 
amounts was more important for NDV resistance than the later secretion of high interferon 
amounts. A low interferon secretion upon NDV infection as seen in the IFNAR knock out 
macrophages could explain the high NDV susceptibility of these cells. As the last parameter 
to be tested remained the interferon-related gene expression with or without IFN-α4 before 
and after NDV infection.
 4.3.3 Expression of interferon-related genes in knock out 
macrophages
In order to ascertain the influence of the five gene knock outs on antiviral gene expression, the 
expression level of RIG-I, IRF3, IRF7 and IFN-β was determined by real-time RT-PCR. The 
basal as well as the NDV-inducible expression levels were determined and in addition the 
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Figure  4 -35: Kinetics of interferon secretion in macrophages with knock-outs in different 
interferon-related genes after infection with NDV Ulster.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7 and IFNAR were 
grown for 7 days in normal growth medium (A) or medium supplemented with 1900 U/mL anti-IFN-β antibody 
(B). After infection with 10 HU per 106 cells NDV Ulster 2*106 cells per well were seeded in 12 well plates with 
2 mL growth medium (see  Figure  4 -29 - 4-33). After 4, 8 and 20 hours supernatant was collected and the 
interferon-α/β level was determined in a VSV based interferon bioassay. IU = international units
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knock out macrophages were pretreated with IFN-α4 to determine how the IFN-α4-induced 
gene expression was influenced by the knocked out genes.
Figure   4  -36 demonstrates  that  the  basal  expression  level  of  RIG-I  was  lowered in  the 
absence of the IFNAR, whereas it was unaltered in the IRF3 and IRF7 knock outs. When 
grown in normal medium (part  A),  the induction of  RIG-I  by NDV Ulster  infection was 
delayed in all knock outs compared to the wildtype. The final RIG-I expression level in IRF3 
knock out macrophages was the same as in the wildtype, while it was slightly reduced in the 
IRF7 and IFNAR knock outs. After IFN-α4 pretreatment (part B) the final RIG-I level after 
NDV infection was lower in all  knock out macrophages compared to the wildtype.  In the 
IFNAR knock out the basal level and the expression at 8 hours after infection was several 
times lower than that of all other macrophages.
The expression of RIG-I was not strongly regulated by IRF3 and IRF7, since their absence did 
just slightly lower and delay the inducible RIG-I expression. IFNAR appeared to be necessary 
for  both  the  basal  and  the  inducible  RIG-I  expression,  but  at  later  time  points  RIG-I 
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Figure  4 -36: RIG-I  expression  in  IRF3,  IRF7  and  IFNAR  knock-out  macrophages  after 
infection with NDV Ulster.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7 and IFNAR were 
grown for 7 days either in normal growth medium (A) or in medium supplemented with 1900 U/mL anti-IFN-β 
antibody (B). For 4 hours before NDV infection one group of cells (B) was grown in medium supplemented with 
120 IU/mL IFN-α4. At 0, 4, 8 and 20 hours after infection with 10 HU NDV Ulster per 106 cells the expression 
level of the RIG-I gene was determined by real-time RT-PCR with the comparative CT method using the acidic 
ribosomal phosphoprotein PO for normalisation. The results are represented as the mean of three measurements. 
Bars indicate standard deviation.
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expression was also increased in the IFNAR knock outs,  pointing to IFNAR-independent 
ways  of  RIG-I  induction.  Next,  the  IRF3 expression  in  the  knock  out  macrophages  was 
analysed.
Figure  4 -37 shows that the basal and NDV-inducible IRF3 expression in IRF7 and IFNAR 
knock  out  macrophages  was  slightly  reduced  compared  to  the  wildtype  (part  A).  This 
reduction  in  expression  was  most  pronounced  20  hours  after  NDV Ulster  infection.  The 
pretreatment with IFN-α4 did not stimulate the IRF3 expression before or in the course of 
NDV infection.
The results confirmed that IRF3 is not strongly inducible neither by IFN-α4 nor by NDV 
infection. IRF7 and the IFNAR seemed to play only a minor role in IRF3 expression, because 
their  absence  decreased  IRF3  expression  only  little.  A  transcription  factor  that  had  been 
shown to be strongly inducible was IRF7, which was analysed next.
Figure  4 -38 demonstrates that the basal and inducible IRF7 expression depended markedly 
on the IFNAR and to a lesser degree on IRF3. In the IFNAR knock out macrophages almost 
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Figure  4 -37: IRF3 expression in IRF7 and IFNAR knock-out macrophages after infection 
with NDV Ulster.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF7 and IFNAR were grown 
for  7  days  either  in  normal  growth  medium (A)  or  in  medium supplemented  with  1900 U/mL anti-IFN-β 
antibody (B, wildtype only). For 4 hours before NDV infection one group of cells  (B) was grown in medium 
supplemented with 120 IU/mL IFN-α4. At 0, 4, 8 and 20 hours after infection with 10 HU NDV Ulster per 106 
cells  the expression level  of  the IRF3 gene was determined by real-time RT-PCR with the comparative CT 
method using the acidic ribosomal phosphoprotein PO for normalisation. The results are represented as the mean 
of three measurements. Bars indicate standard deviation.
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no IRF7 expression could be detected before or during infection with NDV Ulster.  When 
grown in control medium (part A) the IRF7 expression remained nearly undetectable in IRF3 
knock out macrophages except for the 20 hour time point, at which it reached about half the 
expression level of the wildtype. In both the wildtype and the IRF3 knock out macrophages 
IFN-α4 strongly increased the basal IRF7 expression level (part B). Compared to the wildtype 
the IRF7 expression level was slightly reduced in IRF3 knock out macrophages and reached 
about half the level of the wildtype at 0 and 20 hours in IFN-α4 pretreated cells.
The IFNAR seemed to be indispensable for the IRF7 expression, since nearly no IRF7 signal 
could be detected in any of the IFNAR knock out macrophage groups. IRF3 appeared to be 
important in the early phase of IRF7 induction, because the IRF7 level was strongly reduced 
at early time points after NDV infection. This strong reduction could not be found when the 
IRF3 knock out macrophages had been pretreated with IFN-α4. An interpretation would be 
that IRF3 was necessary for the induction of a positive feedback loop via IFN-α4 in the early 
phase of an interferon response, as had been shown in the literature (Sato et al., 1998). When 
IFN-α4 was added this early-phase feedback was short-circuited and IRF7 could be induced 
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Figure  4 -38: IRF7  expression  in  IRF3,  IRF7  and  IFNAR  knock-out  macrophages  after 
infection with NDV Ulster.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7 and IFNAR were 
grown for 7 days either in normal growth medium (A) or in medium supplemented with 1900 U/mL anti-IFN-β 
antibody (B). For 4 hours before NDV infection one group of cells (B) was grown in medium supplemented with 
120 IU/mL IFN-α4. At 0, 4, 8 and 20 hours after infection with 10 HU NDV Ulster per 106 cells the expression 
level of the IRF7 gene was determined by real-time RT-PCR with the comparative CT method using the acidic 
ribosomal phosphoprotein PO for normalisation. The results are represented as the mean of three measurements. 
Bars indicate standard deviation.
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without IRF3. As a last interferon-related gene the IFN-β expression was determined in the 
knock out macrophages.
Figure  4 -39 demonstrates that when infected with NDV Ulster in control medium (part A) 
almost no IFN-β expression could be found in the IRF7 and in the IFNAR macrophages. 
Compared  to  the  wildtype  the  expression  of  IFN-β  was  delayed  in  IRF3  knock  out 
macrophages, but 20 hours after infection the IFN-β was about 4 times of that in the wildtype. 
When pretreated with IFN-α4 a low IFN-β expression in IFNAR knock out macrophages 
could only be observed 20 hours after infection. In the other three macrophages types IFN-β 
expression peaked 8 hours after infection and was markedly lower at 20 hours. The peak in 
expression was highest in the wildtype, about 2.5 times lower in IRF3 knock outs and around 
8 times lower in IRF7 knock out macrophages.
IRF7 and the IFNAR seemed to be crucial for a strong IFN-β expression and in their absence 
almost no IFN-β could be detected in the course of an NDV infection. IRF3 appeared to be 
important for an early expression of IFN-β, since in contrast to the wildtype no IFN-β could 
be detected in IRF3 knock outs 4 and 8 hours after infection.  An important  factor in the 
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Figure  4 -39: IFN-β expression  in  IRF3,  IRF7  and  IFNAR  knock-out  macrophages  after 
infection with NDV Ulster.
Wildtype C57BL/6 macrophages and macrophages with knock-outs in the genes IRF3, IRF7 and IFNAR were 
grown for 7 days either in normal growth medium (A) or in medium supplemented with 1900 U/mL anti-IFN-β 
antibody (B). For 4 hours before NDV infection one group of cells (B) was grown in medium supplemented with 
120 IU/mL IFN-α4. At 0, 4, 8 and 20 hours after infection with 10 HU NDV Ulster per 106 cells the expression 
level of the IFN-β gene was determined by real-time RT-PCR with the comparative CT method using the acidic 
ribosomal phosphoprotein PO for normalisation. The results are represented as the mean of three measurements. 
Bars indicate standard deviation.
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induction of IFN-β expression could be the secretion of IFN-α4 induced by IRF3, because its 
addition led to almost normal IFN-β expression.
In summary it could be said that the expression of RIG-I and IRF3 was relatively independent 
from any of the genes that were knocked out in the macrophages. However, the basal and 
inducible expression of IRF7 was completely dependent on the IFNAR. The expression of 
IRF7 also depended to a lower degree on IRF3, especially with regard to early time points 
after NDV infection. The IFN-β expression depended substantially on both the IRF7 and the 
IFNAR. In the absence of IRF3 the IFN-β expression was delayed in the course of infection.
 4.3.4 NDV infection and gene expression analysis of IFNAR-/- MEF 
Another cell type in which the role of the IFNAR in NDV infection and in the NDV-induced 
interferon response was analysed were mouse embryonic fibroblast (MEF) cells. The MEF 
cell lines had been grown for a long time in vitro and could be expected to respond less to 
growth inhibitory signals as an adaptation to the in vitro culture. The IFN responsiveness of 
the MEF was therefore expected to be lower than that of bone marrow-derived macrophages. 
Wildtype and IFNAR knock out MEF were compared with regard to NDV replication, basal 
and inducible gene expression and IFN responsiveness.
 4.3.4.1 NDV replication
The  first  parameter  that  was  tested  in  the  MEF  was  EGFP  or  M  gene  expression  after 
infection with NDFL-EGFP or NDV Ulster respectively. Before NDV infection some of the 
MEF were  pretreated  with  anti-IFN-α/β antibody to  determine  the  influence  of  the  basal 
interferon secretion of the MEF. Another group of cells was pretreated with IFN-α4 to look 
for  IFN-induced  changes  in  the  resistance  to  NDV infection.  The  EGFP expression  was 
measured in flow cytometry and the M gene level was determined with the help of real-time 
RT-PCR.
Figure  4 -40 demonstrates that the MEF wildtype had a much lower EGFP (part A+B) and M 
gene expression (part C) after NDV infection than the IFNAR knock out. The EGFP and M 
gene signal in the wildtype were not influenced by the anti-IFN-α/β antibody pretreatment. 
Nevertheless, the MEF pretreated with IFN-α4 caused a marked reduction especially with 
regard to M gene expression. In the IFNAR knock out MEF no pretreatment changed the 
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EGFP or M gene signal compared with the control medium. Concerning the EGFP signal 
upon NDFL-EGFP infection in the IFNAR knock out cells (part B) there were apparently two 
populations, one with a low and one with an about 100 times stronger signal (10 versus 1000 
relative fluorescence units). The M gene expression kinetics (part D) revealed that the main 
increase in expression took place between 8 and 20 hours after infection.
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Figure  4 -40: Replication of NDFL-EGFP in wildtype or IFNAR-/- MEF cells.
Wildtype and IFNAR-/- mouse embryonic fibroblasts were grown for 7 days either in normal growth medium 
(■ control group) or in medium supplemented with 1900 U/mL anti-IFN-β antibody (■ anti-IFN-β group and 
■ IFN-α4 group). For 4 hours before NDV infection one group of cells (■ IFN-α4 group) was grown in medium 
supplemented with 120 IU/mL IFN-α4. Afterwards the cells were infected with 10 HU NDFL-EGFP per 106 
cells.  (A + B) The EGFP expression was determined by flow cytometry 20 hours later.  (C) 20 hours after 
infection total RNA was extracted and the expression level of the NDV M gene was determined by real-time RT-
PCR with the comparative CT method using β-actin for normalisation. The results are represented as the mean of 
three measurements. The percentage of M gene expression blocking in comparison to the control is indicated. 
(D) 0, 4, 8 and 20 hours after infection total RNA was extracted from the control and the IFN-α4 group and the 
expression level of the NDV M gene was determined by real-time RT-PCR with the comparative CT method 
using β-actin for normalisation. The results are represented as the mean of three measurements. Bars indicate 
standard deviation.
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The IFNAR seemed to be a crucial factor in NDV resistance, since the IFNAR knock out 
MEF turned out to be much more susceptible to NDV infection than the wildtype MEF. The 
EGFP  signal  in  the  IFNAR  knock  out  MEF  pointed  to  two  populations  with  markedly 
different susceptibilities to NDV, possibly representing two different stages in the cell cycle. 
According  to  this  hypothesis  the  highly  NDV  susceptible  cells  were  proliferating  and 
provided the virus with a high amount of the necessary cellular components for replication. 
The less susceptible cells could be non-proliferating and would therefore be less suitable for 
NDV replication.
Interestingly, the M gene level after NDV infection in the non-tumourigenic wildtype MEF 
was higher than that in tumour cells such as the macrophage-like RAW 264.7 cells analysed 
before (4.2.2.3), perhaps attributable to phenotypic changes in the MEF as an adaptation to 
prolonged in vitro passaging. On the other hand unlike the RAW 264.7 tumour cells the MEF 
responded strongly to interferons and the M gene expression could almost  be completely 
blocked by IFN-α4 pretreatment. As expected IFN-α4 did not influence the NDV infection in 
IFNAR knock out MEF, since the IFNAR is the only known receptor for IFN-α4.
 4.3.4.2 Interferon-related gene expression
One explanation for the clear differences in NDV susceptibility between wildtype and IFNAR 
knock  out  MEF  could  be  differences  in  the  expression  of  genes  related  to  the  antiviral 
interferon  response.  The  expression  of  three  genes  important  in  the  establishment  of  an 
interferon response was followed after NDV infection by real-time RT-PCR.
Figure  4 -41 shows that the basal expression of RIG-I,  IRF7 and IFN-β was moderately 
higher in the IFNAR than in the wildtype MEF. The IFN-α4 pretreatment increased the basal 
gene  expression only in  the  wildtype  MEF and solely  in  these  cells  it  reduced the  gene 
expression  after  NDV  infection.  The  increase  in  basal  gene  expression  by  IFN-α4 
pretreatment was highest for IRF7 (7-fold) and lower for RIG-I (3-fold) and IFN-β (2-fold). 
After infection with NDV Ulster the IFN-β expression in the IFNAR knock out MEF was 10 
– 15 times higher and the RIG-I expression 3 times higher than in the wildtype. The IRF7 
expression after infection was comparable in both MEF cell types.
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Overall the relative gene expression in MEF was substantially lower than in macrophages. 
IFN-α4 pretreatment increased basal gene expression and led to a reduced expression level 
after NDV infection only in wildtype and not in IFNAR knock out MEF, corresponding to the 
assumption that IFN-α4 signals exclusively through the IFNAR.
In contrast to the macrophages analysed earlier (4.3.3) the NDV-inducible expression of IFN-
β and RIG-I was higher in the IFNAR knock out than in the wildtype MEF and the IRF7 
expression was comparable. The stronger gene expression in the IFNAR knock out MEF of 
IFN-β and RIG-I after NDV infection could be explained by more viral danger signals due to 
the better NDV replication in the IFNAR knock outs. IFN-β and RIG-I expression did not 
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Figure  4 -41: Interferon-related  gene  expression  in  wildtype  or  IFNAR-/- MEF cells  after 
infection with NDV.
Wildtype and IFNAR-/- mouse embryonic fibroblasts (MEF) were grown for 7 days either in normal growth 
medium (control group) or in medium supplemented with 1900 U/mL anti-IFN-β antibody (IFN-α4 group). For 
4 hours before NDV infection one group of cells (IFN-α4 group) was grown in medium supplemented with 120 
IU/mL IFN-α4. Afterwards, the cells were infected with 10 HU NDFL-EGFP per 106 cells. At 0 and 20 hours 
after infection total RNA was extracted and the expression level of the RIG-I (A), the IRF7 (B) and the IFN-β 
(C) gene was determined by real-time RT-PCR with the comparative CT method using the acidic ribosomal 
phosphoprotein PO for normalisation.  The results  are represented as the mean of three measurements.  Bars 
indicate standard deviation.
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appear  to  be  strongly  dependent  on  the  IFNAR  signalling  in  macrophages  (4.3.3)  and 
therefore the IFNAR knock out MEF were not expected to be markedly inhibited in their 
ability to synthesise these molecules. Surprisingly,  the IRF7 gene expression was also not 
inhibited although in macrophages it could be shown that IRF7 expression strongly depends 
on IFNAR signalling. Evidently the long in vitro culture had strongly reduced the ability of 
wildtype MEF to express IRF7 since compared to macrophages the basal and inducible IRF7 
expression was decidedly lower than in macrophages.
 4.4 Connection between antiviral gene expression and NDV 
susceptibility in tumour and normal cells
In order to investigate whether the lower basal and inducible expression of interferon-related 
genes that could be observed in some tumour cells (4.1, 4.2) represented a general feature of 
many tumour  cells  and could  therefore  explain  the  generally  high NDV susceptibility  of 
tumour cells,  several  normal and tumour cells  were tested and compared regarding NDV 
replication and antiviral gene expression. The aim was to find out if genes involved in the 
interferon response were differently expressed in normal and in tumour cells. In addition it 
should be examined to what degree NDV resistance could be correlated with the expression 
levels of the analysed genes.
 4.4.1 Analysis of RIG-I, IRF3, IRF7, IFN-β and M gene expression in 
normal and tumour cells
The first parameter that was compared between normal and tumour cells was the M gene 
expression  after  NDV infection.  To  this  end  several  normal  and  tumour  cell  types  were 
infected with NDV Ulster and the M gene expression was measured with real-time RT-PCR 
one day after infection.
Figure  4 -42 shows that the M gene expression one day after infection with NDV was higher 
in tumour than in normal cells. The difference was not statistically significant. In contrast to 
the normal cells there was a high variation in M gene expression in the tumour cells and three 
groups could be distinguished. One group with relatively low M gene expression comprised 
the CT26p (23 relative expression units (REU)), J774A.1 (64 REU) and RAW 264.7 cells 
(3749 REU). A medium expression was found in DA3 (20821 REU), CT26wt (21063 REU) 
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and B16 cells (19973 REU), and a high expression displayed the Esb cells (44529 REU). The 
M gene level in normal cells was always lower than 31 REU.
The results  demonstrated  that  the  M gene expression  after  NDV infection  was  markedly 
higher in tumour than in normal cells. The lack of statistical significance could be explained 
by the high variation of the M gene expression in the tumour cells. Next the expression of 
four interferon-related genes was determined in normal  and tumour cells  before and after 
NDV infection  with  the  help  of  real-time RT-PCR. In addition  the  degree  of  correlation 
between the M and the antiviral gene expression was calculated.
Figure  4 -43 demonstrates that the basal and inducible RIG-I expression was significantly 
higher in normal than in tumour cells. The average basal RIG-I level (part A) was 47 REU in 
normal cells and 7 REU in tumour cells. The NDV-inducible RIG-I level (part C) was on 
average 237 REU in normal and 49 REU in tumour cells. There was a negative correlation 
between the RIG-I expression with the M gene expression one day after infection (part B+D) 
which was stronger for the basal RIG-I level (R = -0.8598) than for the inducible level (R = 
-0.6271). The normal and the tumour cells clearly grouped together with the IFNAR knock 
out macrophages and the CT26p cells being the only exceptions.
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Figure  4 -42: M gene expression in tumour and primary cell types after NDV infection.
Several primary cell types (spleen cells and macrophages from BALB/c, C57BL/6 and DBA/2 mice) and tumour 
cell lines (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16) were infected with 10 HU per 106 cells 
NDV Ulster or NDFL-EGFP and total RNA was extracted 24 hours later. The expression level of the NDV M 
gene was determined by real-time RT-PCR with the comparative CT method using β-actin for normalisation. The 
p value was calculated using an unpaired student's t-test.
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It could be shown that RIG-I is significantly more expressed in normal than in tumour cells 
before as well as after NDV infection. In addition both the basal and the inducible RIG-I 
expression levels correlate negatively with the M gene expression, i.e. the higher the RIG-I 
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Figure  4 -43: Analysis of the basal and inducible RIG-I expression in primary and tumour 
cells before and after NDV infection.
The RIG-I expression level was measured in several primary and tumour cell types before and 24 hours after 
infection with 10 HU NDV Ulster or NDFL-EGFP by real-time RT-PCR. The gene expression was determined 
with the comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. (A) The basal 
RIG-I expression of several primary (macrophages from BALB/c, C57BL/6 and DBA/2 mice, lung tissue, liver 
tissue) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16) is shown. (B) The 
basal RIG-I level of several primary (♦ macrophages from BALB/c, C57BL/6 and DBA/2 mice;  ♦ IFNAR-/- 
macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16; ♦ CT26p) is plotted 
against the NDV M gene expression level after 24 hours (see Figure  4 -42). (C) The inducible RIG-I expression 
level is indicated for several primary (macrophages from BALB/c, C57BL/6 and DBA/2 mice) and tumour cell 
types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16). (D) The inducible RIG-I level of several 
primary (♦ macrophages from BALB/c, C57BL/6 and DBA/2 mice;  ♦ IFNAR-/- macrophages) and tumour cell 
types (♦ CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16;  ♦ CT26p) is plotted against the NDV M gene 
expression level after 24 hours (see Figure  4 -42). The p value was calculated using an unpaired student's t-test. 
Bars indicate standard deviation. The correlation coefficient was calculated with the mean expression values.
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gene expression, the lower the M gene expression. The next interferon-related gene analysed 
was the IRF3 gene.
Figure  4 -42 shows that IRF3 was expressed significantly higher in normal than in tumour 
cells before as well as after infection with NDV. The average basal IRF3 expression (part A) 
was 54 REU for normal and 7 REU for tumour cells. On average the NDV-inducible IRF3 
expression  (part  B)  was  32 REU  for  normal  and  4 REU  for  tumour  cells.  The  negative 
correlation of the IRF3 expression with the M gene expression one day after infection (part 
B+D) was stronger for the basal IRF3 level (R = -0.8308) than for the inducible level (R = 
-0.5725). Again the normal and the tumour cells formed two distinguishable groups with the 
exception of the IFNAR knock out macrophages and the CT26p and J774A.1 tumour cells.
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The basal and NDV-inducible IRF3 expression turned out to be significantly higher in normal 
than in tumour cells.  Additionally there was a negative correlation between the basal and 
inducible IRF3 expression level and the M gene level. Subsequently the IRF7 gene expression 
was investigated.
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Figure  4 -44: Analysis of the basal and inducible IRF3 expression in primary and tumour 
cells before and after NDV infection.
The IRF3 expression level was measured in several primary and tumour cell types before and 24 hours after 
infection with 10 HU NDV Ulster or NDFL-EGFP. The gene expression was determined by real-time RT-PCR 
with the comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. (A) The basal 
IRF3 expression of several primary (macrophages from BALB/c, C57BL/6 and DBA/2 mice, lung tissue, liver 
tissue) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16) is shown. (B) The 
basal IRF3 level of several primary (♦ spleen cells, macrophages from BALB/c and C57BL/6 mice; ♦ IFNAR-/- 
macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16; ♦ CT26p) is plotted 
against the NDV M gene expression level after 24 hours (see Figure  4 -42). (C) The inducible IRF3 expression 
level is indicated for several primary (spleen cells, macrophages from BALB/c and C57BL/6 mice) and tumour 
cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16). (D) The inducible IRF3 level of several 
primary (♦ spleen cells, macrophages from BALB/c and C57BL/6 mice; ♦ IFNAR-/- macrophages) and tumour 
cell types (♦ CT26wt, J774A.1, RAW 264.7, DA3, Esb and B16; ♦ CT26p) is plotted against the NDV M gene 
expression level after 24 hours (see Figure  4 -42). The p value was calculated using an unpaired student's t-test. 
Bars indicate standard deviation. The correlation coefficient was calculated with the mean expression values.
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Figure  4 -45 demonstrates that the basal and NDV-induced IRF7 expression was significantly 
higher  in  normal  than  in  tumour  cells.  The average  basal  IRF7 expression  (part  A)  was 
83 REU in normal and 11 REU in tumour cells, and the average inducible IRF7 expression 
(part  C)  5841 REU  for  normal  and  240 REU  for  tumour  cells.  The  negative  correlation 
between the basal IRF7 level and the M gene expression (part B) was stronger (R = -0.9116) 
than that between the inducible IRF7 and M gene level (part D, R = -0.8244). The normal and 
the tumour cells formed two distinct groups with regard to IRF7 and M gene expression with 
the exception of the IFNAR knock out macrophages and the CT26p and J774A.1 tumour 
cells.
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The basal and NDV-inducible IRF7 expression turned out to be significantly higher in normal 
than in tumour cells.  Additionally there was a negative correlation between the basal and 
inducible IRF7 expression level and the M gene expression. The last antiviral gene analysed 
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Figure  4 -45: Analysis of the basal and inducible IRF7 expression in primary and tumour 
cells before and after NDV infection.
The IRF7 expression level was measured in several primary and tumour cell types before and 24 hours after 
infection with 10 HU NDV Ulster or NDFL-EGFP. The gene expression was determined by real-time RT-PCR 
with the comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. (A) The basal 
IRF7 expression of several primary (spleen cells, bone marrow cells, macrophages from BALB/c, C57BL/6 and 
DBA/2 mice, lung tissue, liver tissue) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb 
and B16) is shown. (B) The basal IRF7 level of several primary (♦ spleen cells, macrophages from BALB/c, 
C57BL/6 and DBA/2 mice; ♦ IFNAR-/- macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, 
DA3, Esb and B16; ♦ CT26p) is plotted against the NDV M gene expression level after 24 hours (see Figure  4
-42). (C) The inducible IRF7 expression level is indicated for several primary (spleen cells, macrophages from 
BALB/c, C57BL/6 and DBA/2 mice) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb 
and B16). (D) The inducible IRF7 level of several primary (♦ spleen cells, macrophages from BALB/c, C57BL/6 
and DNA/2 mice; ♦ IFNAR-/- macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, DA3, Esb 
and B16; ♦ CT26p) is plotted against the NDV M gene expression level after 24 hours (see Figure  4 -42). The p 
value  was  calculated  using  an  unpaired  student's  t-test.  Bars  indicate  standard  deviation.  The  correlation 
coefficient was calculated with the mean expression values.
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in this context was the IFN-β.
Figure  4  -46 demonstrates  that  the basal  and the NDV-inducible  IFN-β expression were 
higher in normal than in tumour cells. The difference was in both cases not significant. The 
average basal IFN-β expression level (part A) was 26 REU for normal and 1 REU for tumour 
cells. For the inducible IFN-β level (part C) the average was 96 REU for normal and 55 REU 
for tumour cells. There was a negative correlation between the basal IFN-β and the M gene 
expression (part B, R = -0.7166). However,  there was only a low correlation between the 
inducible IFN-β and the M gene expression (R = -0.0995).
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It could be demonstrated that IFN-β was expressed more strongly in normal than in tumour 
cells before as well  as after NDV infection.  However, this difference was not statistically 
significant. There was a negative correlation between the basal IFN-β expression and the M 
gene expression, but for the inducible IFN-β level no clear correlation could be found.
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Figure  4 -46: Analysis of the basal and inducible IFN-β expression in primary and tumour 
cells before and after NDV infection.
The IFN-β expression level was measured in several primary and tumour cell types before and 24 hours after 
infection with 10 HU NDV Ulster or NDFL-EGFP. The gene expression was determined by real-time RT-PCR 
with the comparative CT method using the acidic ribosomal phosphoprotein PO for normalisation. (A) The basal 
IFN-β expression of several primary (spleen cells, bone marrow cells, macrophages from BALB/c, C57BL/6 and 
DBA/2 mice, lung tissue, liver tissue) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb 
and B16) is shown. (B) The basal IFN-β level of several primary (♦ spleen cells, macrophages from BALB/c, 
C57BL/6 and DBA/2 mice; ♦ IFNAR-/- macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, 
DA3, Esb and B16; ♦ CT26p) is plotted against the NDV M gene expression level after 24 hours (see Figure  4
-42). (C) The inducible IFN-β expression level is indicated for several primary (spleen cells, macrophages from 
BALB/c, C57BL/6 and DBA/2 mice) and tumour cell types (CT26p, CT26wt, J774A.1, RAW 264.7, DA3, Esb 
and  B16).  (D)  The  inducible  IFN-β  level  of  several  primary  (♦ spleen  cells,  macrophages  from  BALB/c, 
C57BL/6 and DNA/2 mice; ♦ IFNAR-/- macrophages) and tumour cell types (♦ CT26wt, J774A.1, RAW 264.7, 
DA3, Esb and B16; ♦ CT26p) is plotted against the NDV M gene expression level after 24 hours (see Figure  4
-42).  The  p  value  was  calculated  using  an  unpaired  student's  t-test.  Bars  indicate  standard  deviation.  The 
correlation coefficient was calculated with the mean expression values.
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In conclusion it could be stated that the basal and inducible expression levels of RIG-I, IRF3, 
IRF7  and  IFN-β  were  higher  in  normal  than  in  tumour  cells.  These  differences  were 
statistically  significant  except  for  the  IFN-β  gene.  The  expression  of  these  four  genes 
correlated inversely with NDV susceptibility determined by the M gene expression. For IFN-
β the correlation was weaker for the basal expression level compared to the other three genes. 
In contrast to the other three genes there was almost no correlation between the inducible 
IFN-β gene and the M gene expression. The results confirmed the hypothesis that tumour 
cells in general have a lower expression of antiviral genes and that this lower gene expression 
makes them more susceptible to NDV infection than normal, non-malignant cells.
 4.4.2 Differences in NDV infection in CT26 cell lines with different 
origin
Experiments  done  by  Leonidas  Apostolidis  (Department  of  Cellular  Immunology,  DKFZ 
Heidelberg) had shown that the CT26p tumour cell line was much more resistant to NDV 
infection than the CT26wt cell line. The sole difference between the two CT26 cell lines was 
their origin (see  2.11.2). The differences in NDV susceptibility could be confirmed in the 
correlation  analysis  (4.4.1)  and  in  addition  it  was  found  out  that  they  had  a  markedly 
diverging basal and inducible expression of interferon-related genes. In order to investigate 
the  differences  in  NDV  susceptibility  and  antiviral  gene  expression  further,  CT26p  and 
CT26wt cells were infected with different NDV strains and the infection was followed with 
regard to viral and interferon-related gene expression. Furthermore the binding of NDV to the 
cells was tested to ascertain whether the differences in infection could only be explained by 
physiologic differences between the cells.
 4.4.2.1 NDV susceptibility
In order to further analyse the NDV infection CT26p and CT26wt cells were infected with 
NDFL-EGFP  and  the  EGFP  signal  was  measured  after  one  day  by  flow  cytometry. 
Additionally, the two cell lines were infected with NDV Ulster and the M gene expression 
was  determined  by  real-time  RT-PCR.  The  binding  of  NDFL-EGFP after  one  hour  was 
ascertained by measuring NDV HN protein on the cell  surface in flow cytometry.  It  was 
assumed that after this time no virus replication had taken place and that all HN molecules on 
the cell surface must come from bound or fused NDV particles.
116
                                                                                                                                           Results  
Figure  4 -47 shows that there were pronounced differences in NDV infectability between the 
CT26p and the CT26wt cells. After infection with NDFL-EGFP (part A) EGFP expression 
after one day was clearly detectable in CT26wt cells, whereas there was almost no signal in 
the CT26p cells. The differences in M gene expression after infection with NDV Ulster (part 
B) was even stronger and the relative M gene expression in CT26wt cells was around 900 
times stronger than in the CT26p cells. The HN signal one hour after incubation with NDFL-
EGFP was similar for the two cell lines.
The differences in NDV infectability between the CT26p and the CT26wt cells did not appear 
to be attributable to differences in NDV binding, which was very similar in both cell lines. 
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Figure  4 -47: Differences in NDV infectability between CT26 cells with different origin.
(A) Two types of CT26 colon carcinoma cell lines with different origins, denominated CT26wt and CT26p (see 
2.11.2), were infected with 10 HU NDFL-EGFP per 106 cells and expression of EGFP was determined by flow 
cytometry 24 hours later. (B) Total RNA was extracted 24 hours after NDV infection and the expression level of 
the NDV M gene was determined by real-time RT-PCR with the comparative CT method using β-actin for 
normalisation. The results are represented as the mean of three measurements. (C) The binding of NDV to the 
two CT26 cell lines was determined after one hour incubation with 10 HU NDFL-EGFP by flow cytometry. The 
cells were stained with a murine anti-HN antibody and a PE-conjugated GaM antibody.
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The  substantial  differences  in  the  EGFP  and  M  gene  signal  after  NDV  infection  could 
therefore  be  best  explained  by  cell  physiologic  differences.  To  analyse  this  aspect,  the 
antiviral gene expression before and after NDV infection was characterised.
 4.4.2.2 Antiviral gene expression
Since the differing NDV susceptibilities appeared to be due to intrinsic differences between 
the two CT26 cell lines, the expression of the interferon-related genes RIG-I, IRF3, IRF7 and 
IFN-β was analysed by real-time RT-PCR.
Figure  4 -48 demonstrates that the basal expression level of all genes analysed was higher in 
the CT26p than in the CT26wt cells, while for the gene expression level after infection with 
NDFL-EGFP there was no such trend. The differences in basal gene expression was highest 
for IRF7 (41 times), followed by RIG-I (13 times), IFN-β (6 times) and IRF3 (2 times). The 
NDV-inducible gene expression was approximately equal for RIG-I and IRF3. The inducible 
IRF7 expression was three times higher in CT26p cells and the IFN-β expression was 9 times 
lower.
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When the CT26p and CT26wt cells were compared with regard to the interferon-related gene 
expression, the most striking differences could be found in the basal expression level, which 
was substantially higher in the NDV resistant CT26p cells. If the expression of the four genes 
tested was used to explain the differences in NDV susceptibility between the two cell lines, it 
would  seem that  an  increased  basal  gene  expression  was  much  more  important  than  an 
enhanced ability to induce gene expression after NDV infection. A high basal antiviral gene 
expression could enable the cells to react more rapidly to viral infections without the need of 
preceding gene expression.
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Figure  4 -48: Expression of interferon-related genes in different CT26 cell lines.
The two cell lines CT26wt and CT26p were infected with 10 HU NDFL-EGFP per 106 cells. Total RNA was 
extracted before and 24 hours after infection and the expression level of the RIG-I (A), the IRF3 (B), the IRF7 
(C) and the IFN-β (D) gene was determined by real-time RT-PCR with the comparative CT method using the 
acidic  ribosomal  phosphoprotein  PO  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements. Bars indicate standard deviation.
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 4.5 The functional significance of RIG-I in NDV infection
In order to investigate the functional significance of RIG-I in NDV infection, an expression 
plasmid coding for the human RIG-I was obtained and different cell types were transfected 
with this plasmid before NDV infection. The working hypothesis was that if RIG-I was an 
important factor in the detection of NDV infection, an increased RIG-I level could enhance 
the ability of cells to defend against virus infection. This enhanced virus resistance should be 
detectable as a reduction of the expression of viral genes such as the EGFP or the M gene 
after NDV infection. In addition more information about the function of RIG-I was deduced 
from an analysis  of its expression in human cells by Western blot and real-time RT-PCR 
because up to that point only mouse cells had been used to analyse RIG-I.
 4.5.1 NDV infection after transfection of cells with human RIG-I 
expression plasmids
Different human and murine cells were transfected with a plasmid coding for the human RIG-
I protein to elucidate its role in NDV infection. As control an irrelevant plasmid and a plasmid 
coding for a mutated, non-functional RIG-I (RIG-I IKA) were transfected in parallel. It was 
thought that the RIG-I IKA, which was still able to bind dsRNA, might be able to reduce the 
NDV-induced signalling by sequestering viral dsRNA from receptors such as wildtype RIG-I 
or MDA5. One or two days after transfection the cells were infected with NDFL-EGFP and 
the EGFP expression was measured with flow cytometry. In addition the M gene expression 
was determined by real-time RT-PCR to obtain an additional parameter of NDV infection. 
The transfections were also done with the two macrophages-like tumour cell lines J774A.1 
and RAW 264.7, but the transfection efficiencies were too low (data not shown) and therefore 
other cell lines were used subsequently.
Figure  4 -49 shows that in MCF-7 cells there was no clear difference in the EGFP signal one 
day  after  infection  with  NDFL-EGFP  (part  A)  between  the  cells  transfected  with  the 
functional, wildtype RIG-I (RIG-I wt) and the two control transfections (control and RIG-I 
IKA).  The transfection efficiency was about  40 %. Transfection  alone reduced the EGFP 
signal from 48 % to 7.5 % in the control transfected with an irrelevant plasmid. The EGFP 
signals in cells transfected with RIG-I wt or RIG-I IKA were 4.2 and 4.6 %, respectively. The 
M gene  signal  (part  B)  was  also  strongly  reduced  by  the  transfection  with  an  irrelevant 
plasmid alone (from 2033 to 235 REU). The M gene expression for RIG-I wt and RIG-I IKA 
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were both lower than for the irrelevant plasmid with 29 and 56 REU, respectively.
There was no marked difference in the NDV-induced signals in MCF-7 cells that had been 
transfected with RIG-I wt or RIG-I IKA before NDV infection. Only the M gene signal was 
slightly higher in cells that had been transfected with RIG-I IKA. The strong reduction of the 
EGFP or M gene expression by transfection alone could prevent differences in the NDV-
induced signals  from becoming visible.  Therefore  other  cells  were used  in  the  following 
experiments  that  did not show this signal  reduction after  transfection.  First,  CT26wt cells 
were employed, but the transfection efficiency was too low (~ 15 %). L929 cells turned out to 
be well  transfectable  and did not display a marked reduction of NDV-induced signals by 
transfection.
Figure  4 -50 demonstrates that there was a clear difference in the expression of NDV genes 
between the L929 cells transfected with the different RIG-I plasmids. The cells transfected 
with RIG-I wt showed a lower EGFP signal (28 % positive cells, part A) than the control cells 
transfected with an irrelevant plasmid (39 %). The RIG-I IKA transfected cells displayed a 
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Figure  4 -49: NDV infection of MCF-7 tumour cells after transfection with human RIG-I 
expression plasmids.
MCF-7 human breast cancer cells were transfected with expression plasmids coding for the wildtype human 
RIG-I  (pRIG-I wt),  a  mutated,  non-functional  RIG-I  IKA (pRIG-I  IKA) or  an irrelevant  plasmid (pcontrol, 
plasmid no 241, see chapter 2.8). jetPEI™ was used as transfection reagent and as transfection efficiency control 
a plasmid coding for EGFP was used. After 48 hours the cells were infected with NDFL-EGFP and 24 hours 
after infection the EGFP expression was determined by flow cytometry (A). Also, total RNA was extracted 24 
hours after infection and the expression level of the NDV M gene was determined by real-time RT-PCR with the 
comparative  CT method  using  β-actin  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements. Bars indicate standard deviation.
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high EGFP signal with 62 %. There was only a slight reduction in the EGFP signal by the 
transfection alone when the transfected cells were compared with the not transfected cells 
(78 %).  The transfection  efficiency  was  56 %. The M gene expression  (part  B)  was  also 
clearly  lower  in  RIG-I  wt  than  in  RIG-I  IKA  transfected  cells  (222  and  16679  REU, 
respectively).  Transfection reduced the M gene expression from 30910 to 725 REU in the 
control transfected with an irrelevant plasmid.
In L929 cells the expression of NDV-related proteins could be influenced by the induced 
expression of different types of RIG-I proteins. Wildtype RIG-I could reduce the EGFP and 
M gene expression,  whereas RIG-I  IKA could increase it.  As an additional  indicator that 
externally induced RIG-I could change the expression of NDV genes, the two plasmids RIG-I 
wt and RIG-I IKA were mixed in different ratios and were then transfected in L929 cells. This 
was done in order to determine dose-dependent effects of RIG-I on NDV infection.
Figure  4 -51 shows that in this experiment the EGFP expression upon NDFL-EGFP infection 
was clearly lower in the transfected than in the non-transfected cells. Without transfection 
122
Figure  4 -50: NDV infection of L929 fibroblast cells after transfection with human RIG-I 
expression plasmids.
L929 murine fibroblast cells were transfected with expression plasmids coding for the wildtype human RIG-I 
(pRIG-I wt), a mutated, non-functional RIG-I IKA (pRIG-I IKA) or an irrelevant plasmid (pcontrol, plasmid no 
241, see chapter 2.8). jetPEI™ was used as transfection reagent and as transfection efficiency control a plasmid 
coding for EGFP was used. After 48 hours the cells were infected with NDFL-EGFP and 24 hours after infection 
the EGFP expression was determined by flow cytometry (A). In addition, total RNA was extracted 24 hours after 
infection  and  the  expression  level  of  the  NDV  M  gene  was  determined  by  real-time  RT-PCR  with  the 
comparative  CT method  using  β-actin  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements (B). Bars indicate standard deviation.
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98 % of the cells showed EGFP expression, while in the transfected cells the proportion of 
EGFP-expressing cells  ranged from 13 to 45 %. The percentage of EGFP expression was 
around 13 % except if the amount of RIG-I wt in the plasmid mixture was lower than 0.33 out 
of 1. At 0.17 parts out of 1 RIG-I wt the percentage of EGFP expressing cells increased to 31 
and  if  only  RIG-I  IKA  was  transfected  EGFP  expression  was  highest  with  45 %.  The 
transfection efficiency was 51 %.
There were no differences in the percentage of EGFP expressing cells for most of the RIG-I 
wt  /  IKA ratios  tested.  A dose-dependent  increase  in the EGFP signal  with a  decreasing 
amount of the RIG-I wt plasmid could only be observed at a very low RIG-I wt / IKA ratio.
In  general  there  were  only  slight  changes  in  the  expression  of  viral  proteins  after  the 
transfection of plasmids coding for RIG-I wt or RIG-I IKA. In some cells there were no clear 
changes at all in the EGFP or M gene expression, as for the MCF-7 or CT26 cells. In other 
cell types such as the L929 fibroblasts there was an increase or decrease in the viral signals 
for RIG-I IKA or RIG-I wt, respectively. In conclusion it could be said that the expression of 
additional RIG-I or of a mutated, non-functional RIG-I did only have a slight influence on the 
123
Figure  4 -51: NDV infection of L929 fibroblast cells after transfection with different ratios 
of human RIG-I wt versus RIG-I IKA expression plasmids.
L929  murine  fibroblast  cells  were  transfected  with  different  ratios  of  expression  plasmids  coding  for  the 
wildtype human RIG-I (pRIG-I wt) and the mutated, non-functional RIG-I IKA (pRIG-I IKA). jetPEI™ was used 
as transfection reagent and as transfection efficiency control a plasmid coding for EGFP was used. After 48 
hours the cells were infected with NDFL-EGFP and one day after infection the EGFP expression was determined 
by flow cytometry.
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outcome of an NDV infection depending on the cell type.
 4.5.2 The basal and inducible expression of RIG-I in human cell lines
Since so far mostly murine cells had been analysed with regard to the influence of RIG-I on 
NDV infection, human cells were analysed next to obtain information on the importance of 
RIG-I in the human system. After establishing the NDV susceptibility in human PBMC and 
several  human  tumour  cell  lines  the  RIG-I  expression  in  these  cells  was  determined  by 
Western blot analysis and by real-time RT-PCR to find out if there were correlations between 
NDV resistance and the basal and inducible RIG-I expression.
 4.5.2.1 NDV replication
Human PBMC and the human tumour cells MCF-7, Jurkat, U937 and Hela were infected with 
NDFL-EGFP to test  their susceptibility to NDV infection.  The infection was followed by 
measuring the EGFP expression and the M gene expression level in infected and uninfected 
cells with flow cytometry and real-time RT-PCR, respectively.
Figure -52 demonstrates that there was almost no detectable EGFP signal in human PBMC, 
while  the  tumour  cells  all  displayed  EGFP  expression  (part  A).  The  strongest  EGFP 
expression could be found in the Hela cells, followed by the Jurkat, the MCF-7 and the U937 
cells. There was also nearly no M gene signal in the PBMC in contrast to the four tumour cell 
types (part B). Here again the Hela cells had the strongest signal, followed by the U937, the 
Jurkat and the MCF-7 cells. The EGFP and the M gene signals correlated in all tumour cells 
except  for the U937,  which had the lowest  EGFP signal,  but the second highest  M gene 
expression level.
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As in the mouse the primary human PBMC proved to be very resistant to NDV infection, 
while the tumour cells showed different degrees of NDV susceptibility.  The MCF-7 cells 
seemed  to  be  most  resistant  to  NDV,  while  the  Hela  were  most  susceptible  in  this 
experimental setting.
 4.5.2.2 RIG-I expression
After having established the NDV susceptibility the expression of RIG-I with and without 
NDV infection was determined by Western blot analysis and by real-time RT-PCR.
Figure -53 shows that in the Western blot (part A+B) the basal RIG-I expression was highest 
in the MCF-7 cells, followed by the Hela and the Jurkat cells. The PBMC had the lowest RIG-
I  expression  together  with  the  U937  cells.  The  highest  NDV-inducible  RIG-I  level  was 
reached in MCF-7 and Hela cells. PBMC showed an intermediate inducible RIG-I expression 
level, while the expression was low in U937 and almost absent in Jurkat cells. In the real-time 
RT-PCR analysis  the  basal  RIG-I  gene  expression  was  by a  wide  margin  the  highest  in 
PBMC, while it was similarly low in the tumour cell lines (part C). NDV infection strongly 
induced RIG-I expression in all cell types except for the Jurkat cells. The inducible RIG-I 
expression level was higher in U937 and Hela cells than in PBMC and MCF-7 cells. 
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Figure  4 -52: NDV replication in human PBMC and human tumour cell lines.
Human PBMC and the human tumour cell lines MCF-7, Jurkat, U937 and Hela were infected with 10 HU per 
106 cells NDFL-EGFP and EGFP expression was determined 48 hours after infection (A). In addition, total RNA 
was extracted 24 hours after infection and the expression level of the NDV M gene was determined by real-time 
RT-PCR with the comparative CT method using human β-actin for normalisation. Uninfected control cells for 
each cell type were negative for M gene expression (data not shown). The results are represented as the mean of 
three measurements (B). Bars indicate standard deviation.
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The Western  blot  and the  real-time  RT-PCR analysis  of  RIG-I  yielded  divergent  results. 
While the basal RIG-I expression measured by real-time RT-PCR was high in PBMC and low 
in the tumour cell lines corresponding to the NDV resistance, the PBMC showed the lowest 
RIG-I expression of all cells when measured by Western blot. The diverging results obtained 
with  the  two  methods  could  be  due  to  differences  in  the  regulation  of  RIG-I  mRNA 
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Figure  4 -53: RIG-I expression in human PBMC and human tumour cell  lines before and 
after NDV infection.
Human PBMC and the human tumour cell lines MCF-7, Jurkat, U937 and Hela were infected with 10 HU per 
106 cells NDFL-EGFP. (A) 48 hours after infection the cells were lysed and the lysates were used for Western 
blot analysis of the RIG-I expression. As loading control human β-actin was used. (B) The intensity of the bands 
in the Western blot was determined with a software for densitometric analysis. The intensities of the RIG-I bands 
were normalised with the intensities of the β-actin band intensities. (C) Total RNA was extracted 48 hours after 
NDV infection  and the  expression level  of  the  RIG-I  gene was determined by real-time RT-PCR with  the 
comparative  CT method  using  β-actin  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements. Bars indicate standard deviation.
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processing that could lead to different RIG-I mRNA translation rates. Another possible reason 
could  be  unspecific  binding  of  the  polyclonal  anti-RIG-I  serum,  which  generated  a  high 
background on the Western blot x-ray film (data not shown).
In summary it could be stated that the basal expression of RIG-I measured by real-time RT-
PCR corresponded to the NDV resistance. However, since the Western blot analysis yielded 
different results it remained unclear whether this correlation of the basal RIG-I expression and 
the NDV resistance was true.
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 5 Discussion
In this thesis the basal and NDV-inducible interferon response was analysed in normal and 
tumour cells. The working hypothesis was that a defective interferon response in tumour cells 
could explain the tumour selective replication of NDV (figure 1-6). It could be shown that the 
expression  of  antiviral  genes  was  higher  in  normal  than  in  tumour  cells.  Antiviral  gene 
expression was examined in macrophages, macrophage-like tumour cells and other normal or 
tumour cell  types.  Normal cells displayed a high basal expression of molecules important 
during an interferon response such as cytosolic viral RNA receptors, transcription factors for 
interferons,  interferons  and  molecules  with  direct  antiviral  properties.  It  could  be 
demonstrated that upon NDV infection normal cells reacted with a much stronger induction of 
these genes than tumour cells. The IFN responsiveness was also much higher in normal cells 
after  IFN  treatment  with  regard  to  antiviral  gene  expression  and  inhibition  of  NDV 
replication. A strong, negative correlation between NDV susceptibility and the expression of 
genes important in the interferon response was discovered. This could explain the ability of 
some tumour cells to resist NDV infection much better than most other tumour cells.
Furthermore the role of some interferon-induced antiviral proteins in NDV infection could be 
investigated in knock out macrophages. It could be demonstrated that the two most important 
transcription factors for the induction of type I interferons, IRF3 and IRF7, are important at 
distinct time points during the interferon response. The absence of IRF3 limited antiviral gene 
expression  in  the  early  but  not  in  the  late  phase  of  the  interferon  response,  while  IRF7 
appeared to be crucial for the strong expression of antiviral genes after virus infection. In 
addition, the IFNAR proved to be a bottleneck in the interferon signalling and its absence 
dramatically increased the NDV susceptibility of cells.
In  summary  the  results  support  the  hypothesis  that  defects  in  the  interferon  response  in 
tumour cells can explain the tumour selective replication of NDV. Tumour cells showed a 
diminished expression of pivotal antiviral  genes and a low expression of these genes was 
strongly correlated with NDV susceptibility.
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 5.1 Quantification of gene expression by real-time RT-PCR
Quantitative real-time RT-PCR was used throughout this thesis to determine the expression of 
viral  or interferon-related genes.  The employment  of the real-time RT-PCR technique for 
gene detection and quantification offers the advantages of high sensitivity and reproducibility, 
combined with an extremely broad dynamic detection range. Since the cDNA to be analysed 
is amplified in the real-time PCR, a low amount of tissue or a low number of cells is sufficient 
to carry out an analysis. It could be shown that the sensitivity of some of the primer systems 
applied in this thesis still  detected down to a few copies of the target sequences (chapter 
4.1.1). Hence the RNA that is extracted from a sample of one million cells, a typical sample 
size that was used in the experiments of this thesis, is sufficient for multiple determination of 
the  expression  of  a  high  number  of  genes  and  to  repeat  experiments  several  times. 
Furthermore the analysis of gene expression does not depend on living cells as, for example, 
flow  cytometric  analysis,  and  because  RNA  or  cDNA  samples  can  be  stored  almost 
indefinitely at low temperatures, the samples can be used again to determine the expression of 
additional genes when new questions arise in the course of a series of experiments. Compared 
to conventional RT-PCR, real-time RT-PCR is significantly less variable (Heid et al., 1996).
Quantification  of  gene  expression  by  real-time  RT-PCR can  either  be  done  by  using  an 
external standard curve or by employing one or more co-amplified internal control mRNAs 
for  normalisation  (Bustin,  2000).  In  this  thesis  the  samples  were  normalised  relative  to 
internal housekeeping genes, i.e. genes that are thought to be expressed at a constant level 
irrespective of the conditions in which a cell is growing. This method of quantification has the 
advantage  of  compensating  for  all  the  steps  that  are  required  to  obtain  the  final  PCR 
measurement such as different input RNA amounts used in the reverse transcription step due 
to  varying  amounts  of  biological  material  available  for  RNA  extraction.  A  possible 
disadvantage of the quantification using endogenous control genes is that the expression of 
housekeeping genes is sometimes not absolutely constant.
In general the mRNA expression levels of a gene can be expected to correlate strongly with 
the protein level. Since there are further steps and regulatory mechanisms that influence the 
gene expression on the protein level it is nevertheless possible that the mRNA and the protein 
level for a gene vary. Yet, when the NDV M gene expression was analysed with real-time 
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RT-PCR and with flow cytometry, the results were very similar (figure 4-10, 4-40 or 4-52), 
pointing to a strong connection between the mRNA and the protein level.
The ability of real-time RT-PCR to generate accurate quantitative data has had a huge impact 
on the study of viral agents of infectious disease. It is helping to clarify disputed infectious 
disease processes and demonstrates links between specific viral sequences and patient clinical 
symptoms  (Mackay  et  al.,  2002).  There  are,  for  example,  various  viruses  targeting  the 
respiratory tract such as influenza virus types A and B or RSV, which are important causes of 
severe  lower  respiratory  tract  disease  in  elderly  and  immunocompromised  patients  with 
significant morbidity and mortality (Bustin and Mueller, 2005). Since these respiratory viral 
pathogens produce very similar clinical symptoms, differential diagnosis of the pathogens is 
required. Real-time RT-PCR assays have been developed to distinguish these viruses and their 
subtypes  and to adjust  the therapy accordingly (Kuypers  et al.,  2004; Stone  et al.,  2004). 
During the outbreak of SARS in China real-time RT-PCR proved to be more sensitive and 
faster than other methods such as conventional RT-PCR and more suitable for the necessary 
high throughput analysis of samples. Real-time RT-PCR was invaluable for the rapid, early 
diagnosis of SARS (Poon  et al., 2003), the elucidation of viral pathogenesis (Peiris  et al., 
2003) and the provision of prognostic information for clinical  management  (Cheng  et al., 
2004). Other examples of the widespread use of real-time RT-PCR in clinical virus detection 
are HBV, HCV and HIV-1 (Candotti et al., 2004).
The real-time RT-PCR assay that was applied in this thesis to detect the NDV M gene has 
been developed to measure NDV RNA in clinical samples (Wise  et al., 2004). It could be 
shown that most NDV isolates can be detected with this assay, presumably because the assay 
amplifies a relatively conserved region near the 5´ end of the M gene (Seal et al., 2000). It is 
also possible to differentiate NDV strains by a melting-curve analysis after a real-time RT-
PCR amplification of a region of the F gene (Pham et al., 2005).
In cancer treatment real-time RT-PCR can be employed to monitor disease-specific markers 
and  to  evaluate  MRD  (minimal  residual  disease).  For  example,  the  detection  of  typical 
cytogenetic abnormalities in CML (chronic myeloid leukaemia) by real-time RT-PCR is an 
important  prognostic  parameter  for  the  assessment  of  complete  remission  and  long-term 
survival.  Real-time RT-PCR has been found to be more sensitive  and reliable  than other 
methods for molecular follow-up of CML (Kim et al., 2002; Raanani et al., 2004). Since the 
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monitoring of the dynamics of residual disease in CML patients can predict clinical relapse, 
the real-time RT-PCR data are useful in guiding clinical therapeutic decisions (Goldman et  
al., 1999; Moravcova et al., 1999).
Apart from determining the expression of viral genes or MRD, real-time RT-PCR has also 
been used in this thesis to measure the relative expression of cellular genes. The rationale was 
that  if  a  gene  played  a  role  in  special  cellular  conditions  such  as  a  virus  infection,  its 
expression level was likely to change compared to control conditions without virus. If a gene 
product  is  indicated  to  play  a  role  in  cellular  processes  under  certain  physiological, 
pathophysiological  or  developmental  conditions,  for  example,  due  to  indications  from its 
known  function  or  because  of  previous  microarray  data,  it  is  a  common  approach  to 
corroborate  this  indication  by  real-time  RT-PCR expression  analysis  (Valasek  and  Repa, 
2005). All in all it can be said that real-time RT-PCR has become a reliable and widely used 
method for the rapid and accurate assessment of changes in gene expression to enhance the 
understanding of biological processes. For clinical molecular diagnostics real-time RT-PCR 
has become indispensable to measure viral loads or to evaluate cancer status.
 5.2 NDV infection in normal and tumour cells
It is known that in general NDV can replicate substantially better in cancer cells than in most 
normal cells (Reichard et al., 1992; Schirrmacher et al., 1999a). Tumour cells are in general 
more susceptible to virus infection as a result of their unrestricted growth, their deficiency in 
controlling nucleic acid synthesis and defects in their antiviral interferon response (Fiola  et  
al.,  2006,  Stojdl  et  al.,  2000).  In  addition  it  has  been  suggested  that  for  efficient  NDV 
replication an activated ras-pathway is necessary (Lorence et al., 1994b). In contrast to many 
other viruses the tumour selectivity of NDV is inherent and it does not have to be genetically 
modified to grow specifically in tumour cells. This makes NDV an attractive candidate for 
cancer therapy (Csatary et al., 2004; Freeman et al., 2006; Lorence et al., 2007; Schirrmacher, 
2005; Sinkovics and Horvath, 2000). Inherent tumour selectivity is a characteristic of many 
RNA viruses such as echovirus type 1 (Shafren et al., 2005), poliovirus (Ochiai et al., 2006), 
mumps virus (Myers  et al.,  2005), VSV (Barber,  2004) or reovirus (Figova  et al.,  2006). 
Naturally occurring infections with these viruses cause either asymptomatic or relatively mild 
disease in humans and therefore these viruses have a good intrinsic safety profile. In contrast 
131
Discussion                                                                                                                                      
there  are  oncolytic  viruses  that  are  derived  from  viruses  that  naturally  target  also  non-
malignant  cells.  These  viruses  can  be  made  tumour  selective  by  modifying  the  cellular 
tropism  at  the  level  of  replication  in  a  way  that  they  become  dependent  on  specific 
characteristics of tumour cells for viral replication. This can be achieved by deleting viral 
genes that are critical for viral replication in healthy cells but are dispensable upon infection 
of neoplastic cells. Other approaches to make viruses tumour selective are the use of tumour 
specific promoters upstream of viral genes or the modification of the viral coat to enable 
tumour selective binding and uptake. Examples of viruses that have been modified to replicate 
only in tumour cells are adenovirus (Relph et al., 2005), HSV (Shen and Nemunaitis, 2006) 
and vaccinia virus (Thorne et al., 2005). 
Here it could be demonstrated that several strains of NDV replicated substantially better in 
tumour than in normal cells. Even when high doses of NDV were used for infection, normal 
cells  proved to be strongly resistant  to  NDV replication  (figure 4-1).  In  macrophage-like 
tumour cells there were pronounced differences in NDV susceptibility. Viral replication was 
much stronger in the RAW 264.7 than in the J774A.1 cells. When compared to the J774A.1 
cells,  the  RAW  264.7  cells  displayed  a  50 %  higher  growth  rate  and  a  lower  IFN 
responsiveness  with  regard  to  the  blocking  of  NDV  infection  and  to  the  reduction  of 
proliferation after IFN pretreatment. In addition the RAW 264.7 cells showed a lower basal 
and inducible expression of important interferon-related antiviral genes. So the RAW 264.7 
cells appeared to have a more malignant phenotype with faster proliferation and insensitivity 
to  anti-growth  signals.  The  RAW 264.7  cells  were  derived  from a  virus-induced  tumour 
(chapter  2.11.2) and could therefore be expected to be more susceptible to virus infection. 
These data could explain the higher NDV susceptibility of the RAW 264.7 cells. They point 
to  an  increased  ability  of  NDV to  replicate  in  tumour  cell  subtypes  that  display  a  more 
malignant phenotype.
Even  within  the  same  tumour  cell  line  there  can  be  substantial  differences  in  NDV 
susceptibility as was observed for CT26 colon carcinoma cells (figure 4-47). In general CT26 
cells  are  well  infectable  by  NDV (Schirrmacher  et  al.,  2001)  or  other  oncolytic  viruses 
(Malhotra et al., 2007; Smyth et al., 2005). The two CT26 cell lines here were derived from 
different sources and displayed strong variations in the basal expression of antiviral genes. 
These variations could explain the differences in NDV replication. The differences in gene 
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expression  had  probably  been  acquired  because  of  varying  ways  of  cultivation  at  the 
laboratories from which the cells were obtained. Perhaps the more NDV susceptible CT26 
cells were cultivated for a longer time and had therefore an increased probability to acquire 
mutations  that  gave them a selective advantage.  This could have been an increase in the 
growth  rate  by  the  downregulation  of  interferon-related  genes  which  led  to  an  increased 
responsiveness  to  anti-growth  effects  of  IFN but  at  the  same  time  made  the  cells  more 
susceptible to virus infection.
A high variation in NDV susceptibility of tumour cells could also be found in the comparison 
of other normal and tumour cells (figure 4-42). The variation seemed to be connected to the 
extent  to  which the tumour cells  had acquired defects  in  the antiviral  interferon response 
(figure 4-43 – 4-46). The importance for an intact interferon response for NDV resistance 
could be clearly seen in cells that had gene knock outs for crucial antiviral genes such as the 
IFNAR.  However,  since  IFNAR-/- macrophages  are  still  more  NDV  resistant  than  most 
tumour cells there must be other factors influencing NDV susceptibility.
Low cell proliferation rates could explain the NDV resistance of normal cells even when they 
show a strongly reduced interferon response due to the knock out of crucial antiviral genes 
such as the IFNAR. In highly replicating tumour cells the cellular machinery that is necessary 
for the replication of the cell as well as that of the virus is expressed much stronger than in 
resting normal cells. That makes it possible for a virus to replicate better in tumour cells than 
in normal cells. This hypothesis could also explain that NDV infects quickly proliferating, 
wildtype MEF cells better than resting IFNAR-/- macrophages. A detailed discussion of the 
interferon response and other properties different between normal and tumour cells and their 
influence on NDV infection can be found in the next chapter.
When different  strains  of  NDV were  used  for  the  infection  of  normal  and tumour  cells, 
different levels of viral gene expression could be observed. Infection of macrophages with the 
velogenic NDV strain Italien and to a lesser degree also with the mesogenic strain NDFLtag-
EGFP generated a higher expression of viral genes than the infection with the lentogenic 
strains Ulster and NDFL-EGFP (figure 4-7). As might have been expected it seems that the 
more virulent an NDV strain is, the better it can replicate in a cell. One explanation could be 
an increased ability of velogenic strains to limit  the induction of antiviral  responses. This 
hypothesis is substantiated by the fact that in macrophages the induction of antiviral gene 
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expression was generally lower for NDV Italien than for NDV Ulster.
 5.3 The interferon response in normal and tumour cells in the 
context of NDV infection
Defects  in  the interferon response are thought  to  make many tumour  cells  susceptible  to 
viruses that  do not infect  normal,  non-neoplastic cells.  This has been suggested for NDV 
(Fiola et al., 2006), VSV (Stojdl et al., 2000, 2003) and influenza virus (Muster et al., 2004) 
and  others.  A  defective  interferon  response  is  thought  to  give  tumour  cells  a  selective 
advantage  by  making  them  less  sensitive  to  growth-inhibitory  effects  of  interferons  and 
allowing them to grow faster in the presence of low basal interferon levels that can be found 
in the absence of  viral  infection (chapter  1.3.5).  The exact  nature  of  the  defects  and the 
molecules  that  are  affected in the signalling chains necessary for the establishment  of  an 
antiviral response are not known. An important question is, for example, if only a limited 
number of key molecules  of the interferon response are downregulated or defective,  or if 
many components of the antiviral response are involved. It is also not known which points in 
the  signalling  cascade  that  leads  to  a  cellular  response  are  affected:  are  the  relevant 
differences  more  at  the  level  of  the  basal  or  the  inducible  antiviral  gene  expression,  the 
secretion of interferons or the ability to respond to external interferons? These questions could 
be answered in the  course of  the  experiments  of  this  thesis  and will  be discussed in the 
following.
 5.3.1 Cytosolic pattern recognition receptors
Cytosolic pattern recognition receptors are indispensable for the detection of virus infection 
inside a cell. They are one of two different receptor systems for virus infection which are 
located in different cellular compartments. The other receptor system is constituted by TLRs 
that  are  located  mainly  on  endosomal  membranes  (chapter  1.3.2).  Cytosolic  pattern 
recognition  receptors  belong  to  the  family  of  DExD/H-box  helicases  and  recognise  viral 
RNAs. One important factor for the differentiation of self and non-self RNA that has recently 
been discovered is 5´-triphosphate RNA (Hornung  et al., 2006; Pichlmair  et al., 2006). In 
addition, the 5´-triphosphate ended viral leader transcript of measles virus, which is a member 
of  the  paramyxoviridae  like  NDV,  was  found  to  be  an  activator  of  the  RIG I-mediated 
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interferon response (Plumet et al., 2007).
Since RNA helicases are crucial molecules to start an antiviral response after virus infection, a 
different expression of RIG-I or MDA5 could be related to differences in NDV susceptibility 
between normal and tumour cells. Indeed it could be observed in macrophages that the basal 
and inducible expression level of these genes correlated negatively with NDV susceptibility. 
The correlation was underlined by the fact that the J774A.1 cells with an intermediate NDV 
susceptibility also showed intermediate basal and inducible gene expression levels for the two 
helicases.  In  addition there  was also  a  strong,  short-lived induction of  RIG-I  and MDA5 
expression by UV-inactivated NDV, pointing to replication-independent ways of induction. 
NDV Ulster induced a stronger gene expression than NDV Italien, which could explain the 
higher virulence of the latter strain by its ability to limit the expression of antiviral genes.
The importance of RIG-I and MDA5 for virus recognition has shown to depend on the virus. 
For NDV, RIG-I seems to be more important than MDA5 (Kato et al., 2006). This might be 
due to the fact that most paramyxoviruses target MDA5, but not RIG-I with their V proteins 
(Childs  et  al.,  2007).  The  functional  significance  of  RIG-I  in  NDV  infection  could  be 
confirmed here in transfection experiments with plasmids encoding wildtype or mutated, non-
functional RIG-I.  MDA5 was induced stronger  in macrophages upon NDV infection than 
RIG-I  but  that  does  not  necessarily  indicate  a  higher  importance  of  MDA5.  The  basal 
expression  level  of  these  viral  detection  molecules  is  probably  more  important  than  the 
inducible level to limit NDV infection. A substantial induction after NDV infection of RIG-I 
and MDA5 mRNA took 8 to 12 hours, so that on the protein level at least half a day passes 
until  there is a significant increase in danger signalling. After 12 hours NDV has already 
reached its maximum of gene expression (see for example figure 4-7), so the induction of 
viral  detection molecules  would be too late  to significantly  restrict  NDV replication.  The 
importance of an early induction of an antiviral response is underlined by the higher NDV 
susceptibility of IRF3 than of IRF7 knock out macrophages, since IRF3 is important in the 
early phase of an interferon response. The special importance of RIG-I for the early induction 
of antiviral responses has also been shown in the infection with other viruses such as RSV 
(Liu et al., 2007).
When  several  normal  and  tumour  cell  types  were  compared  (figure  4-43)  it  could  be 
demonstrated that RIG-I was significantly higher expressed in normal cells than in tumour 
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cells. Furthermore there was a strong negative correlation between the RIG-I expression and 
NDV susceptibility. Exceptionally NDV resistant CT26 tumour cells or uncommonly NDV 
susceptible normal cells such as IFNAR-/- macrophages had respectively an unusually high or 
low RIG-I level. These findings suggest that differences in RIG-I expression in normal and 
tumour cells can account for differences in NDV susceptibility.
In human cells  a  high basal  rather  than inducible  RIG-I  expression correlated with NDV 
resistance at the mRNA level (figure 4-53). At the protein level the tendency was similar, 
although some tumour cells showed a higher RIG-I level than PBMC. In contrast to the tested 
mouse cell types the NDV-inducible RIG-I level in human cells was not correlated to NDV 
susceptibility. This might point to differences in the regulation of RIG-I expression in murine 
and human cells. However, this suggestion needs to be confirmed by testing more human 
normal and tumour cells before general conclusions can be drawn.
It is not yet clear what the regulatory mechanisms are that could lead to a downregulation of 
RIG-I in tumour cells. RIG-I is inducible by IFN pretreatment in macrophages (figure 4-25 
and 4-36) and dendritic cells (Yount et al., 2007). In contrast, the expression of MDA5 seems 
to be independent of type I interferons but it appears to be strongly linked to IRF3 (Yount et  
al., 2007). RIG-I expression must also be regulated by IFN-independent mechanisms since the 
basal and NDV-inducible RIG-I expression in IFNAR or IRF7 knock out macrophages was 
not much lower than in the wildtype. These mechanisms are probably similar to the general 
regulation of DExD/H box RNA helicases. These can be expected to be widely expressed 
because they are active in all  processes involving RNA molecules including transcription, 
editing, splicing, ribosome biogenesis, RNA export, translation, RNA turnover, and organelle 
gene expression (Tanner and Linder, 2001). In human endothelial cells RIG-I expression was 
upregulated by IFN-γ (Imaizumi et al., 2004) and in human keratinocytes by IFN-γ or TNF-α 
(Kitamura et al., 2007), pointing to a role of RIG-I in inflammatory processes.
The RNA helicase LGP2 has been suggested as a negative regulator of RIG-I and MDA5 
signalling since it lacks the CARD domain necessary for signal transmission after the binding 
of viral RNA (Rothenfusser et al., 2005; Yoneyama et al., 2005). Results indicate that LGP2 
can inhibit antiviral signaling independently of dsRNA or virus infection intermediates by 
engaging in a protein complex with MAVS (Komuro and Horvath, 2006). The expression of 
LGP2 was therefore analysed in normal and tumour cells to investigate whether differences in 
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expression can be related to differences in NDV susceptibility. However, the results did not 
suggest LGP2 as a factor involved in the varying NDV replication in normal and tumour cells. 
Normal macrophages showed the highest basal and inducible LGP2 level (figure 4-18). It is of 
course possible that there are differences in protein modification after the translation process 
that cannot be seen at the mRNA level. There is, for example, a repressor domain in RIG-I 
and LGP2 (Saito et al., 2007) that might function differently in normal and tumour cells.
 5.3.2 Membrane-bound pattern recognition receptors
Apart from the cytosolic pattern recognition receptors, membrane-bound pattern recognition 
receptors constitute the second major detection system for viral infection and the induction of 
type I interferons. Most members of these receptors belong to the TLRs and each member 
recognises a different repertoire of pathogen-associated molecular patterns. The main TLRs 
for the detection of virally-derived nucleic acids are TLR 3, 7, 8 and 9, and they are mostly 
located on the membranes of endosomes (chapter  1.3.2). TLRs are important danger signal 
receptors  in  tissues  because  they  detect  viral  nucleic  acids  that  are  released  from  other 
infected and lysed cells and can thereby induce an antiviral state in so far uninfected cells. By 
this mechanism the spread of viruses in tissues can be effectively limited. TLRs are expressed 
mainly by specialised cell types such as macrophages and dendritic cells and are crucial for 
the secretion of large amounts of type I IFNs by pDCs (Colonna et al., 2004). In macrophages 
TLRs play central roles in the induction of proinflammatory cytokine expression during viral 
infection (Mogensen and Paludan, 2005).
The results obtained with the TLR3 and TLR7 knock out macrophages with regard to NDV 
replication and secretion of type I interferons were generally very similar to those obtained 
with the wildtype macrophages. The secretion of IFN-α/β appeared to be slightly lower in the 
two knock outs but since the experiment could only be carried out once it could not be said if 
this slight difference was significant. All in all the results indicated that the two TLRs were 
not involved in the signalling of NDV infection in the tested experimental  setting.  TLR3 
recognises dsRNA (Alexopoulou et al., 2001) and TLR7 viral ssRNA (Diebold et al., 2004; 
Heil et al., 2004) and since the two receptors face the outside of a cell the nucleic acids have 
to be located in the extracellular fluid to be recognised. In the infection experiments carried 
out  here  there  could  not  be  any  viral  nucleic  acids  in  the  extracellular  space  since  the 
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macrophages were rarely killed by the NDV infection and because the experiment lasted only 
about one day. This period of time was too short for the release of large amounts of viral RNA 
from NDV-infected cells that might have died following NDV infection. The TLR3/7 knock 
out  mice  can  be  assumed to  have  a  much  stronger  effect  on  virus  resistance  in  vivo.  A 
comparison between fibroblasts and macrophages revealed the importance of TLR3 for the 
latter  cell  type  in response  to  viral  PAMPs.  The ability  of  bone marrow derived murine 
macrophages  to respond to dsRNA was largely dependent  on TLR3 (Alexopoulou  et  al., 
2001), while in fibroblasts the response was TLR3-independent (Hemmi et al., 2004). TLR7 
could also be shown to be critical for antiviral responses in vivo since TLR7 knock out mice 
were defective in their response to VSV and influenza virus (Lund et al., 2004). 
 5.3.3 Interferon regulatory factors
IRF3 and IRF7 are the two most important transcription factors for the induction of type I 
interferons.  They  are  activated  by  cytosolic  RNA  helicases  as  well  as  TLRs  upon  viral 
infection. On the gene expression level the major difference between IRF3 and IRF7 is that 
the former is expressed constitutively whereas the expression of IRF7 is not and depends on 
induction. During the two-step induction of type I interferons, IRF3 is more important in the 
early phase while IRF7 is crucial in the later phase (chapter 1.3.3.2).
In macrophages IRF3 expression increased slightly after NDV infection while the expression 
remained almost constant in macrophage-like tumour cells. When the induction of IRF3 is 
compared with all other interferon-related genes analysed in this thesis it can be said to be 
very moderate. Therefore there is no contradiction to the general assumption that IRF3 action 
is mostly constitutive, as shown for example by Juang et al. (1998). In the macrophage cell 
types there was a correlation between NDV resistance and IRF3 expression, suggesting a role 
of this molecule for NDV resistance of cells. A low expression of IRF3 in tumour cells could 
lead to a diminished signal transduction after the detection of viral danger signals and would 
lead to a  weaker  antiviral  response.  This  hypothesis  was  corroborated by the  analysis  of 
several normal and tumour cells types.  IRF3 was significantly higher expressed in normal 
cells at the basal as well as at the inducible level and there was a strong negative correlation 
between IRF3 expression and NDV susceptibility (figure 4-44).
IRF7 was found to be highly inducible by NDV infection in spleen cells (figure 4-4) and in 
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macrophages  and  macrophage-like  tumour  cells  (figure  4-20),  confirming  its  strong 
inducibility  described  in  the  literature  (Marie  et  al.,  1998;  Sato  et  al.,  1998).  In  the 
macrophage cell types there was a negative correlation between NDV susceptibility and IRF7 
expression level after NDV infection, indicating IRF7 as a further factor involved in NDV 
resistance. This conclusion was corroborated by the analysis of several normal and tumour 
cell types (figure 4-45). IRF7 was significantly more expressed in normal cells and there was 
a strong negative correlation between IRF7 expression and NDV susceptibility. In addition 
NDV  Ulster  induced  IRF7  expression  more  strongly  than  NDV  Italien,  pointing  to  an 
increased ability of NDV Italien to limit antiviral gene expression, which could explain its 
higher virulence.
IRF7 is a crucial  molecule for the induction of antiviral  responses. Its importance for the 
enhancement and diversification of IFN induction has been confirmed in earlier studies (Levy 
et al., 2002). It has even been proposed that IRF7 is the master regulator of type I interferon-
dependent immune responses and that all elements of IFN responses, whether the systemic 
production of IFN in innate  immunity or  the local  action of  IFN from pDCs in adaptive 
immunity,  are  under  the control  of IRF7 (Honda  et  al.,  2005).  IRF7 is  often targeted by 
viruses to limit antiviral responses and to increase virus survival and replication. For example, 
a Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I 
interferon by blocking IRF7 phosphorylation and nuclear accumulation (Zhu  et al., 2002). 
Also the herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated 
activation of interferon-stimulated genes (Lin et al., 2004). Often viral proteins increase the 
degradation of  IRF7 such as  the rotavirus  NSP1 protein  (Barro and Patton,  2007)  or  the 
KSHV immediate-early transcription factor RTA that encodes a ubiquitin E3 ligase activity 
that targets IRF7 for proteasome-mediated degradation (Yu et al., 2005).
When  macrophages  were  treated  with  IFN-α4  there  was  a  strong  induction  of  IRF7 
expression, whereas the IRF3 expression did not change (figure 4-26 and 4-27). This is in 
accordance with the view that IRF3 is constitutively expressed while IRF7 is highly inducible. 
For  IRF7 the  increase  in expression brought  about  by IFN-α4 correlated  also  with  NDV 
susceptibility  and  was  much  higher  in  normal  macrophages  than  in  the  macrophage-like 
tumour cells lines. These results showed that tumour cells can have defects not only in the 
ability to secrete IFN upon virus infection, but also in the ability to respond to external IFNs. 
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The expression of IRF7 is thought to be induced by early IFNs and depends on the ISRE 
present in the IRF7 promoter (Lu et al., 2000). In addition IFN-independent mechanisms for 
the induction of IRF7 by virus infection have been suggested (Ning et al., 2005). It is likely 
that both mechanisms play a role for the differential expression of IRF7 in normal and tumour 
cells  because  on  the  one  hand  tumour  cells  displayed  limits  in  their  ability  to  secrete 
interferons,  but  on  the  other  hand  the  J774A.1  cells  secreted  high  amounts  of  type  I 
interferons  at  later  time  points  after  NDV  infection  and  still  showed  only  a  low  IRF7 
expression (figure 4-14). Another explanation for the low expression of IRF7 in spite of the 
considerable IFN secretion after  NDV infection would be defects  in  the signalling of the 
IFNAR or a downregulation of the IFNAR.
The functional importance of IRF3 and IRF7 for NDV resistance and the interferon response 
became apparent in the analysis of knock out macrophages. The absence of both transcription 
factors  increased the  susceptibility  of  macrophages  for  NDV infection.  The increase  was 
higher in the IRF3 than in the IRF7 knock out cells. The kinetics of NDV infection showed 
that virus replication was comparable at early time points. Thereafter it increased in the IRF3 
knock outs while it decreased in the IRF7 knock outs (figure 4-31). This suggests that the 
secretion  of  early  IFNs,  which  depends  on  IRF3,  is  more  important  for  limiting  NDV 
infection than the secretion of high amounts of all IFN types. Furthermore the lack of IRF3 
clearly delays and limits the expression of IRF7 (figure 4-38) so that until later time points the 
IRF3 knock out macrophages display almost a IRF3/7 double knock out phenotype and are 
therefore  especially  vulnerable  to  NDV  infection.  On  the  other  hand  IRF7  knock  out 
macrophages still express almost the same amount of IRF3 than the wildtype (figure 4-37) 
and are therefore not inhibited in their ability to establish the early phase of the interferon 
response. 
The IFN-α4 pretreatment was sufficient to limit NDV replication in the IRF3 and IRF7 knock 
out macrophages almost as strongly as in the wildtype. It seems that in the tested experimental 
setting no additional secretion of IFN-α4 or of other type I IFNs mediated by IRF3/7 was 
necessary to strongly inhibit NDV replication. However, it cannot be concluded that IFN-α4 
is the only IFN that plays a role in the interferon response to NDV infection. It is known that 
NDV infection  stimulates  the  expression  of  several  IFN-α subtypes  (Marie  et  al.,  1998). 
Unfortunately a real-time RT-PCR assay could not be established to elucidate the expression 
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of different IFN-α genes at different time points after NDV infection. There are more than a 
dozen IFN-α genes in the mouse and it proved to be very difficult to find primer systems that 
detect only one member of this gene family.
The IFN secretion upon NDV infection was clearly reduced in IRF7 knock out macrophages, 
while IRF3 knock out macrophages showed an IFN secretion similar to the wildtype. This 
underlines the role of IRF7 as the master regulator of the IFN response but confirms also that 
for NDV resistance in vitro an early interferon response is more important than the ability of a 
cell  to secrete large amounts of type I IFNs. The IFN-α4 pretreatment reduced the type I 
interferon secretion in the IRF3/7 knock outs as well as in the wildtype probably because of 
the reduction of NDV replication and hence the decreased concentration of IFN-stimulating 
viral danger signals. 
IRF3 and IRF7 did not seem to be required for the induction of RIG-I by NDV infection or by 
IFN-α4 since the RIG-I  expression in the knock outs  was comparable  with the wildtype. 
Nevertheless, the expression of IFN-β was strongly compromised in the IRF3/7 knock outs 
(figure 4-39). In the absence of IRF3 the IFN-β expression was clearly delayed, while almost 
no IFN-β was expressed at any time point after NDV infection when IRF7 was lacking. This 
indicates that although IFN-β is regarded as an early IFN it requires not only the presence of 
IRF3 but also that of IRF7 for its expression. An initial model suggested that only IRF3 is 
involved in the early phase of IFN-β induction by forming a multi-protein complex called an 
enhanceosome (Maniatis  et al., 1998). Meanwhile it could be shown in knock out mice that 
the presence of IRF7 is also crucial for the IFN-β induction after HSV, VSV and EMCV 
infection (Honda et al., 2005). So the low amounts of IRF7 that are expected to be present in 
the absence of virus infection seem to be of importance for IFN-β induction. The high IFN-β 
expression in the IRF3 knock outs at the latest time point occurred probably because of the 
higher NDV replication in these cells that could be translated into a stronger response when 
finally enough IRF7 had been synthesised.
It can thus be concluded that IRF3 and IRF7 play a role in the generation of differences in 
NDV susceptibility  between normal and tumour cells.  Firstly,  it  could be shown that  the 
expression of both transcription factors is significantly downregulated in tumour cells and 
secondly, their importance for NDV resistance and the establishment of an interferon response 
could be demonstrated in knock out macrophages. However, they cannot be the only antiviral 
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factors  for  which differences exist  between normal and tumour cells,  because the IRF3/7 
knock out macrophages display still a low viral replication compared to tumour cells.
 5.3.4 Type I interferons and the IFNAR
In the experiments for this thesis the expression of the type I IFN-β could be followed in 
normal and tumour cells  upon NDV infection by real-time RT-PCR. IFN-β expression is 
induced early in  an antiviral  interferon response by IRF3 and it  is  important  for  positive 
feedback  mechanisms  and  the  induction  of  key  molecules  such  as  IRF7.  IFN-β  signals 
through the IFNAR which is the only known receptor for type I interferon signalling. Upon 
binding of  type  I  IFNs the  signal  is  transmitted  via  the activation of  STAT transcription 
factors which form the protein complex ISGF3. This protein complex translocates into the 
nucleus and induces the expression of hundreds of genes containing an ISRE motif in their 
promoter.
The basal expression of IFN-β was found to be substantially lower in tumour than in normal 
cells. Its NDV-inducible expression was generally also lower in tumour cells, although in both 
cases the difference was not  statistically significant.  Hence a downregulation of IFN-β in 
tumour cells before virus infection seemed to better explain the higher NDV susceptibility of 
tumour cells than a limited inducible IFN-β level. One possible reason for the lower basal 
IFN-β level in tumour cells in accordance with the data gathered in this thesis would be the 
lower IRF3 level in tumour cells. IRF3 is important for the induction of IFN-β (Sato  et al., 
2000) and if there is a lower level of IRF3 in tumour cells in the absence of virus infection, 
the induction of IFN-β stimulated by a low constitutive IFN secretion can also expected to be 
limited.  The  kinetics  of  IFN-β  expression  during  NDV  infection  demonstrated  that  after 
induction  it  was  more  strongly  downregulated  than the  other  analysed  genes,  pointing to 
strong negative regulatory mechanisms. There was no positive feedback regulation of IFN-β 
by IFN-α4 since no change in the IFN-β expression could be found after IFN-α4 treatment.
The  IFN-β  gene  induction  is  a  highly  ordered  process  and  it  is  regulated  by  multiple 
transcription factors (Honda et al., 2006a). Its importance for NDV resistance could be shown 
in IRF3 knock out macrophages, in which the lack of the early induction of IFN-β made them 
even  more  susceptible  to  NDV  infection  than  the  IRF7  knock  out  macrophages.  The 
importance of IFN-β for virus resistance can also be deduced from the fact that the IFN-β-
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inducing IRF3 is commonly targeted by viruses to limit the induction of antiviral responses. 
In the case of influenza A virus, the viral nonstructural protein 1 prevents the induction of the 
IFN-β  promoter  by  inhibiting  the  activation  of  transcription  factors  including  IRF3 
(Mibayashi  et al., 2007). The HCV NS3/4A serine protease blocks the phosphorylation and 
effector action of IRF3 (Foy et al., 2003) and the induction of IFNs by HSV was shown to be 
counteracted  by  ICP27  targeting  NF-κB  and  IRF3  (Melchjorsen  et  al.,  2006). 
Paramyxoviruses  also  target  IRF3  and  downregulate  IFN-β  to  inhibit  antiviral  responses, 
usually via their V proteins. Sendai virus C and V proteins target signalling pathways leading 
to IRF3 activation for the negative regulation of  interferon-β production (Komatsu  et  al., 
2004)  and in  another  study the  V proteins  of  simian  virus  5  and other  paramyxoviruses 
inhibited the induction of IFN-β (Poole et al., 2002). In the same study it was found that NDV 
is a potent inducer of IFN-β in mammalian cells. Furthermore a strong induction of type I 
IFNs by NDV has been shown in several other studies (Fournier et al., 2003; Washburn et al., 
2002; Zeng et al., 2002a; Zorn et al., 1994). These findings underline the importance of IFN-β 
in antiviral responses and suggest that the limited IFN-β expression in tumour cells is related 
to their high NDV susceptibility. Moreover, the homozygous deletion of IFN-α/β genes in 
human leukemia and derived cell lines have been associated with tumour development (Diaz 
et al., 1988) and recombinant type I interferons are used in the treatment of different kinds of 
cancers (Vannucchi et al., 2007; Yoshida et al., 2004).
The importance  of  the IFNAR during NDV infection could be assessed with the help of 
IFNAR knock out macrophages and MEF. It was shown that the IFNAR is crucial for NDV 
resistance. In its absence the cells were much more susceptible to NDV infection than the 
wildtype and also than the IRF3/7 knock out cells. Considering the M gene expression, the 
IFNAR knock out macrophages were almost as susceptible to NDV infection as tumour cells. 
In addition the cells became completely irresponsive to IFN-α4 pretreatment with regard to 
inhibition of NDV replication or to induction of interferon-related gene expression.
The wildtype MEF cells were susceptible to NDV infection although they are non-malignant 
cells. The MEF constitute an immortalised cell line that grows permanently in contrast to the 
macrophages. They therefore provide a better environment for NDV replication since much of 
the  cellular  machinery  that  is  required  for  cell  proliferation  is  also  necessary  for  virus 
replication. Resting cells such as macrophages are already more resistant to NDV infection 
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than  MEF  cells  since  there  are  only  low  concentrations  of  proteins  involved  in  cell 
proliferation.  Another  factor  for  NDV  susceptibility  in  MEF  was  apparently  the 
downregulation  of  important  interferon-related  genes  such  as  RIG-I,  IRF7 or  IFN-β.  The 
expression of these molecules might have decreased because cells with a low expression of 
interferon-related proteins are less sensitive to anti-growth effects of IFN and have therefore a 
higher proliferation rate and a selective advantage in in vitro cell culture. Nevertheless, when 
the IFNAR knock out MEF cells were compared with the wildtype there was a strong increase 
in NDV replication and a complete abrogation of the responsiveness to IFN-α4. This indicated 
that the defects acquired in the IFN response in wildtype MEF were probably not directly 
concerning  the  IFNAR  but  were  rather  related  to  other  components  of  the  IFN  system. 
Interestingly, the IFNAR knock out had almost no influence on the expression of interferon-
related  genes  (figure  4-41),  possibly  because  these  genes  were  already  expressed  at  a 
relatively low level in the wildtype MEF.
The data suggest a crucial  role of the IFNAR in the defence against NDV infection. The 
importance of the IFNAR in antiviral responses has also been shown for other viruses. IFNAR 
knock out mice proved to be highly susceptible to infection by SFV and EMCV (Hwang et  
al., 1995) and to infection by VSV or vaccinia virus (van den Broek et al., 1995). However, 
the IFNAR seems not to be essential in the defence against MMTV infections (Maillard et al., 
1998).  The IFNAR represents  a  bottleneck in the type  I  interferon  signalling required to 
induce antiviral responses because it is the only receptor for type I interferons. It is therefore 
an attractive target for virus interference. Vaccinia virus, for example,  expresses a soluble 
IFN-α/β receptor that binds to the cell surface and protects cells from the antiviral effects of 
IFN (Alcami  et al., 2000). Measles virus suppresses IFN-α signalling by the suppression of 
Jak1 phosphorylation and association of viral accessory proteins C and V with the IFNAR 
complex (Yokota et al., 2003) and the V protein of mumps virus induces the dissociation of 
STAT-1 from the IFNAR complex (Kubota et al., 2002). The NDV V protein can also inhibit 
the IFN response (Huang et al., 2003), but its IFN antagonist activity is species specific and in 
contrast  to  avian  cells  it  cannot  prevent  the  induction  of  a  strong  interferon  response  in 
mammalian cells (Park et al., 2003).
The mechanism that leads to the dramatic increase in NDV susceptibility in the absence of the 
IFNAR is  likely  the  abrogation  of  type  I  interferon  signalling,  the  main  road  via  which 
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antiviral  responses  are  induced.  There  is  also  no  more  secretion  of  IFN-α/β without  the 
IFNAR (figure 4-34), demonstrating the crucial importance of positive feedback signalling for 
the induction of IFNs. In the IFNAR knock outs it could also nicely be seen that type I IFNs 
are essential for the induction of IRF7 and IFN-β but not for RIG-I or IRF3.
There are indications that defects in the IFNAR signalling are involved in tumourigenesis and 
present a selective advantage for tumour cells. In mice lacking a functional IFNAR tumour 
development  and  ensuing  mortality  were  enhanced,  indicating  that  endogenous  IFN-
alpha/beta production is a mediator of natural immunity against tumour development (Picaud 
et al., 2002). The IFNAR was found to be expressed on epithelial tumours but was missing in 
lymphomas,  sarcomas  and  endocrine  tumours  (Navarro  et  al.,  1996),  suggesting  an 
involvement  of  this  receptor  in  tumourigenesis  of  the  latter  cancer  types.  In  addition the 
transfection of tumour cells with a type I IFN receptor chain increased the rate of apoptosis 
and sensitivity to the antiproliferative effects of IFNs (Wagner  et al., 2004). In melanoma 
cells defects in the IFNAR JAK-STAT pathway could have led to cancer progression through 
loss of growth-restraining functions of IFN (Pansky et al., 2000).
 5.3.5 Antiviral effector molecules
Among the hundreds of genes that are induced by IFNs there are genes that directly interfere 
with viral infection. These antiviral effector molecules usually inhibit crucial steps of the viral 
replication inside a cell such as RNA translation or the assembly of viral particles. In this 
thesis the expression of the three antiviral effector molecules PKR, OAS1a and Mx1 has been 
analysed  in  tumour  and normal  cells  to  find  out  whether  there  are  indications  that  these 
molecules are involved in the generation of differences in NDV susceptibility.
The basal expression of all three antiviral effector molecules was found to be higher in normal 
than in macrophage-like tumour cells and correlated negatively with NDV susceptibility. This 
was also true for the NDV-inducible expression of OAS1a and Mx1, but for PKR one tumour 
cell line showed a higher inducible expression than the primary macrophages. These results 
suggest that the differences in NDV infection in normal and tumour cells could be due to the 
different expression of the three analysed molecules. The highest expression of the PKR in a 
more resistant macrophage-like tumour cell line could be one reason for the relatively high 
NDV resistance of these cells compared to other tumour cells. Mx1 was induced about 10-
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fold more than PKR and OAS1a, pointing to a higher sensitivity of this gene to IFN-induced 
transcription  factors.  This  could  be  explained,  for  example,  by  a  different  promoter 
organisation.  However,  it  is  difficult  to generalise  that  high Mx1 expression is  of special 
significance for NDV resistance.
The importance of Mx proteins in the defence against viral infections was first established 
when the increased susceptibility of inbred mice against influenza and influenza-like viruses 
could be related to defects in the Mx1 gene (Staeheli  et al., 1988). Mx proteins could be 
shown to be crucial for the defence against orthomyxoviruses or bunyaviruses (Haller et al., 
1998), but they can also inhibit paramyxovirus infections (Schneider-Schaulies et al., 1994).
The antiviral effects of PKR have been well-studied. PKR inhibits infection by many viruses . 
It is therefore a common target for interference by many different viruses. HCV, for example, 
inhibits PKR via its NS5A and its E2 protein (Gale et al., 1998; Taylor et al., 1999) and HSV 
suppresses PKR activation (Peters et al., 2002) or reverses the phosphorylation of the eIF-2α 
by PKR, thereby precluding the shut-off of protein synthesis (He et al., 1997). Furthermore, 
the influenza A virus protein NS1 binds to PKR and prevents its activation (Dauber  et al., 
2006; Li et al., 2006) and the reovirus sigma3 protein blocks the activation of PKR (Yue and 
Shatkin, 1997). The role of PKR for paramyxovirus infection is less clear, but it could be 
shown  that  PKR  expression  upon  NDV  infection  correlates  negatively  with  NDV 
susceptibility of normal and tumour cells (Fiola et al., 2006).
The OAS family proteins have also been demonstrated to possess broad antiviral activities 
and some viruses target these proteins for inhibition.  The influenza A virus, for example, 
binds viral RNA by its NS1 protein to inhibit the OAS/RNase L pathway (Min and Krug, 
2006) and cellular OAS is inhibited by the herpes simplex virus type 1 Us11 protein (Sanchez 
and Mohr, 2007). During NDV infection the expression of OAS did not correlate with NDV 
susceptibility in malignant and non-malignant cells in contrast to PKR (Fiola et al., 2006).
The  above  data  suggest  an  important  role  of  PKR,  OAS1a  and  Mx1  in  viral  defences. 
Therefore  their  different  expression  in  tumour  and  normal  cells  could  in  part  explain 
differences in NDV susceptibility. The possible involvement of the three analysed antiviral 
effector molecules in tumourigenesis has not been addressed thoroughly. An involvement can 
be expected, for example, because of pro-apoptotic actions which are known for PKR (Gil 
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and Esteban, 2000; Lee and Esteban,  1994) or OAS1a (Castelli  et al.,  1998; Zhou  et al., 
1998). Some studies have implicated the involvement of PKR in the development of chronic 
lymphocytic leukemia (Hii  et al., 2004) and other cancer types (Jagus et al., 1999). PKR is 
switched off in tumour cells due to ras transformation (Mundschau and Faller,  1995) and 
defects  in  translational  regulation  renders  tumour  cells  insensitive  to  PKR  action 
(Balachandran and Barber,  2004).  In  addition several  tumour  suppressors  such as  MDA7 
regulate PKR to induce apoptosis in tumour cells (Pataer et al., 2002) and oncogenes repress 
PKR action such as the NPM oncogene in Karpas 299 tumour cells (Friedrich et al., 2005). 
RNase L, which is activated by OAS, has been implicated in the pathology of prostate and 
colorectal cancer (Bisbal and Silverman, 2007).
There could be other factors involved in the generation of differences in NDV susceptibility 
between normal and tumour cells that were not analysed in this study. The existence of such 
factors  can  be  deduced  from the  finding  that  cells  from so-called  triple  knock-out  mice 
lacking PKR, RNaseL and Mx still exhibit a limited IFN-induced antiviral state (Zhou et al., 
1999). 
 5.3.6 The replication-independent induction of antiviral responses by 
NDV
A main mechanism for the induction of antiviral responses in cells infected by NDV starts 
with  recognition  of  viral  RNAs  in  the  cytosol  by  receptors  such  as  RIG-I.  After  the 
recognition  of  the  RNAs  a  signal  is  transmitted  downstream and leads  ultimately  to  the 
induction of IFNs and IFN-related genes. However,  in the analysis  of NDV-induced gene 
expression  in  macrophages  and  macrophage-like  tumour  cells  in  this  thesis  there  was  a 
characteristic peak in expression after 8 hours when UV-inactivated NDV was used. This 
inactivated NDV did not replicate any more and therefore no viral RNA was generated in the 
cytosol. The peak in expression could only be observed in primary macrophages and had the 
same magnitude as the gene expression induced by live virus. After reaching the peak the 
expression usually decreased quickly for cells treated with UV-inactivated NDV and levelled 
out somewhat higher than the basal level. In contrast the infection with live NDV usually led 
to a sustained increase in gene expression.
These data strongly suggest another mechanism for the induction of IFN by NDV independent 
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of viral RNA. The only viral RNA in the treatments with inactivated NDV could come from 
the viral capsid. It is hard to imagine that this alone could induce gene expression almost as 
well as the large amounts of viral RNA that are generated during infection with live NDV. It 
is conceivable that some viral proteins such as the membrane proteins F or HN interact with 
pattern recognition receptors on the cell  surface such as TLRs to induce a response. This 
hypothesis is supported by the fact that the NDV HN protein could induce the production of 
IFN-α in human PBMCs while the F protein did not induce IFNs (Fournier et al., 2003; Zeng 
et al., 2002a). It has been suggested that this induction of IFN-α is based on the interaction of 
the viral  HN molecule with cellular sialic  acid expressing receptors (Zeng  et  al.,  2002b). 
These could possibly be coupled to TLRs.
Nucleic acid-independent ways of virus recognition are also known for other viruses. In most 
of  these  cases  viral  proteins  are  recognised  by  TLR2  and  TLR4.  For  example,  the 
hemagglutinin protein of wild-type measles virus activates TLR2 signalling (Bieback et al., 
2002) and human cytomegalovirus activates inflammatory cytokine responses via CD14 and 
TLR2 (Boehme  et  al.,  2006;  Compton  et  al.,  2003).  In  addition  TLR4 and again  CD14 
respond to the fusion protein of RSV to mediate antiviral responses (Kurt-Jones et al., 2000) 
and MMTV activates B cells via interaction with TLR4 (Rassa et al., 2002).
Tumour cells did not respond to inactivated NDV in contrast to normal cells. Limitations of 
malignant cells to use replication-independent ways of NDV recognition have been observed 
before (Fiola et al., 2006; Washburn and Schirrmacher, 2002). This could be another reason 
why tumour cells are more susceptible to NDV infection than normal cells.
 5.4 The correlation between interferon-related gene 
expression and NDV resistance
In most instances NDV replicates much better in tumour than in normal cells. However, there 
are deviations from this rule. On the one hand some tumour cells are almost resistant to NDV 
infection such as the CT26p colon carcinoma cell line (figure 4-48). On the other hand some 
normal cells are exceptionally susceptible to NDV infection such as the IFNAR knock out 
macrophages. CT26p cells showed a basal expression of some interferon-related genes that 
was unusually high for tumour cells and the IFNAR knock outs only weakly expressed these 
genes compared to other  normal cells.  Thus,  the expression of interferon-related antiviral 
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genes in cells can strongly influence susceptibility to infection by NDV.
The analysis of about a dozen normal and tumour cells revealed a strong negative correlation 
between the expression of RIG-I, IRF3, IRF7 and in part of IFN-β and the susceptibility to 
NDV (figure 4-43 – 4-46). When NDV replication was plotted against the basal and inducible 
gene expression level of normal and tumour cells two clusters could be distinguished. The 
correlation coefficient R was between -0.6 and -0.9. In general a correlation coefficient that is 
above 0.5 or  below -0.5 is  regarded as  a  strong indication  of  a  connection between two 
variables (oral communication, Axel Benner, Central Unit Biostatistics, DKFZ Heidelberg). A 
correlation of two variables is not necessarily a proof of a causal relation, but because the 
antiviral  effects  of  the  analysed  molecules  are  known the  correlation  strongly indicates  a 
functional  role  of  the molecules  for  NDV resistance.  In  addition the  correlation can also 
explain the exceptions mentioned above.
In summary it can be concluded that defects in the basal or inducible expression of interferon-
related genes makes cells susceptible to infection by NDV. In principal such defects can be 
acquired  by  any  cell  type  but  because  they  confer  survival  and  growth  advantages  they 
usually develop in tumour cells.  This is a main reason for the high susceptibility of most 
tumour  cells  to  NDV infection.  The  above  conclusion  also  predicts  differences  in  NDV 
susceptibility  in  tumour  cells  depending  on  the  severity  of  the  acquired  defects  in  the 
interferon system. This is a new finding that has implications for the use of viruses in cancer 
treatment that will be discussed in the next chapter. 
 5.5 Implications for the use of NDV in tumour therapy
NDV is not pathogenic in humans and replicates substantially better in tumour than in normal 
cells. These two properties make NDV a promising candidate for the application in cancer 
therapy. There are two major therapeutical approaches: active-specific immunotherapy (ASI), 
i.e.  the  anti-tumour  stimulation  of  the  immune  system  with  oncolysates  or  whole  cell 
vaccines, and oncolytic virus therapy with lytic NDV strains that directly kill tumour cells. 
For  both  approaches  clinical  studies  have  been  undertaken  that  demonstrate  the  good 
tolerability and apparent anti-tumour efficacy.
In this thesis it was confirmed that NDV replicates selectively in tumour cells. In addition a 
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strong induction of IFNs and interferon-related genes could be observed in normal cells upon 
NDV infection. This underlines the role of NDV in the stimulation of the immune system that 
is crucial for ASI involving NDV but that can also be a beneficial side-effect for oncolytic 
virus therapy.
The results of this thesis have additional implications for the use of NDV in tumour therapy. It 
could be shown that there can be a great variability in NDV susceptibility of tumour cells and 
that some tumour cells are almost as resistant to NDV infection as normal cells. Even with 
tumour  cell  lines  of  the  same origin,  but  maintained  in  different  laboratories,  there  were 
tremendous differences in NDV susceptibility as observed with the colon carcinoma cell line 
CT26. Furthermore it could be shown that the expression of interferon-related genes strongly 
correlates  with  NDV  susceptibility.  This  correlation  could  also  explain  the  exceptional 
resistance to NDV infection of certain tumour cell lines.
An important finding with implications for the use of NDV in cancer treatment was the strong 
correlation of the basal  expression of certain antiviral  genes with NDV resistance.  If  this 
correlation could be reproduced in human cells, this knowledge would enable a clinician to 
pretest  the tumour of the patient  to evaluate  its  suitability for NDV virotherapy.  A small 
tumour  sample  would  be  sufficient  for  RNA  extraction  and  the  subsequent  expression 
analysis of interferon-related genes such as RIG-I or IRF7. By this proceeding oncolytic NDV 
therapy would be used preferentially in those cases for which a high susceptibility of the 
tumour would be predicted. For the tumours that show a relatively high expression of the 
analysed  genes  and  that  would  therefore  likely  be  resistant  to  NDV  other  therapeutical 
approaches had to be chosen.
The analysis  of  basal  gene  expression  to predict  the susceptibility  of  a  tumour  for  NDV 
infection has important  advantages over other  methods. An alternative would only be the 
preparation of living tumour material and its subsequent infection with NDV. This proceeding 
would have several  disadvantages.  The isolation, culture and infection of tumour material 
would be more laborious and time consuming than the immediate RNA extraction and PCR 
analysis. In addition, more tumour material of a better quality would be needed for the latter 
approach.  A possible  confounding factor  for the analysis  of the basal  gene expression of 
tumour tissue could be non-malignant cells such as stromal cells that can also be found in a 
tumour. This point could be tested, for example, in a mouse model in which the tumour cells 
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would be injected into mice to form tumours before the RNA of these tumours would be 
prepared and used for a gene expression analysis. By a comparison of  in vitro and  in vivo 
results one could evaluate if the confounding of the results by normal cells is strong. If the 
latter is the case the problem could be circumvented by analysing areas from the tumour tissue 
that contain only tumour cells. These areas could be selected, for example, by a pathologist in 
a tissue slice. Only little tissue material would be necessary for a PCR analysis.
The general approach of analysing a cancer patient and its special tumour type before the 
selection of a treatment protocol is becoming more and more widespread to improve treatment 
efficacy (Gasparini  et al.,  2006).  It  is  likely that  the expression of certain antiviral  genes 
strongly correlates with the susceptibility to the infection with other viruses than NDV. Hence 
the analysis of gene expression to select tumours that are especially suitable for virotherapy 
might also be extended to other viruses and could improve therapy efficacy.
The use of oncolytic viruses in cancer therapy is a rapidly developing field and for many 
viruses clinical trials have been carried out. Table 5-1 gives an overview over the oncolytic 
viruses that have been tested in clinical studies:
Virus Mechanism of tumour 
targeting
Phase of 
development
Results Ref.
Adenovirus Targets to tumour 
antigens; conditionally 
replicating
Phase III conducted; 
approval for cancer 
treatment in China
Recombinant H101 in combination 
with cisplatin and 5-FU showed 
efficacy in patients with squamous 
cell cancer of head and neck or 
oesophagus after intratumoural 
injection
1, 2
Reovirus Selectively infects ras-
transformed cells
Phase I conducted Systemic treatment well tolerated in 
patients with metastatic disease, 
observation of virus-induced tumour 
necrosis associated with 
intratumoural viral replication
3
Herpes simplex 
virus 1
Only replicates in tumour 
cells
Phase I conducted G207 and HSV1716 were found to 
be well tolerated when given 
intratumourally in patients with 
glioma
4, 5
Newcastle 
disease virus
Selectively replicates in 
interferon-defective cells
Phase I/II conducted Systemic administration of PV701 
and NDV-HUJ was found to be well 
tolerated and anti-tumour responses 
was found in some patients
6, 7
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Virus Mechanism of tumour 
targeting
Phase of 
development
Results Ref.
Vaccinia virus Gains access to tumour by 
vascular leakiness
Phase I conducted Recombinant vaccinia was found to 
be well tolerated in phase I clinical 
trials when given intratumourally 
into melanomas or systemically for 
pancreatic cancer or various 
advanced tumours
8, 9, 
10
Coxsackievirus Selectively infects tumour 
cells that overexpress DAF
Phase I conducted Coxsackievirus A21 was found to be 
well tolerated when administered by 
intratumoural injection in patients 
with melanoma
11
Measles virus Virus re-targeting to 
tuomour antigens; 
overexpression of virus 
receptor (CD46) on some 
tumour cells
Phase I ongoing Intraperitoneal treatment was well 
tolerated in patients with ovarian 
cancer
11
Table 5-1: Clinical development of oncolytic viral vectors.
List of references: 1) Xia et al., 2004; 2) Garber, 2006; 3) Vidal et al., 2006; 4) Shah et al., 2003; 5) Markert et  
al., 2000; 6) Laurie et al., 2006; 7) Freeman et al., 2006; 8) Eder et al., 2000; 9) Mastrangelo et al., 1999; 10) 
Marshall et al., 2000; 11) Parato et al., 2005. Adapted from Parato et al., 2005. Ref. = References
Oncolytic viruses are promising tools in the treatment of cancer. They have the potential to 
amplify  their  anti-tumour  effect  by  the  generation  of  virus  progeny  and  they  can  reach 
disseminated  tumour  cells  in  the  body when  given systemically.  In  addition  they  can be 
genetically  modified  to  improve  tumour  selectivity,  tumour  killing  or  the  stimulation  of 
immune cells. However, there are problems in the clinical application of viruses that have to 
be addressed such as tumour targeting,  intratumoural  dissemination,  immune clearance or 
safety issues. Regarding the latter point NDV is an ideal therapeutic because it is naturally 
tumour selective and does not cause disease in humans. Furthermore NDV replication takes 
place in the cytosol of the host cell and there is no danger of malignant transformation by the 
integration  of  parts  of  the  virus  into  the  host  genome.  NDV  has  also  a  high 
immunostimulatory potential and induces a strong interferon response as could be shown in 
this and other studies (Washburn and Schirrmacher, 2002). The stimulation of the immune 
system by NDV is important for immunotherapy but can also be helpful for the oncolytic 
approach to achieve the establishment of post-oncolytic protective anti-tumour immunity.
It remains to be seen if in future studies the good safety profile of NDV can be complemented 
with an improved oncolytic efficacy. If so, cancer therapy with NDV may become a widely 
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available therapeutic tool that can be used in a multi-modal approach together with standard 
therapies such as radio- or chemotherapy to achieve the highest possible anti-cancer effect.
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 7 Appendix
 7.1 Systemic in vivo application of NDV
 7.1.1 Biodistribution of NDV after systemic application
The data of this chapter has already been published in Bian et al. (2006).
NDV can be applied systemically as an oncolytic virus therapeutic to target cancer cells (see 
for example Laurie et al., 2006). In order to investigate the biodistribution kinetics of native 
NDV,  the  M  gene  expression  was  followed  in  different  mouse  organs  after  systemic 
application of NDV Italien. This velogenic NDV strain was used because it is more virulent 
and has therefore a higher oncolytic potential than the lentogenic NDV strains employed so 
far  in  this  thesis.  In  addition  NDV Italien  replicates  multicyclically  and generates  viable 
offspring that can reinfect tumour cells in the body.
Figure 7-1 shows that M gene expression could be detected in all the analysed organs after 
systemic application of NDV Italien. The M gene level declined in all organs in the course of 
the treatment. A high M gene expression could be found in lung, blood, liver and spleen. In 
the lung and in the spleen M gene expression could still be detected after 14 days. In the liver 
M gene expression lasted four days and in the blood no M gene expression could be detected 
later than 12 hours. In the kidney the M gene expression was low and lasted until day 2, while 
in the thymus a low M gene signal could only be detected at 12 hours.
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The biodistribution kinetics demonstrated that most of the M gene expression could be found 
in the lung. The lung is well supplied with blood and it was the second organ after the blood 
iiself which was reached after NDV had entered the body via the tail vein and had then passed 
the heart. The blood showed high M gene levels because this is the organ into which NDV 
had been injected. However, NDV appeared to be cleaned quickly from the blood, probably 
by binding to endothelial cells in the network of blood vessels that supplied other organs and 
tissues in the body or by active removal by the immune system. Besides the lung, the liver and 
the spleen are also well supplied by blood vessels, which could explain the relatively high 
amounts of virus found there.
 7.1.2 Biodistribution after systemic application of encapsulated NDV
NDV binds to sialic acid containing receptors that are present on most mammalian cells. It 
can be  expected that  a  large  fraction of  NDV does not  reach tumour  cells  when applied 
systemically  due  to  unspecific  binding  to  all  kinds  of  cells  in  the  body.  This  unspecific 
binding  could  be  demonstrated  in  the  preceding  chapter.  One  approach  to  improve  the 
targeting of NDV to tumour cells is to encapsulate the virus in liposomes. The rationale is that 
encapsulated NDV will be prevented from unspecific binding to, for example, erythrocytes 
and could therefore circulate for a longer time in the blood system. The targeting could be 
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Figure  7 -1: Biodistribution of NDV Italien in mice.
1500 HU NDV Italien was injected i.v. into DBA/2 mice. Different organs (lung, liver, spleen, kidney, thymus 
and blood) were collected at different time points (2 mice for each analysis) after virus administration. Total 
RNA was extracted and the expression level of the NDV M gene was determined by real-time RT-PCR with the 
comparative  CT method  using  β-actin  for  normalisation.  The  results  are  represented  as  the  mean  of  three 
measurements. Bars indicate standard deviation.
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further  improved because  the  liposomes might  be expected to leave the  blood vessels  of 
tumour tissues more readily than that of healthy, normal tissues, since the endothelium of 
blood vessels in tumours is thought to be more leaky. In addition, the circulation time and 
thereby the chance of an encounter of NDV with a tumour cell could be improved by an 
increased protection against immunological clearance of encapsulated NDV.
The encapsulation of NDV Ulster was carried out with the help and in the laboratory of PD 
Dr. Ulrich Massing, Tumor Biology Center, Department of Clinical Research/Phospholipids, 
Freiburg,  Germany.  The  virus  particles  were  encapsulated  in  a  mixture  of  egg 
phosphatidylcholine 3 (EPC3) / cholesterol (55/45 mol%, manufactured by Lipoid Germany). 
The virus was mixed with the lipoid and also with 100 % (w/w) glass beads and then the vials 
were placed into a mixer.  The vials  were mixed several times and in between they were 
cooled on ice.
As a first step Eb-M7 tumour cells that were used later on to generate tumours in mice were 
infected with native and encapsulated virus to ascertain if there were differences in the ability 
to infect these cells. As a measure for NDV Ulster infection the HN expression on the cell 
surface was determined by flow cytometry.
Figure 7-2 shows that after the infection of Eb-M7 cells with different amounts of native and 
encapsulated NDV Ulster the HN expression on the cell surface was comparable. Only when 
infected with 100 HU per 106 cells the HN signal was slightly lower for the encapsulated 
NDV.
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After it had been confirmed that the encapsulation did not significantly reduce the ability of 
NDV to infect Eb-M7 cells, the biodistribution of encapsulated NDV Ulster after systemic 
application in mice was tested. In the mice Eb-M7 cells had been injected subcutaneously 
about one week before the virus was given.
Figure 7-3 demonstrates that the M gene expression at a similar level could be detected in the 
tumours  for  the  native  and  for  the  encapsulated  NDV 1,  6  and  36  hours  after  systemic 
application. At 24 hours M gene expression could only be detected for the native virus and at 
all other time points no M gene expression could be observed. The M gene level was highest 
at 6 and 24 hours and lower at 1 and 36 hours after virus application.
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Figure  7 -2: HN surface  expression on Eb-M7 cells  after  infection with encapsulated or 
native NDV Ulster.
Encapsulated and native NDV Ulster was used to infect Eb-M7 cells with 10 HU per 106 cells. After 24 hours 
the HN expression of the cells was determined by flow cytometry after staining with a murine primary antibody 
against the viral surface protein HN and a secondary GaM PE-labelled antibody.
0
20
40
60
80
100
1 10 100
Virus amount [HU / 106 cells]
H
N
 p
os
iti
ve
 c
el
ls
 [%
]
native encapsulated
Appendix                                                                                                                                        
The  results  showed  that  the  M  gene  expression  was  comparable  for  the  native  and  the 
encapsulated virus. The M gene level rose between 1 and 6 hours because of the progressing 
virus replication probably related to more virus reaching the tumour. Surprisingly there was 
no detectable M gene expression at 12 hours and at 24 hours only in the mice treated with 
native NDV there was an NDV signal. This could either mean that NDV infection stopped 
after 12 hours and restarted again at 24 hours or was more likely related to variations because 
of the small sample size, because only one mouse was sacrificed per time point and only a 
part of the tumours was taken for RNA extraction.
At  time  points  later  than 36  hours  no  M gene  could  be  observed  in  tumours  any more, 
indicating  that  virus  replication  and  reinfection  of  tumour  cells  could  not  be  sustained. 
Possible reasons for this could have been the clearance of the virus by the immune system or 
limited viral spread in the tumour mass due to NDV resistant stromal cells or necrotic areas. 
Next  lung and  liver  tissue  was  tested  for  viral  replication  to  ascertain  whether  liposome 
encapsulation  changed  the  amount  of  virus  that  reached  these  tissues  after  systemic 
application.
Figure 7-4 demonstrates  that  the  encapsulation  reduced the M gene signal  after  systemic 
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Figure   7  -3: Virus M gene expression in tumours after i.v. application of encapsulated or 
native NDV Ulster.
DBA/2 mice were irradiated with 4.5 Gray at day -8 and 5*106 Eb-M7 cells in 300 µL volume were injected 
subcutaneously at day -7. At day 0 2000 HU native or liposome-encapsulated NDV Ulster were injected into the 
tail vein of the mice. At the given time points after virus application one animal was sacrificed for each group 
and total RNA was extracted from the tumour. The expression level of the NDV M gene was determined by real-
time RT-PCR with the comparative CT method using β-actin for normalisation. The results are represented as the 
mean of three measurements. Bars indicate standard deviation.
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application of NDV Ulster compared to the native virus at all measured time points (part A). 
For both virus batches the M gene expression levels increased up to 12 hours after the virus 
application and then they declined again until 120 hours. The average M gene expression for 
the whole time course was 77 REU for the native NDV and 20 REU for the encapsulated 
NDV. In the liver samples (part B) the M gene expression levels were similar at most time 
points. Only at 12 hours the M gene level was higher in the mice treated with encapsulated 
NDV.
Liposome encapsulation strongly reduced the  amount of virus  that  reached the lung after 
systemic application, whereas it did not diminish the M gene expression in liver tissue. There 
seemed to be some factor that specifically limited the binding of encapsulated NDV to lung 
tissue.
In conclusion it could be said that liposome encapsulation of NDV proved to feasible without 
reducing the ability of the virus to infect cells. However, in the setting tested no improvement 
of the targeting of NDV to tumours could be observed.
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Figure  7 -4: M gene expression in lung and liver tissue after i.v. application of encapsulated 
or native NDV Ulster.
DBA/2 mice were irradiated with 4.5 Gray at day -8 and 5*106 Eb-M7 cells in 300 µL volume were injected 
subcutaneously at day -7. At day 0 2000 HU native or liposome-encapsulated NDV Ulster were injected into the 
tail vein of the mice. At the given time points after virus application one animal was sacrificed for each group 
and total RNA was extracted from the lung or liver, respectively. The expression level of the NDV M gene was 
determined by real-time RT-PCR with the comparative CT method using β-actin for normalisation. The results 
are represented as the mean of three measurements. Bars indicate standard deviation.
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 7.1.3 Tumour targeting of NDV with bispecific molecules
The data of this chapter has already been published in Bian et al. (2006).
Another approach to improve tumour targeting that had already been successfully employed 
by our research group was the use of bispecific adaptor proteins. These proteins block the 
native cell binding site of NDV and introduce a new binding site for tumour-associated targets 
(Bian et al., 2005a-c). In the following experiments the influence of the modification of NDV 
particles with bispecific molecules was analysed regarding side effects induced by systemic 
application. The bispecific protein introduced a binding site for the IL-2 receptor (IL-2R). The 
Eb-M7  tumour  cells  displayed  a  high  expression  of  the  IL-2R  and  were  obtained  by 
successive sorting. In addition to the side effects the targeting of modified NDV to tumour 
cells  was  also  determined.  In  contrast  to  earlier  studies  with lentogenic  NDV strains  the 
velogenic NDV Italien was used for the analysis.
As a parameter for NDV-induced side effects the body weight was followed in the course of 
NDV treatment. The anti-tumour effects were determined by measuring the tumour volumes 
at different time points after NDV application.
Figure 7-5 shows that there was a significant difference in body weight variation on day 4 and 
6 between the medium dose native NDV (NAT MED) and the medium dose modified NDV 
(MOD MED) group (part A). All groups treated with NDV displayed a reduction in the body 
weight in contrast to the PBS treated group. The reduction increased up to day 4 when it 
reached -4 – -9 %. On day 6 the body weight of the mice in the NDV groups had partly 
recovered and reached from -5 – 0 %. The tumour volume in the NDV treatment groups was 
always  lower  than  in  the  PBS  control  group  (part  B).  This  difference  was  statistically 
significant on day 9. The tumour volumes in the NDV treatment groups were comparable at 
all time points.
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The results demonstrated that the modification of NDV with bispecific molecules reduced the 
cytopathic effects in systemic therapy. At the same time it could be shown that NDV could be 
systemically  applied  to  reduce  the  growth  of  a  locally  growing  tumour  and  that  the 
modification  did  not  substantially  diminish  the  anti-tumour  effects.  Therefore  the 
modification protocol might be used to reduce side effects in future NDV tumour therapy 
approaches.
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Figure  7 -5: Anti-tumour effects and side effects after systemic NDV application.
Irradiated  DBA/2 mice were s.c.  inoculated with 5*106 Eb-M7 (IL-2R+)  cells.  One day later,  they received 
500 HU of NDV Ulster i.v. as a means of desensitization. For therapy, the animals received three i.v. injections 
of different NDV Italien preparations at days 2, 3 and 4. PBS was added to the virus preparation to a final  
volume of 300 µL. Modified NDV was obtained by incubation of 2000 HU of the virus with 250 µg αHN-IL-2 
in a final volume of 300 µL for 1 hour on ice. (A) Mouse body weights were measured every other day. The 
mean body weight change was calculated as the percentage of the body weight ± standard error of the mean 
(SEM) among a cohort of 10 mice in each group. NAT MED, native NDV Italien 1000 HU per injection; MOD 
MED, modified NDV Italien/·HN-IL-2 1000 HU per injection; MOD HIGH, modified NDV Italien/·HN-IL-2 
2000 HU per  injection.  The  P-values  were  calculated:  *P<0.0006,  **P=0.03.  (B)  The tumor volumes  were 
determined in 10 miceat the time-points indicated. The P-values were corrected for multiple testing. *P<0.05.
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 7 Appendix
 7.2 Description of the oligonucleotides used for quantitative real-time PCR
 7.2.1 Oligonucleotides
Name Species Gene Sequence 5´ - 3´ Oligo (bp) Amplicon (bp) Origin
Arbp_1 Mouse Acidic ribosomal phosphoprotein PO CGACCTGGAAGTCCAACTAC 20 109
Simpson et al., Mol Vis. 2000 
Oct 5;6:178-83.
Arbp_2 Mouse Acidic ribosomal phosphoprotein PO ATCTGCTGCATCTGCTTG 18
Simpson et al., Mol Vis. 2000 
Oct 5;6:178-83.
β-2-
microg_1 Mouse β-2-microglobulin GCTATCCAGAAAACCCCTCAA 21 300
Schmittgen et al., J Biochem 
Biophys Methods. 2000 Nov 
20;46(1-2):69-81.
β-2-
microg_2 Mouse β-2-microglobulin CATGTCTCGATCCCAGTAGACGGT 24
Schmittgen et al. J Biochem 
Biophys Methods. 2000 Nov 
20;46(1-2):69-81.
bactin_1 Mouse β-Actin ACGGCCAGGTCATCACTATTG 21 84 Bian et al., Int J Oncol. 2006 Dec;29(6):1359-69.
bactin_2 Mouse β-Actin AGGATTCCATACCCAAGAAGGAA 23 Bian et al., Int J Oncol. 2006 Dec;29(6):1359-69.
IFNb_1 Mouse Interferon β AGCTCCAAGAAAGGACGAACAT 22 82 Doyle et al., Immunity. 2002 Sep;17(3):251-63.
IFNb_2 Mouse Interferon β GCCCTGTAGGTGAGGTTGATCT 22 Doyle et al., Immunity. 2002 Sep;17(3):251-63.
IRF3_7 Mouse Interferon regulatory factor 3 GTGCCTCTCCTGACACCAAT 20 84 NM_016849
IRF3_8 Mouse Interferon regulatory factor 3 CCAAGATCAGGCCATCAAAT 20 NM_016849
IRF7_1 Mouse Interferon regulatory AAGCTGGAGCCATGGGTATG 20 148 Prakash et al., J Biol Chem. 
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Name Species Gene Sequence 5´ - 3´ Oligo (bp) Amplicon (bp) Origin
factor 7 2005 May 13;280(19):18651-7.
IRF7_2 Mouse Interferon regulatory factor 7 GACCCAGGTCCATGAGGAAG 20
Prakash et al., J Biol Chem. 
2005 May 13;280(19):18651-7.
LGP2_5 Mouse D11lgp2 GCTGCCTTTGTAGCCAAGAG 20 150 AF316999
LGP2_6 Mouse D11lgp2 GTCCCCACTCAGGGTTGTTA 20 AF316999
mda-5_1 Mouse
Melanoma 
differentiation-
associated gene-5
TGTCTTGGACACTTGCTTCG 20 121 NM_027835
mda-5_2 Mouse
Melanoma 
differentiation-
associated gene-5
CTGCACAATCCTTCTCAGCA 20 NM_027835
Mx_1 Mouse Myxovirus (influenza 
virus) resistance 1 AAACCTGATCCGACTTCACTTCC 23 83
Doyle et al., Immunity. 2002 
Sep;17(3):251-63.
Mx_2 Mouse Myxovirus (influenza 
virus) resistance 1 TGATCGTCTTCAAGGTTTCCTTGT 24
Doyle et al., Immunity. 2002 
Sep;17(3):251-63.
OAS1a_5 Mouse 2'-5' Oligoadenylate 
synthetase 1A CTTAGCATGGAGCACGGACT 20 102 NM_145211
OAS1a_6 Mouse 2'-5' Oligoadenylate 
synthetase 1A TTTGACATCAGCACCAAAGG 20 NM_145211
PKR_3 Mouse Protein kinase PKR GTTAAAGAGCCCGCCGAAA 19 75 Khabar et al., J Biol Chem. 2003 May 30;278(22):20124-32.
PKR_4 Mouse Protein kinase PKR CTGCTGGAAAAGCCACTGAAT 21 Khabar et al., J Biol Chem. 2003 May 30;278(22):20124-32.
RIG-I_3 Mouse Retinoic acid-inducible gene I; Ddx58 CCCAACCGATATCATTTCTGA 21 154 NM_014314
RIG-I_4 Mouse Retinoic acid-inducible gene I; Ddx58 AGTTTTGGGCCAGTTTTCCT 20 NM_014314
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Name Species Gene Sequence 5´ - 3´ Oligo (bp) Amplicon (bp) Origin
matrix_1 NDV NDV matrix protein AGTGATGTGCTCGGACCTTC 20 121 Bian et al., Int J Oncol. 2006 
Dec;29(6):1359-69.
matrix_2 NDV NDV matrix protein CCTGAGGAGAGGCATTTGCTA 21 Bian et al., Int J Oncol. 2006 
Dec;29(6):1359-69.
hb-actin_1 Human β-Actin AGTACTCCGTGTGGATCGGC 20 68
Gutala et al., J Neurosci 
Methods. 2004 Jan 
15;132(1):101-7.
hb-actin_2 Human β-Actin GCTGATCCACATCTGCTGGA 20
Gutala et al., J Neurosci 
Methods. 2004 Jan 
15;132(1):101-7.
hRIG-I_11 Human Retinoic acid-inducible gene I; Ddx58 AGGCTGCCACACTTTTTCTC 20 124 NM_014314
hRIG-I_12 Human Retinoic acid-inducible gene I; Ddx58 TCCCAACTTTCAATGGCTTC 20 NM_014314
The primer pairs were either designed with the Primer3 software (Rozen and Skaletsky, 2000; web software provided by the Whitehead Institute for 
Biomedical Research, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) based on the sequence of the mentioned mRNA locus or were taken 
from the quoted publications.
 7.2.2 Oligonucleotide probes
Name Species Gene Sequence 5´ - 3´ Oligo (bp) Modification Origin
b-actin Mouse β-Actin CAACGAGCGGTTCCGATGCCC 21 5´ 6-FAM3´ TAMRA
Jens Derbinski, DKFZ 
Heidelberg; oral communication
matrix NDV Matrix protein TTCTCTAGCAGTGGGACAGCCTGC 24 5´ 6-FAM3´ TAMRA
Wise et al., J Clin Microbiol. 
2004 Jan;42(1):329-38.
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